var title_f34_53_35664="One hand technique";
var content_f34_53_35664=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    One-handed chest compressions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 307px; height: 433px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    For children (from one year until the start of puberty), chest compressions may be performed with the heel of one hand placed over the lower half of the sternum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_53_35664=[""].join("\n");
var outline_f34_53_35664=null;
var title_f34_53_35665="IVUS artery remodeling";
var content_f34_53_35665=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Remodeling of a coronary artery assessed with intracoronary ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 316px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Remodeling is a physiologic way of maintaining blood flow as plaque builds up inside an artery. The wall of the artery expands as the plaque accumulates, keeping the lumen open as long as possible. The reverse of this process, negative remodeling, can happen after angioplasty, as contraction of the treated segment leads to accelerated renarrowing or \"restenosis.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     By permission from Yock P, Fitzgerald P, Popp R. Science and Medicine 1995; 2:68.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_53_35665=[""].join("\n");
var outline_f34_53_35665=null;
var title_f34_53_35666="Melasma cheek";
var content_f34_53_35666=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Melasma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A mottled hyperpigmented patch is present on the cheek.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_53_35666=[""].join("\n");
var outline_f34_53_35666=null;
var title_f34_53_35667="Patient information: Cardiac catheterization (The Basics)";
var content_f34_53_35667=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16653\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/42/36516\">",
"         Chambers and valves of the heart",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/37/16980\">",
"          Cardiac catheterization",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?38/24/39298\">",
"         Patient information: Angioplasty and stenting for the heart (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?20/34/21027\">",
"         Patient information: Chest pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/10/27809\">",
"         Patient information: Coronary heart disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/53/10068\">",
"         Patient information: Heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/42/36514\">",
"         Patient information: Heart murmurs (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/10/43170\">",
"         Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?42/9/43157\">",
"         Patient information: Chest pain (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/16/40195\">",
"         Patient information: Heart attack (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/5/33877\">",
"         Patient information: Heart failure (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/38/18020\">",
"         Patient information: Heart stents and angioplasty (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Cardiac catheterization (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/cardiac-catheterization-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6753019\">",
"      <span class=\"h1\">",
"       What is cardiac catheterization?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cardiac catheterization, sometimes called &ldquo;cardiac cath,&rdquo; is a procedure doctors can do to look for certain heart problems. Doctors usually do cardiac cath to understand how your heart is working or why you have symptoms such as chest pain.",
"     </p>",
"     <p>",
"      Most people who have a cardiac cath have a test called &ldquo;coronary angiography&rdquo; done at the same time. Doctors do coronary angiography to look at the arteries in a person&rsquo;s heart. That way, they can see if there are any blockages in the arteries and how serious the blockages are.",
"     </p>",
"     <p>",
"      Some people have a cardiac cath without having coronary angiography. Doctors can do a cardiac cath to look for problems in the heart chambers or valves (",
"      <a class=\"graphic graphic_figure graphicRef58389 \" href=\"mobipreview.htm?35/42/36516\">",
"       figure 1",
"      </a>",
"      ). To get information about the heart chambers or valves, doctors can measure the pressures or amounts of oxygen in the blood in different parts of the heart.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6753034\">",
"      <span class=\"h1\">",
"       How do I prepare for a cardiac cath?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor will tell you how to prepare for your cardiac cath. You should not eat or drink anything after midnight the night before your test. You might need to change your medicines or stop taking some of them beforehand.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6753049\">",
"      <span class=\"h1\">",
"       What happens during a cardiac cath?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A cardiac cath is done in the hospital. You will be awake during the procedure, but your doctor will give you medicine to help you feel relaxed.",
"     </p>",
"     <p>",
"      Your doctor will make a very small cut in the top, inner part of your leg, or in the middle of your arm. (He or she will numb this area first.) He or she will put a thin plastic tube, called a &ldquo;catheter,&rdquo; in a blood vessel below the cut. Then he or she will advance the tube through your blood vessels to your heart (",
"      <a class=\"graphic graphic_figure graphicRef77943 \" href=\"mobipreview.htm?16/37/16980\">",
"       figure 2",
"      </a>",
"      ). While this is happening, an X-ray will take pictures of the tube in your body. This helps your doctor know when the tube has reached the correct place in your heart.",
"     </p>",
"     <p>",
"      When the tube is in place, your doctor will do tests. If you are having coronary angiography, your doctor will inject a dye into the tube that shows up on an X-ray. This dye can show if any of the arteries in your heart are clogged. Your body might feel warm during this part of the test.",
"     </p>",
"     <p>",
"      If your arteries are clogged, your doctor might do a procedure to open them. If there is a chance you will have this procedure, your doctor will talk with you about it in his or her office before your cardiac cath (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/24/39298?source=see_link\">",
"       \"Patient information: Angioplasty and stenting for the heart (The Basics)\"",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6753064\">",
"      <span class=\"h1\">",
"       What happens after a cardiac cath?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After the procedure, your doctor will remove the tube from your body and put pressure on the cut to prevent bleeding. You will need to rest in the hospital for a few hours. You will probably be able to go home after that, but someone else will need to drive you. If your doctor fixes any of your arteries, you will probably need to stay in the hospital overnight.",
"     </p>",
"     <p>",
"      Before you leave, your doctor will tell you when you can drive and do your usual activities again. He or will make a follow-up appointment to see you in about a week to talk about the results of your cardiac cath.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6753079\">",
"      <span class=\"h1\">",
"       What problems can happen after a cardiac cath?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common problems are bleeding, bruising, and soreness in the area where the tube was put in. These problems can last for a few days, especially if the tube was put in the leg.",
"     </p>",
"     <p>",
"      Other problems can happen during or after a cardiac cath, but they are rare. They include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Heart attack",
"       </li>",
"       <li>",
"        Stroke (when a part of the brain goes without blood for too long)",
"       </li>",
"       <li>",
"        Death",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      A cardiac cath does involve a small amount of radiation. Too much radiation can cause serious health problems, such as cancer. The small amount of radiation from 1 cardiac cath will not cause any long-term problems in many people. But your doctor will talk with you about the possible long-term side effects of radiation.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6753094\">",
"      <span class=\"h1\">",
"       When should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse if any of the following happen after your cardiac cath:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The area where the tube went in bleeds a lot.",
"       </li>",
"       <li>",
"        You get a fever or have pain, swelling, or redness where the tube went in. These symptoms could mean that you have an infection.",
"       </li>",
"       <li>",
"        Your leg is weak or numb.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6753109\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/53/10068?source=see_link\">",
"       Patient information: Heart attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/34/21027?source=see_link\">",
"       Patient information: Chest pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/10/27809?source=see_link\">",
"       Patient information: Coronary heart disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/42/36514?source=see_link\">",
"       Patient information: Heart murmurs (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/24/39298?source=see_link\">",
"       Patient information: Angioplasty and stenting for the heart (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/16/40195?source=see_link\">",
"       Patient information: Heart attack (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/9/43157?source=see_link\">",
"       Patient information: Chest pain (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=see_link\">",
"       Patient information: Heart failure (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/38/18020?source=see_link\">",
"       Patient information: Heart stents and angioplasty (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/10/43170?source=see_link\">",
"       Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/53/35667?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16653 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E570A510C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_53_35667=[""].join("\n");
var outline_f34_53_35667=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6753019\">",
"      What is cardiac catheterization?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6753034\">",
"      How do I prepare for a cardiac cath?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6753049\">",
"      What happens during a cardiac cath?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6753064\">",
"      What happens after a cardiac cath?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6753079\">",
"      What problems can happen after a cardiac cath?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6753094\">",
"      When should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6753109\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16653\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/42/36516\">",
"      Chambers and valves of the heart",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/37/16980\">",
"       Cardiac catheterization",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/10/43170?source=related_link\">",
"      Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/24/39298?source=related_link\">",
"      Patient information: Angioplasty and stenting for the heart (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/9/43157?source=related_link\">",
"      Patient information: Chest pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/34/21027?source=related_link\">",
"      Patient information: Chest pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/10/27809?source=related_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/16/40195?source=related_link\">",
"      Patient information: Heart attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/53/10068?source=related_link\">",
"      Patient information: Heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/42/36514?source=related_link\">",
"      Patient information: Heart murmurs (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/38/18020?source=related_link\">",
"      Patient information: Heart stents and angioplasty (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_53_35668="Treatment of attention deficit hyperactivity disorder in children";
var content_f34_53_35668=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Treatment of attention deficit hyperactivity disorder in children (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?34/53/35668/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35668/contributors\" id=\"au4805\">",
"       Kevin R Krull, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?34/53/35668/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35668/contributors\" id=\"se219\">",
"       Marilyn Augustyn, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?34/53/35668/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35668/contributors\" id=\"de5754\">",
"       Mary M Torchia, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/53/35668?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Attention deficit hyperactivity disorder (ADHD) is a condition that causes trouble paying attention, hyperactivity, and impulsive behavior. It is often first recognized in early childhood. ADHD can affect a child's thinking, performance in school, behavior, feelings, and relationships with others. It often continues into adulthood.",
"    </p>",
"    <p>",
"     Treatments for ADHD include medicines, behavior training, counseling, and changes at school. These treatments can be used alone or in combination. The best treatment or combination of treatments depends on your child's situation. A doctor or nurse can guide you and your child as treatment begins.",
"    </p>",
"    <p>",
"     The treatment of attention deficit hyperactivity disorder in children and adolescents will be reviewed here. A topic that discusses the symptoms and diagnosis of ADHD is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/8/33922?source=see_link\">",
"      \"Patient information: Symptoms and diagnosis of attention deficit hyperactivity disorder in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     More detailed information about ADHD in children is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=see_link\">",
"      \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/19/14650?source=see_link\">",
"      \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32730?source=see_link\">",
"      \"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      DOES MY CHILD NEED ADHD TREATMENT?",
"     </span>",
"    </p>",
"    <p>",
"     Some parents wonder if treatment for ADHD is necessary. Most experts agree that unrecognized and untreated ADHD can have serious consequences, including school failure and drop out, depression, poor behavior, failed relationships, poor performance in the workplace, and drug or alcohol abuse. Treatment can help a child to:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Have better relationships with parents, teachers, siblings, or peers (eg, play without fighting at recess)",
"      </li>",
"      <li>",
"       Perform better in school (eg, finish school work)",
"      </li>",
"      <li>",
"       Follow rules (eg, not appear to be disobedient to the teacher)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      What treatment is best?",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most effective treatment for most school-aged children with ADHD is a stimulant medicine. Behavioral treatments and counseling are sometimes added if needed.",
"    </p>",
"    <p>",
"     Parents who prefer that their school-aged child avoid medicine should work closely with the child's doctor or nurse. While it is reasonable to consider using behavioral treatments alone, this may not work as well as medicine alone.",
"    </p>",
"    <p>",
"     The American Academy of Child and Adolescent Psychiatry, in partnership with the American Psychiatric Association, has developed a",
"     <a class=\"external\" href=\"file://www.parentsmedguide.org/pmg_adhd.html\">",
"      medicine guide for parents",
"     </a>",
"     .",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      ADHD STIMULANT MEDICINES",
"     </span>",
"    </p>",
"    <p>",
"     Stimulant medicines are the first-line ADHD treatment for school-aged children. However, there are criteria that must be met before medicine is considered. In addition, parents (and the child, when appropriate) should understand the need for close monitoring during treatment.",
"    </p>",
"    <p>",
"     Despite their name, stimulants do not cause a child with ADHD to become more stimulated, but instead improve communication between several areas of the brain. This helps to improve attention and concentration. However, medicines do not cure ADHD or teach the child to behave, work well with others, follow rules in school, or be motivated. Behavioral treatments can be added to the medicine to address these issues.",
"    </p>",
"    <p>",
"     Two medicines, methylphenidate and amphetamines, are the most commonly used stimulants for the treatment of ADHD.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Methylphenidate &ndash; Methylphenidate (sample brand names: Ritalin&reg;, Methylin&reg;, Concerta&reg;, Focalin&reg;, Metadate&reg;) is available as a tablet, capsule, and liquid.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Short-acting formulas are usually started with one dose per day, and then increased to twice daily.",
"      </li>",
"      <li>",
"       Long-acting formulas are usually taken once per day.",
"      </li>",
"      <li>",
"       A methylphenidate patch (brand name: Daytrana&reg;) is also available; the child wears the patch on the skin for up to nine hours per day.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Amphetamines &ndash; Amphetamines are also available in short-acting and long-acting formulas (sample brand names: Dexedrine&reg;, Dextrostat, Adderall&reg;).",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Lisdexamfetamine (brand name: Vyvanse&reg;) is a long-acting amphetamine that is taken once per day. It was developed to discourage drug abuse because it does not cause a \"high\" feeling.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      How well do stimulants work?",
"     </span>",
"     &nbsp;&mdash;&nbsp;If the short-acting stimulant dose is correct, it will begin to work within 30 to 40 minutes. If the dose is not correct (for example, if the dose is too small, which is common when starting treatment), most experts recommend waiting three to seven days before increasing the dose. Your doctor or nurse will tell you when or if you should increase your child's stimulant dose.",
"    </p>",
"    <p>",
"     At least 80 percent of children with ADHD will respond to a stimulant. However, is not clear if stimulants have a long-term benefit for the child's thinking, school performance, behavior, or feelings.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Stimulant medicines have a long history of being safe and working well when used properly, and few children have serious side effects. Stimulants are not addictive. Methylphenidate and amphetamines are equally likely to cause side effects. Some of the most common side effects include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Decreased appetite",
"      </li>",
"      <li>",
"       Trouble with sleep",
"      </li>",
"      <li>",
"       Weight loss",
"      </li>",
"      <li>",
"       Motor tics (sudden, involuntary movements)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Less common side effects include increased heart rate and blood pressure, headache, social withdrawal, nervousness, irritability, stomach pain, and moodiness.",
"    </p>",
"    <p>",
"     Many of these side effects are mild and temporary. Decreases in appetite can be improved by taking the medicines after meals, or eating within 30 to 40 minutes after taking the medicine.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Cardiovascular effects &ndash; Stimulants are not recommended for children with serious heart problems. There have been rare reports of serious side effects, including sudden unexpected death, in children taking stimulant medicines. However, it is not clear that the stimulant was the cause of death. Millions of children with ADHD have used stimulants and very few have had serious side effects.",
"      </li>",
"      <li>",
"       Psychiatric effects &ndash; There have been a small number of reports of children who take stimulant medicines developing suicidal thinking, hallucinations, or aggressive behavior.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Call your child's doctor or nurse if you notice irritability, anxiety, panic, difficulty sleeping, hostility, suicidal thinking or behavior, or other unusual changes in behavior. The child should also see a doctor or nurse on a regular basis while taking stimulant medicines.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Dosing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Stimulants are generally started at a low dose on the weekend so that parents can observe the child more closely. The dose and time the medicine is taken can be adjusted as needed (this is called \"titrating\" the dose).",
"    </p>",
"    <p>",
"     The child may need to try more than one medicine or dose to find the one that works best and has the fewest side effects. Typically, only one stimulant is used at a time.",
"    </p>",
"    <p>",
"     If the child needs to take medicine at school, he or she should have a separate bottle. A school nurse or faculty member should keep this medicine and give it to the child at the appropriate time. To avoid misuse and loss, the child should not keep the medicine in his or her school bag or desk.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Drug holidays",
"     </span>",
"     &nbsp;&mdash;&nbsp;A \"drug holiday\" is a time when medicine is not taken on the weekend or during school vacations. If you or your child is interested in trying a drug holiday, talk to the child's doctor or nurse.",
"    </p>",
"    <p>",
"     Certain children can consider trying a drug holiday, including those who:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Only need ADHD treatment on school days",
"      </li>",
"      <li>",
"       Are having trouble with weight loss because of an ADHD medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Stopping stimulants",
"     </span>",
"     &nbsp;&mdash;&nbsp;The length of treatment with a stimulant medicine depends upon the child's situation. For some children with ADHD, it is reasonable to consider a trial period without medicine. Talk to your child's doctor or nurse about the risks and benefits of stopping treatment.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      ATOMOXETINE (STRATTERA&reg;)",
"     </span>",
"    </p>",
"    <p>",
"     Atomoxetine (brand name: Strattera&reg;) is a non-stimulant medicine used in the treatment of ADHD. It is more expensive than stimulant medicines. Atomoxetine is an alternative to stimulants that can be used in patients with a history of drug abuse or who have family members with a history of drug abuse. It can also be used if a child has intolerable side effects with stimulants.",
"    </p>",
"    <p>",
"     Atomoxetine is usually taken once or twice per day, and is available only in capsule form. Capsules should not be opened or chewed. Drug holidays are not recommended with atomoxetine.",
"    </p>",
"    <p>",
"     Atomoxetine works as well as methylphenidate for treatment of ADHD.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Side effects of atomoxetine can include weight loss, decreased appetite, vomiting, nausea, upset stomach, and trouble sleeping. Severe liver injury has been reported in children and adults treated with atomoxetine. Call your child's doctor or nurse immediately if the child develops jaundice (yellowing of the skin or whites of the eyes), which is a sign of liver injury.",
"    </p>",
"    <p>",
"     There is also a small increased risk of suicidal thinking with atomoxetine, similar to stimulant medicines. (See",
"     <a class=\"local\" href=\"#H6\">",
"      'Side effects'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Other medicines",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are other medicines available to treat ADHD if stimulants or atomoxetine do not work or have unacceptable side effects. A developmental behavioral pediatrician, child psychiatrist, or psychopharmacologist is usually consulted in these situations.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      ADHD BEHAVIORAL TREATMENTS",
"     </span>",
"    </p>",
"    <p>",
"     Behavioral treatments for ADHD include changes in a child's environment, which are designed to help the child change his or her behavior.",
"    </p>",
"    <p>",
"     Behavioral treatments work to improve problems with:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Behavior and learning at school",
"      </li>",
"      <li>",
"       Relationships with friends, parents, and siblings",
"      </li>",
"      <li>",
"       Following through with adult requests",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A professional training program is recommended for parents because it can be difficult to learn these techniques and use them effectively without support. Adults can help to shape the behavior of a child who has ADHD with the following techniques:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Follow a daily schedule",
"      </li>",
"      <li>",
"       Keep distractions to a minimum",
"      </li>",
"      <li>",
"       Provide specific and logical places for the child to keep schoolwork, toys, and clothes",
"      </li>",
"      <li>",
"       Set small, reachable, and clear goals",
"      </li>",
"      <li>",
"       Reward positive behavior (eg, a sticker chart with a bigger reward for a certain number of stickers)",
"      </li>",
"      <li>",
"       Use charts and checklists to help the child stay \"on task\"",
"      </li>",
"      <li>",
"       Suggest physical activity breaks during tasks that require attention",
"      </li>",
"      <li>",
"       Limit choices",
"      </li>",
"      <li>",
"       Find activities where the child can be successful (eg, hobbies, sports)",
"      </li>",
"      <li>",
"       Use calm discipline (eg, time out, distraction, removing the child from the situation)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      ADHD AND SCHOOL",
"     </span>",
"    </p>",
"    <p>",
"     Children who are diagnosed with ADHD may need changes in how they are taught, including extra help with school work during or after class. This extra help can be given in the classroom or in a \"resource\" room setting.",
"    </p>",
"    <p>",
"     Other suggestions for teachers include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Write homework assignments down (on paper or send by email)",
"      </li>",
"      <li>",
"       Have the child sit near the front of the classroom",
"      </li>",
"      <li>",
"       Allow the child extra time to complete school work",
"      </li>",
"      <li>",
"       Give the child a private signal when he or she is \"off-task\"",
"      </li>",
"      <li>",
"       Use a daily report card to help parents to monitor their child's symptoms and how well the current ADHD treatment plan is working",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Sometimes children with ADHD also have learning disabilities. If attention and behavior improve with treatment, but the child still struggles with specific types of school work (eg, reading comprehension or mathematics), he or she may need to be evaluated for a specific learning disability.",
"    </p>",
"    <p>",
"     More information for teachers of children with ADHD is available through the",
"     <a class=\"external\" href=\"file://www.help4adhd.org/en/education\">",
"      National Resource Center on ADHD",
"     </a>",
"     .",
"    </p>",
"    <p>",
"     ADHD is considered to be a disability under the Individuals with Disabilities Education Act (IDEA [PL-101-476]). Under this act, children with ADHD may qualify for special education or related services. Alternatively, the child may qualify for changes in the regular classroom setting under Section 504 of the Rehabilitation Act of 1973.",
"    </p>",
"    <p>",
"     In addition, the Americans with Disabilities Act may provide individuals with ADHD reasonable accommodations in certain private schools and colleges (",
"     <a class=\"graphic graphic_table graphicRef76196 \" href=\"mobipreview.htm?43/29/44508\">",
"      table 1",
"     </a>",
"     ). To learn more about a child's educational rights, contact a local",
"     <a class=\"external\" href=\"file://www.parentcenternetwork.org/\">",
"      Parent Technical Assistance Center",
"     </a>",
"     (available in every state in the United States).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      COMPLEMENTARY AND ALTERNATIVE TREATMENTS FOR ADHD",
"     </span>",
"    </p>",
"    <p>",
"     Complementary and alternative medicine (CAM) treatments are treatments or products that are not considered to be part of conventional medicine. CAM treatments advertised to improve ADHD include vision training, special diets (eg, avoiding sugar, allergy triggers, or particular food additives), megavitamins, herbal and mineral supplements, EEG biofeedback, and applied kinesiology.",
"    </p>",
"    <p>",
"     These treatments are often used by parents of children with ADHD because of advertising that these treatments \"are safer than traditional medicines\", \"are natural\", or \"can cure ADHD\".",
"    </p>",
"    <p>",
"     However, studies have not confirmed the benefits of these treatments, and the risks are not well understood. One significant risk is that the treatment will fail and cause a setback for the child if symptoms of ADHD continue. Another risk is that these treatments are expensive; CAM therapies are generally not covered by health insurance.",
"    </p>",
"    <p>",
"     Any parent who is considering use of a CAM treatment should gather information about the safety, risks, and benefits of the treatment. You can find reliable information about alternative treatments from your child's healthcare team (physician, nurse, dietitian) and the",
"     <a class=\"external\" href=\"file://www.nccam.nih.gov/\">",
"      National Center for Complementary and Alternative Medicine",
"     </a>",
"     .",
"    </p>",
"    <p>",
"     If you are considering a complementary or alternative treatment for your child, ask the following questions:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Does it claim to cure ADHD and multiple other health problems? There is currently no known cure for ADHD, and no single treatment is likely to cure multiple health problems.",
"      </li>",
"      <li>",
"       Does it claim to be harmless or natural? Natural does not necessarily mean safe.",
"      </li>",
"      <li>",
"       Is it offered by only one individual or is it a secret that only certain people can share? Reputable treatments that work well should be available from any licensed healthcare professional.",
"      </li>",
"      <li>",
"       Is it based on multiple studies that have been published? To confirm the safety and benefit of a treatment, multiple clinical studies should be published in mainstream medical journals (see",
"       <a class=\"external\" href=\"file://www.pubmed.gov/\">",
"        www.pubmed.gov",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Is it expensive? Spending a large amount of money on a treatment that is not proven is risky.",
"      </li>",
"      <li>",
"       Is the group or person promoting the CAM treatment an expert in ADHD treatment? Verify the education and licensing of any person who claims to be an expert. All states within the United States have a licensing board that can verify a person's credentials.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      LIVING WITH ADHD",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Other family members",
"     </span>",
"     &nbsp;&mdash;&nbsp;Because ADHD is usually an inherited condition, parents and siblings of a child with ADHD could also have ADHD. Talk to your doctor or nurse to see if you should be evaluated. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/8/33922?source=see_link&amp;anchor=H9#H9\">",
"      \"Patient information: Symptoms and diagnosis of attention deficit hyperactivity disorder in children (Beyond the Basics)\", section on 'Diagnostic criteria'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Driving",
"     </span>",
"     &nbsp;&mdash;&nbsp;Adolescents with untreated ADHD are two to four times more likely to have motor vehicle accidents than those without ADHD. They also are more likely to have their driver's license suspended or revoked.",
"    </p>",
"    <p>",
"     As a result, parents of adolescents with ADHD should discuss the issues surrounding driving before the adolescent is licensed to drive. A longer period of supervision (eg, the adolescent drives with an adult) can help to ensure that the teen is able to use good judgment, can react quickly and carefully, and is safe to drive independently.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Discussing medicines",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you decide to use medicine to treat ADHD, you should discuss this decision with your child. This includes discussing:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       The purpose and expected benefits of the medicine",
"      </li>",
"      <li>",
"       The need for the child to follow the rules and make good choices with the help of the medicine",
"      </li>",
"      <li>",
"       The possible need to try more than one medicine or dose",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Diversion and misuse of stimulant medicines are common concerns of many parents.",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Diversion is defined as giving, selling, or trading stimulants",
"      </li>",
"      <li>",
"       Misuse is defined as using a stimulant in higher-than-prescribed doses or in combination with illegal drugs or alcohol",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Ways to avoid these problems include using long-acting medicines, keeping track of prescription dates, and talking to the child about the possibility that friends or peers may ask them to divert or misuse medicine.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Seek support",
"     </span>",
"     &nbsp;&mdash;&nbsp;Parenting a child with ADHD can be emotionally and physically exhausting, and most parents need support to cope. Support can come from multiple resources, including family, friends, and support groups. There are a number of organizations that can provide information about parenting a child with ADHD. (See",
"     <a class=\"local\" href=\"#H22\">",
"      'Where to get more information'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      ADHD in adulthood",
"     </span>",
"     &nbsp;&mdash;&nbsp;For many children, the effect of ADHD on behavior, social skills, and school performance continues into adolescence and adulthood. A separate topic discusses ADHD in adults. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/63/32761?source=see_link\">",
"      \"Adult attention deficit hyperactivity disorder\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       For adolescents or adults who have difficulty with organization and time management, certified \"coaches\" are available to provide support and instruction. Additional information about ADHD coaches can be obtained through the",
"       <a class=\"external\" href=\"file://www.help4adhd.org/en/living/coaching\">",
"        National Resource Center on ADHD",
"       </a>",
"       .",
"      </li>",
"      <li>",
"       Counseling or self-help groups also can provide support to adults with ADHD. Counseling is usually recommended along with medicines and skills training programs. Adults with newly diagnosed ADHD sometimes have a long history of low self-esteem, school failure, frequent job changes, and relationship problems.",
"      </li>",
"      <li>",
"       Counseling for married adults can focus on improving communication skills, resolving conflict and solving problems, and educating the patient's spouse about ADHD.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H221\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H181961584\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/32/11778?source=see_link\">",
"      Patient information: Attention deficit hyperactivity disorder (ADHD) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/42/3746?source=see_link\">",
"      Patient information: Medicines for attention deficit hyperactivity disorder (ADHD) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/4/12355?source=see_link\">",
"      Patient information: Fragile X syndrome (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H181961610\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/8/33922?source=see_link\">",
"      Patient information: Symptoms and diagnosis of attention deficit hyperactivity disorder in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=see_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4954?source=see_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/19/14650?source=see_link\">",
"      Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/39/34423?source=see_link\">",
"      Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32730?source=see_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32665?source=see_link\">",
"      Specific learning disabilities in children: Clinical features",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35944?source=see_link\">",
"      Specific learning disabilities in children: Evaluation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/63/32761?source=see_link\">",
"      Adult attention deficit hyperactivity disorder",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/attentiondeficithyperactivitydisorder.html\">",
"      www.nlm.nih.gov/medlineplus/attentiondeficithyperactivitydisorder.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Mental Health",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nimh.nih.gov/health/publications/attention-deficit-hyperactivity-disorder/complete-index.shtml\">",
"      www.nimh.nih.gov/health/publications/attention-deficit-hyperactivity-disorder/complete-index.shtml",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Children and Adults with Attention Deficit Hyperactivity Disorder",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.chadd.org/\">",
"      www.chadd.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?34/53/35668/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/53/35668?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35668/abstract/1\">",
"      Brown RT, Amler RW, Freeman WS, et al. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics 2005; 115:e749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35668/abstract/2\">",
"      A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999; 56:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35668/abstract/3\">",
"      Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, Wolraich M, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011; 128:1007.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: Diagnosis and management of ADHD in children, young people and adults. 2008. file://www.nice.org.uk/CG72 (Accessed on October 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35668/abstract/5\">",
"      Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:894.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f34_53_35668=[""].join("\n");
var outline_f34_53_35668=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           DOES MY CHILD NEED ADHD TREATMENT?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           ADHD STIMULANT MEDICINES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           ATOMOXETINE (STRATTERA&reg;)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           ADHD BEHAVIORAL TREATMENTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           ADHD AND SCHOOL",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           COMPLEMENTARY AND ALTERNATIVE TREATMENTS FOR ADHD",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           LIVING WITH ADHD",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/29/44508\" title=\"table 1\">",
"           Amer Disabilities Act PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f34_53_35669="Straddle injuries";
var content_f34_53_35669=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Straddle injuries",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/53/35669/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35669/contributors\">",
"     Donna Reyes Mendez, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/53/35669/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35669/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/53/35669/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35669/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/53/35669/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Straddle injuries occur when a child straddles an object as he or she falls, striking the urogenital area with the force of his or her body weight. Injury is caused by the compression of soft tissues against the bony margins of the pelvic outlet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/1\">",
"     1",
"    </a>",
"    ]. Straddle injuries are common in children and occur most often during bicycle riding, falls, and playing on monkey bars [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/52/12106?source=see_link\">",
"     \"Prevention of falls in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differentiation of straddle injuries from sexual abuse and the treatment for specific types of injury are presented here. The physical examination of the perineum is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10295?source=see_link\">",
"     \"The pediatric physical examination: The perineum\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43316?source=see_link\">",
"     \"Gynecologic examination of the newborn and child\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIFFERENTIATING STRADDLE INJURY FROM SEXUAL ABUSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful history and physical examination should be performed in children with straddle injuries. The history must correlate with the physical findings to confirm nonsexual trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/3\">",
"     3",
"    </a>",
"    ]. Examination of the child with a straddle injury may be difficult because of anxiety and pain. Pain may be controlled with the application of 2 percent",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    jelly to the affected area with a gauze pad. Sedation may be necessary to complete the examination or if sutures are indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Straddle injuries typically are unilateral and superficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. They involve the anterior portion of the genitalia in both boys and girls. Most straddle injuries in girls involve the mons, clitoral hood, and the labia minora anterior or lateral to the hymen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/6\">",
"     6",
"    </a>",
"    ]. Straddle injury to the hymen or posterior fourchette is less common and should raise concern for sexual abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/7\">",
"     7",
"    </a>",
"    ]. As an example, a laceration to the hymenal area that extends from 3 o'clock to 9 o'clock is consistent with a penetration injury and must be explored further [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/8\">",
"     8",
"    </a>",
"    ]. The examiner must have an understanding of normal hymenal variants if he or she is to identify abnormal hymenal findings caused by trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43316?source=see_link&amp;anchor=H10#H10\">",
"     \"Gynecologic examination of the newborn and child\", section on 'Evaluation of the hymen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Straddle injuries are classified as penetrating or nonpenetrating. Nonpenetrating injuries typically cause minor trauma to the external genitalia: superficial lacerations of the scrotum or penis in boys and lacerations or abrasions of the labia in girls. Perianal and testicular trauma rarely result from nonpenetrating injuries. Penetrating injuries are more serious and extensive (eg, vaginal-peritoneal perforation, rectal injury) and more often indicative of sexual assault [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following clinical findings in the evaluation of children with straddle injuries should prompt evaluation for sexual abuse and involvement of an experienced child protection team (eg, social worker, nurse, physician with more extensive experience in the management of child sexual abuse)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    referral to a child sexual abuse center, if available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/1,4,12,14\">",
"     1,4,12,14",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35258?source=see_link\">",
"     \"Evaluation of sexual abuse in children and adolescents\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infant younger than nine months",
"     </li>",
"     <li>",
"      Perianal, rectal, vaginal, or hymenal injury without history of penetrating trauma",
"     </li>",
"     <li>",
"      Extensive or severe trauma",
"     </li>",
"     <li>",
"      Presence of nonurogenital trauma",
"     </li>",
"     <li>",
"      Lack of correlation between history and physical findings",
"     </li>",
"     <li>",
"      Abnormal genital secretions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In many parts of the world (including the US, UK, and Australia), a mandatory report to appropriate governmental authorities is also required. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/5/35927?source=see_link&amp;anchor=H3#H3\">",
"     \"Child abuse: Social and medicolegal issues\", section on 'Reporting suspected abuse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Findings at examination that support unintentional injury include single or stellate lacerations and a bruise in the shape of the blunt object that was identified in the history as the cause of the injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT OF SPECIFIC INJURIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have straddle injuries may have associated injuries of the urethra, bladder, peritoneum, and rectum. As a general rule, any child with genital trauma should be kept inactive (except for toileting and tub baths) for the first 24 hours after injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Girls",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar trauma can cause significant bleeding because the area is highly vascular and the loose subcutaneous tissues afford little resistance to large hematoma formation. In addition, the immature labia do not have fat pads, which protect the vulvar area in adults. Vulvar hematomas and vulvar and vaginal lacerations are the primary straddle injuries in girls. The clinician needs to assure that the injury is fully seen and that the patient can void in order to determine the need for surgical intervention. Observational studies from pediatric referral centers suggest that up to 50 percent of these injuries result in surgical or gynecologic consultation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/1,5,12,15\">",
"     1,5,12,15",
"    </a>",
"    ]. Examination under anesthesia, conscious sedation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laceration repair is utilized in up to 40 percent of cases and is associated with hymenal injury, larger lacerations,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    major trauma with suspicion for pelvic floor or urethral disruption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Vulvar hematomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most vulvar hematomas do not require special treatment. They are classified as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Small &ndash; The size of a hen's egg",
"     </li>",
"     <li>",
"      Medium &ndash; The size of an orange",
"     </li>",
"     <li>",
"      Large &ndash; The size of a grapefruit or larger (greater than 15 cm in diameter)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most vulvar hematomas will resolve spontaneously. Small hematomas usually can be controlled by bedrest and applying pressure with an ice pack. Treatment with ice is recommended during the first 12 to 24 hours after injury to reduce edema. Warm tub baths or sitz baths three to four times per day may then be instituted. Tub baths keep the wound clean and may facilitate voiding in girls with mild urinary retention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/16\">",
"     16",
"    </a>",
"    ]. The ability to urinate should be assessed because large hematomas may obstruct the urethra. Occasionally, draining the bladder, usually by insertion of a suprapubic catheter, is necessary. Urinary retention that persists after the swelling subsides may indicate urethral avulsion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Large hematomas typically are managed with ice packs, bladder drainage, and analgesia. Sitz baths also may be used to remove secretions and contaminants. Pressure necrosis of the swollen external genitalia may be prevented by having the patient rest primarily on her side or back and use an air-filled rubber or foam \"doughnut\" when sitting.",
"   </p>",
"   <p>",
"    Surgical drainage usually is avoided because the small vessels that are involved in hematoma formation are difficult to identify. In addition, surgical disruption of the skin facilitates introduction of bacteria and may predispose the child to abscess formation. Hematomas that continue to increase in size may need surgical treatment to evacuate the clot and identify and ligate bleeding points.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Vulvar lacerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin suturing should be avoided in the treatment of vulvar lacerations. Usually, the best procedure is to allow wounds on the lateral walls of the vestibule to heal by secondary intent. Perineal sutures, if necessary, should be placed with the child under general anesthesia or conscious sedation to decrease additional trauma for the child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Vaginal injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most vaginal injuries occur as the result of penetrating trauma. The injury typically occurs when an object penetrates the vagina through the hymenal opening, creating a laceration or tear of the hymenal ring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/20\">",
"     20",
"    </a>",
"    ]. The object that pierces the perineum also may cause direct vaginal injury.",
"   </p>",
"   <p>",
"    Bleeding of vaginal origin is unlikely if the hymen is intact and a source of bleeding on the external genitalia exists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/16\">",
"     16",
"    </a>",
"    ]. Bleeding that occurs after hymenal injuries is often minimal and in itself requires no treatment. However, such injuries indicate vaginal penetration and possible vaginal injury. A detailed examination must be performed to exclude injuries of the upper vagina and intrapelvic viscera [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/21\">",
"     21",
"    </a>",
"    ]. This examination should be performed by a gynecologist while the patient is under general anesthesia.",
"   </p>",
"   <p>",
"    Many vaginal lacerations are superficial and limited to the mucosal and submucosal tissues. The child may not complain of pain, and usually little blood loss occurs unless a major vessel is torn. Lacerations confined to the vaginal mucosa are repaired with the child under general anesthesia with fine suture material placed deep into the wound to approximate the tissues and obtain hemostasis.",
"   </p>",
"   <p>",
"    Hematomas of the vaginal wall may occur if bleeding vessels are not ligated before repair of the overlying vaginal mucosa. As in vulvar hematomas, the pressure created by the blood clot usually controls the bleeding. These hematomas may be managed with observation and analgesia if active bleeding stops; the blood clot eventually will resorb and the swelling subside. However, if the bleeding continues, the repaired laceration should be opened, the blood clot evacuated, and the bleeding points ligated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/20\">",
"     20",
"    </a>",
"    ]. Packing the vagina also may be useful.",
"   </p>",
"   <p>",
"    The laceration may extend to the vaginal vault if the upper vagina has been penetrated directly by a sharp object. Exploratory laparotomy is necessary to rule out an extension of the tear into the broad ligament or the peritoneal cavity if such an injury is suspected. In addition, bladder and bowel integrity must be confirmed by catheterization and rectal palpation. Major blood vessels above the pelvic floor (eg, the ovarian, internal iliac, and external iliac vessels) may be torn in penetrating vaginal injuries that do not extend into the broad ligament. The vessels retract into the abdominal cavity after rupture, creating massive hemorrhage into the retroperitoneal space. Although the increased pressure caused by the hematoma may eventually control the bleeding, girls with such injuries may need intravascular fluid and blood replacement. In addition, large hematomas may compress the ureters and obstruct urinary flow. Exploratory laparotomy is necessary to evacuate the clot and ligate bleeding vessels if retroperitoneal hematomas continue to increase in size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Boys",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urethral injuries and penile and scrotal lacerations are the primary straddle injuries in boys.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Urethral injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Straddle injuries in boys may compress the bulbar urethra against the symphysis pubis, resulting in injury to the anterior urethra [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/22\">",
"     22",
"    </a>",
"    ]. Clinical findings of anterior urethral injury include blood at the meatus, difficulty voiding, and periurethral or perineal swelling or bruising [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/23\">",
"     23",
"    </a>",
"    ]. The diagnosis can be made by performing a retrograde urethrogram documenting extravasation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/23\">",
"     23",
"    </a>",
"    ]. Anterior urethral injuries typically are managed with 7 to 10 days of urethral catheterization and antibiotic therapy. More extensive injuries may require urinary diversion.",
"   </p>",
"   <p>",
"    Posterior urethral injuries usually occur with more extensive trauma, particularly in association with pelvic fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Clinical findings include blood at the meatus, inability to void, perineal bruising, and displacement of the prostate on rectal examination. Diagnosis is made with retrograde urethrogram. Long-term complications are more common in injuries proximal to the prostatomembranous region and include impotence, strictures, and urinary incontinence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Testicular and scrotal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular injury occurs when the testis is forced against the ramus of the pubic bone, causing the inelastic tunica albuginea to be torn. This injury is an uncommon one in infants and young boys because of the small size and mobility of the testicles. Diagnosis is confirmed with ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/23,25\">",
"     23,25",
"    </a>",
"    ]. Testicular injuries and hematomas should be managed in conjunction with a pediatric urologist. Penetrating testicular injuries require surgical exploration.",
"   </p>",
"   <p>",
"    Scrotal hematomas, ecchymoses, and injuries to the dartos can be managed with ice packs and scrotal support if no injury to the testes has occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/23\">",
"     23",
"    </a>",
"    ]. Superficial scrotal lacerations usually can be repaired with absorbable sutures with the child under local anesthesia. Urology should be consulted if the laceration extends through the dartos [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Penile injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt penile trauma may occur in straddle injury, but significant injury to the corporal bodies or the urethra rarely occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/23\">",
"     23",
"    </a>",
"    ]. In one case, high flow priapism was reported in a seven-year-old boy after a straddle injury that induced formation of an arteriocavernosal fistula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most boys with penile injuries can be managed with warm soaks, which may facilitate voiding. Superficial lacerations of the penile shaft can be repaired using absorbable sutures and with the child under local anesthesia. A urologist should be consulted for management of lacerations of the ventral surface of the penis and lacerations that extend to the corporal bodies or the urethra [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35669/abstract/23\">",
"     23",
"    </a>",
"    ]. Boys with these injuries should have a retrograde urethrogram to evaluate the extent of urethral injury. They may require urinary diversion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Straddle injuries are common in children and occur most often during bicycle riding, falls, and while playing on monkey bars. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unintentional straddle injuries typically are unilateral and superficial. They involve the anterior portion of the genitalia in both boys and girls. Adequate visualization of the genital injury may require procedural sedation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Differentiating straddle injury from sexual abuse'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"       \"Procedural sedation in children outside of the operating room\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In girls, vulvar hematomas and superficial vulvar lacerations that are not suspicious for sexual abuse are managed with sitz baths and local care. In most instances, suturing of vulvar lacerations is not indicated. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Vulvar hematomas'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Vulvar lacerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Girls with vaginal bleeding whose source cannot be seen on examination or with other evidence of penetrating injury to the vagina",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rectum should undergo examination under anesthesia and operative repair, as needed, by a pediatric surgeon or gynecologist. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Vaginal injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Boys with blood at the meatus, difficulty or inability to void, testicular rupture by ultrasound, or laceration through the dartos warrant evaluation by a pediatric urologist. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Urethral injuries'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Testicular and scrotal injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain clinical findings in the evaluation of children with straddle injuries should prompt investigation for sexual abuse (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Differentiating straddle injury from sexual abuse'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35258?source=see_link\">",
"       \"Evaluation of sexual abuse in children and adolescents\"",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Infant younger than nine months",
"     </li>",
"     <li>",
"      Perianal, rectal, vaginal, or hymenal injury without history of penetrating trauma",
"     </li>",
"     <li>",
"      Extensive or severe trauma",
"     </li>",
"     <li>",
"      Presence of nonurogenital trauma",
"     </li>",
"     <li>",
"      Lack of correlation between history and physical findings",
"     </li>",
"     <li>",
"      Abnormal genital secretions",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/1\">",
"      Dowd MD, Fitzmaurice L, Knapp JF, Mooney D. The interpretation of urogenital findings in children with straddle injuries. J Pediatr Surg 1994; 29:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/2\">",
"      Waltzman ML, Shannon M, Bowen AP, Bailey MC. Monkeybar injuries: complications of play. Pediatrics 1999; 103:e58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/3\">",
"      Benjamins LJ. Genital trauma in pediatric and adolescent females. J Pediatr Adolesc Gynecol 2009; 22:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/4\">",
"      Lynch JM, Gardner MJ, Albanese CT. Blunt urogenital trauma in prepubescent female patients: more than meets the eye! Pediatr Emerg Care 1995; 11:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/5\">",
"      Bond GR, Dowd MD, Landsman I, Rimsza M. Unintentional perineal injury in prepubescent girls: a multicenter, prospective report of 56 girls. Pediatrics 1995; 95:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/6\">",
"      Iqbal CW, Jrebi NY, Zielinski MD, et al. Patterns of accidental genital trauma in young girls and indications for operative management. J Pediatr Surg 2010; 45:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/7\">",
"      West R, Davies A, Fenton T. Accidental vulval injuries in childhood. BMJ 1989; 298:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/8\">",
"      Emans SJ, Woods ER, Flagg NT, Freeman A. Genital findings in sexually abused, symptomatic and asymptomatic, girls. Pediatrics 1987; 79:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/9\">",
"      Berenson A, Heger A, Andrews S. Appearance of the hymen in newborns. Pediatrics 1991; 87:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/10\">",
"      Berenson AB, Heger AH, Hayes JM, et al. Appearance of the hymen in prepubertal girls. Pediatrics 1992; 89:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/11\">",
"      McCann J, Voris J, Simon M, Wells R. Perianal findings in prepubertal children selected for nonabuse: a descriptive study. Child Abuse Negl 1989; 13:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/12\">",
"      Pokorny SF, Pokorny WJ, Kramer W. Acute genital injury in the prepubertal girl. Am J Obstet Gynecol 1992; 166:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/13\">",
"      Jones JG, Worthington T. Genital and anal injuries requiring surgical repair in females less than 21 years of age. J Pediatr Adolesc Gynecol 2008; 21:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/14\">",
"      Kini N, Lazoritz S. Evaluation for possible physical or sexual abuse. Pediatr Clin North Am 1998; 45:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/15\">",
"      Spitzer RF, Kives S, Caccia N, et al. Retrospective review of unintentional female genital trauma at a pediatric referral center. Pediatr Emerg Care 2008; 24:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/16\">",
"      Pokorny SF. Genital trauma. Clin Obstet Gynecol 1997; 40:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/17\">",
"      Propst AM, Thorp JM Jr. Traumatic vulvar hematomas: conservative versus surgical management. South Med J 1998; 91:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/18\">",
"      HUDOCK JJ, DUPAYNE N, MCGEARY JA. Traumatic vulvar hematomas; report of six cases and review of the literature. Am J Obstet Gynecol 1955; 70:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/19\">",
"      Benrubi G, Neuman C, Nuss RC, Thompson RJ. Vulvar and vaginal hematomas: a retrospective study of conservative versus operative management. South Med J 1987; 80:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/20\">",
"      Muram D. Genital tract injuries in the prepubertal child. Pediatr Ann 1986; 15:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/21\">",
"      Okur H, K&uuml;&ccedil;&iuml;kaydin M, Kazez A, et al. Genitourinary tract injuries in girls. Br J Urol 1996; 78:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/22\">",
"      Lim PH, Chng HC. Initial management of acute urethral injuries. Br J Urol 1989; 64:165.",
"     </a>",
"    </li>",
"    <li>",
"     Garcia CT. Genitourinary trauma. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1463.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/24\">",
"      Boone TB, Wilson WT, Husmann DA. Postpubertal genitourinary function following posterior urethral disruptions in children. J Urol 1992; 148:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/25\">",
"      Adams RJ, Attia M, Cronan K. Report of 4 cases of testicular rupture in adolescent boys secondary to sports-related trauma. Pediatr Emerg Care 2008; 24:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35669/abstract/26\">",
"      Dewan PA, Lorenz C, Davies RP. Posttraumatic priapism in a 7-year-old boy. Eur Urol 1994; 25:85.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6560 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-6A12EA632A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_53_35669=[""].join("\n");
var outline_f34_53_35669=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIFFERENTIATING STRADDLE INJURY FROM SEXUAL ABUSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT OF SPECIFIC INJURIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Girls",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Vulvar hematomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Vulvar lacerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Vaginal injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Boys",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Urethral injuries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Testicular and scrotal injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Penile injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/5/35927?source=related_link\">",
"      Child abuse: Social and medicolegal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35258?source=related_link\">",
"      Evaluation of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43316?source=related_link\">",
"      Gynecologic examination of the newborn and child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/52/12106?source=related_link\">",
"      Prevention of falls in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10295?source=related_link\">",
"      The pediatric physical examination: The perineum",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_53_35670="Complex sleep apnea";
var content_f34_53_35670=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complex sleep apnea",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/53/35670/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35670/contributors\">",
"     Sairam Parthasarathy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/53/35670/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35670/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/53/35670/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35670/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/53/35670/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H18678839\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complex sleep apnea (CompSA, also called &ldquo;treatment-emergent central sleep apnea&rdquo;) is the emergence or increase of central apneas and hypopneas during the initiation of continuous positive airway pressure therapy (or bilevel positive airway pressure without a backup respiratory rate) for obstructive sleep apnea (OSA). Alternative definitions of CompSA have been used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/1-5\">",
"     1-5",
"    </a>",
"    ], but they all share the presence of new or increased central apneas and hypopneas that prevent the apnea hypopnea index from normalizing despite the disappearance of obstructive apneas and hypopneas. CompSA is detected in up to 18 percent of patients who undergo positive airway pressure titration for OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/2,4,6-9\">",
"     2,4,6-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, clinical presentation, clinical findings, diagnostic criteria, and management of CompSA are reviewed here. The diagnosis and management of OSA and central sleep apnea are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=see_link\">",
"     \"Management of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/29/44502?source=see_link\">",
"     \"Central sleep apnea: Risk factors, clinical presentation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39239?source=see_link\">",
"     \"Central sleep apnea: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18678846\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CompSA is more common among men than women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. CompSA is also more common among patients with heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/7,9\">",
"     7,9",
"    </a>",
"    ], among patients with severe OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/10\">",
"     10",
"    </a>",
"    ], and among patients with a mixture of obstructive and central apneas during initial polysomnography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/10\">",
"     10",
"    </a>",
"    ]. Additional factors associated with CompSA include non-rapid eye movement sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], use of higher levels of continuous positive airway pressure (ie, over-titration) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/13\">",
"     13",
"    </a>",
"    ], use of a high pressure support level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/14\">",
"     14",
"    </a>",
"    ], high altitude [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/15\">",
"     15",
"    </a>",
"    ], oral breathing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/3\">",
"     3",
"    </a>",
"    ], opioid narcotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/4\">",
"     4",
"    </a>",
"    ], and, possibly, sleeping in a supine position (",
"    <a class=\"graphic graphic_table graphicRef84027 \" href=\"mobipreview.htm?4/4/4171\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18678853\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether or not CompSA and OSA are separate disorders is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The observation that CompSA and OSA respond differently to therapy suggests that they result from distinct pathophysiologic mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/1\">",
"     1",
"    </a>",
"    ]. Continuous positive airway pressure therapy and bilevel positive airway pressure therapy immediately reduce the apnea hypopnea index of patients with OSA. However, they do not reduce the apnea hypopnea index of patients with CompSA due to the appearance of central apneas.",
"   </p>",
"   <p>",
"    In contrast, the existence of numerous potential mechanisms by which treatment of OSA may induce central apneas suggests that CompSA and OSA are not separate disorders, but rather that the central apneas that characterize CompSA are merely an effect of treating the OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loop gain &ndash; Loop gain refers to the ratio of a corrective ventilatory response to a disturbance. If the response exceeds the disturbance (ie, loop gain &gt;1), then self-sustaining periodic breathing with central apneas may result. Patients with obstructive sleep apnea (OSA) frequently exhibit &ldquo;high loop gain&rdquo; or &ldquo;ventilatory instability&rdquo;, at baseline, which is augmented by positive airway pressure therapy. As a result, minor disturbances (eg, arousals from sleep) result in an exuberant corrective ventilatory response (ie, hyperpnea) and then central apnea if the arterial carbon dioxide tension (PaCO",
"      <sub>",
"       2",
"      </sub>",
"      ) falls below the apneic threshold. The central apnea, in turn, prompts a reciprocal corrective response, establishing a pattern of periodic breathing. High loop gain is more prevalent in patients with severe OSA than those with mild OSA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/10\">",
"       10",
"      </a>",
"      ], as well as in patients who receive bilevel positive airway pressure rather than continuous positive airway pressure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Carbon dioxide excretion &ndash; Positive airway pressure therapy relieves repetitive upper airway obstruction, which increases the elimination of carbon dioxide, lowers the PaCO",
"      <sub>",
"       2",
"      </sub>",
"      , and induces central apnea if the PaCO",
"      <sub>",
"       2",
"      </sub>",
"      falls below the apneic threshold [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/10,17-19\">",
"       10,17-19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stretch receptor activation &ndash; Positive airway pressure therapy activates stretch receptors, which inhibits central respiratory output and causes central apnea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these mechanisms directly link positive airway pressure therapy to the development of central apneas, it is important to realize that other factors may contribute in some situations. These include loss of the wakefulness stimulus to breath during sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/20\">",
"     20",
"    </a>",
"    ], baseline hypocapnia due to heart failure or high altitude [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/15\">",
"     15",
"    </a>",
"    ], and concomitant hypoxia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16270696\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9126221\">",
"    <span class=\"h2\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;CompSA presents as an incidental polysomnographic finding during the initial in-laboratory titration of continuous positive airway pressure therapy (or bilevel positive airway pressure without a backup respiratory rate) for obstructive sleep apnea. Specifically, central apneas and hypopneas emerge or increase during the titration, which prevent the apnea hypopnea index from normalizing despite the disappearance of obstructive apneas and hypopneas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link&amp;anchor=H3#H3\">",
"     \"Sleep related breathing disorders in adults: Definitions\", section on 'Apnea'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link&amp;anchor=H7#H7\">",
"     \"Sleep related breathing disorders in adults: Definitions\", section on 'Hypopnea'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link&amp;anchor=H12#H12\">",
"     \"Sleep related breathing disorders in adults: Definitions\", section on 'Apnea hypopnea index'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9126308\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who continue the same positive airway pressure regimen on which the CompSA was detected may remain asymptomatic or manifest symptoms and signs of disrupted sleep due to the central apneas and accompanying arousals. The symptoms and signs may include excessive daytime sleepiness, poor subjective sleep quality, repetitive awakenings, insomnia, fatigue, inattention, poor concentration, and moodiness. Patients may also report symptoms related to recurrent oxyhemoglobin desaturation, including morning headaches and nocturnal angina. Some patients describe paroxysmal nocturnal dyspnea due to the compensatory hyperpnea that follows a central apnea. Snoring is not a typical finding because patients with CompSA have had their recurrent upper airway obstruction alleviated by the positive airway pressure therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9126315\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no physical findings that are specific for CompSA. However, most patients have physical features that are typical of patients with OSA, including obesity, a large neck circumference,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a crowded upper airway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4855760\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CompSA is a polysomnographic phenomenon that occurs during the titration of positive airway pressure therapy for OSA. No additional diagnostic testing is indicated or required. Criteria used by the Centers for Medicare and Medicaid Services are generally accepted as diagnostic criteria for CompSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients must have confirmed OSA, defined as predominantly obstructive or mixed apneas occurring at a frequency of &ge;5 events per hour (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\", section on 'Diagnostic criteria'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Upon exposure to continuous positive airway pressure or bilevel positive airway pressure without backup rate, all of the following must be present:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Apnea hypopnea index &ge;5 events per hour",
"     </li>",
"     <li>",
"      Central apneas and hypopneas make up more than 50 percent of the apnea hypopnea index",
"     </li>",
"     <li>",
"      Central apnea hypopnea index &ge;5 events per hour",
"     </li>",
"     <li>",
"      Symptoms of excessive daytime sleepiness or disrupted sleep",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Obstructive apneas, central apneas, mixed apneas, hypopneas, and the apnea hypopnea index are defined separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link&amp;anchor=H3#H3\">",
"     \"Sleep related breathing disorders in adults: Definitions\", section on 'Apnea'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link&amp;anchor=H7#H7\">",
"     \"Sleep related breathing disorders in adults: Definitions\", section on 'Hypopnea'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link&amp;anchor=H12#H12\">",
"     \"Sleep related breathing disorders in adults: Definitions\", section on 'Apnea hypopnea index'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16270712\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;CompSA appears to vary over time. It generally begins with the initiation of continuous positive airway pressure therapy (or bilevel positive airway pressure without a backup rate), but by three months has resolved spontaneously in 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/1,3,4,22,23\">",
"     1,3,4,22,23",
"    </a>",
"    ] to 75 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/24\">",
"     24",
"    </a>",
"    ] of patients. CompSA can begin later than three months after the initiation of therapy, although this is uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18678874\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive airway pressure therapy should not be abandoned if a patient develops CompSA because there is extensive evidence that treatment of OSA improves clinical outcomes. Instead, options include changing the mode of positive airway pressure to either adaptive servo-ventilation (ASV) or bilevel positive airway pressure (BPAP) with a backup rate, or continuing the continuous positive airway pressure (CPAP).",
"   </p>",
"   <p>",
"    Unfortunately, there is no high quality evidence to guide the decision about whether to change to either ASV or BPAP with a backup respiratory rate, or to continue CPAP. The existing evidence is seriously limited because it consists of small trials that measured physiological outcomes rather than patient-important outcomes and were often funded by the makers of the positive airway pressure device being studied.",
"   </p>",
"   <p>",
"    Since the short-term risks of central apneas and hypopneas are generally uncertain and have not been well studied, it seems prudent in most cases to use ASV or BPAP with a backup rate if these alternative modes are available and affordable. However, if these modes are unavailable or too costly, continuing CPAP is preferable to discontinuing the treatment of OSA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18678881\">",
"    <span class=\"h2\">",
"     Adaptive servo-ventilation (ASV)",
"    </span>",
"    &nbsp;&mdash;&nbsp;ASV provides a varying amount of inspiratory pressure superimposed on a low level of CPAP, with a backup respiratory rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. The magnitude of the inspiratory pressure provided by the device is reciprocal to changes in peak flow, determined over a three to four minute moving window (",
"    <a class=\"graphic graphic_figure graphicRef84026 \" href=\"mobipreview.htm?5/35/5680\">",
"     figure 1",
"    </a>",
"    ). Thus, peak flows that are lower than the average peak flow induce an increase in the amount of inspiratory pressure; conversely, peak flows that are higher than the average peak flow induce a decrease in the amount of inspiratory pressure. The back-up respiratory rate can be set automatically by the device or manually and is an important aspect of ASV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. ASV is used to treat CompSA, central sleep apnea associated with Cheyne-Stokes breathing, and other types of central sleep apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39239?source=see_link&amp;anchor=H902709#H902709\">",
"     \"Central sleep apnea: Treatment\", section on 'Adaptive servo-ventilation (ASV)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Small clinical trials have consistently shown that the apnea hypopnea index (ie, the combined frequency of obstructive and central apneas and hypopneas) is lower in patients with CompSA during ASV therapy than during the initiation of CPAP therapy: 35 versus 6 events per hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/30\">",
"     30",
"    </a>",
"    ], 42 versus 1 event per hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/25\">",
"     25",
"    </a>",
"    ], 34 versus 8 events per hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/9\">",
"     9",
"    </a>",
"    ], 34 versus 6 events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/8\">",
"     8",
"    </a>",
"    ], and 44 versus 2 events per hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/31\">",
"     31",
"    </a>",
"    ]. These trials were seriously limited by imprecise estimates of effect due to their small size, as well as the use of physiologic rather than patient-important outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18678888\">",
"    <span class=\"h2\">",
"     Bilevel positive airway pressure (BPAP) with a back-up respiratory rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;BPAP delivers positive airway pressure at different, but fixed, levels during inspiration and expiration. The level during inspiration is called the inspiratory positive airway pressure (IPAP) and the level during expiration is called the expiratory positive airway pressure (EPAP). BPAP has two major effects. First, it splints the upper airway open. Second, it increases alveolar ventilation by augmenting the tidal volume. The tidal volume is directly related to the difference between the IPAP and EPAP. As an example, the tidal volume is greater when the IPAP is set at 15 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O and the EPAP at 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O (difference of 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O), than when the IPAP is set at 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O and the EPAP at 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O (difference of 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O).",
"   </p>",
"   <p>",
"    BPAP should be used with a set backup respiratory rate. The apnea hypopnea index is lower in patients with CompSA during BPAP with a backup respiratory rate than during the initiation of CPAP. This was demonstrated by a trial that included nine patients with CompSA and found that BPAP with a backup respiratory rate decreased the apnea hypopnea index from 42 to 6 events per hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/25\">",
"     25",
"    </a>",
"    ]. These results are supported by a retrospective cohort study that included 63 patients with CompSA and found that BPAP with a backup rate decreased the apnea hypopnea index from 30 to 13 events per hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/12\">",
"     12",
"    </a>",
"    ]. Indirect evidence from a randomized trial that enrolled 14 patients with central sleep apnea associated with Cheyne-Stokes breathing further supports the notion that BPAP with a backup rate decreases the apnea hypopnea index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to BPAP with a backup rate, BPAP without a backup rate does",
"    <strong>",
"     not",
"    </strong>",
"    decrease the apnea hypopnea index during BPAP compared with during the initiation of CPAP in patients with CompSA, and it may even worsen the apnea hypopnea index. This was suggested by a retrospective cohort study of 63 patients with CompSA that found that BPAP without a backup rate increased the apnea hypopnea index from 30 to 52 events per hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/12\">",
"     12",
"    </a>",
"    ] and supported by indirect evidence from a retrospective cohort study of 95 patients with various types of central apnea that found that BPAP without a backup rate was more likely to be associated with increasing central events than decreasing central events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/14\">",
"     14",
"    </a>",
"    ]. Therefore, BPAP without a back-up rate is not recommended in patients with CompSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10817986\">",
"    <span class=\"h2\">",
"     ASV versus BPAP with a back-up respiratory rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of ASV and BPAP with a backup respiratory rate have been directly compared in patients with CompSA. In a randomized trial that included nine patients with CompSA, ASV reduced the apnea hypopnea index from 52 to 1 event per hour while BPAP with a backup rate reduced the apnea hypopnea index from 52 to 6 events per hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/25\">",
"     25",
"    </a>",
"    ]. Similarly, in a retrospective cohort study of 63 patients with CompSA, the apnea hypopnea index of patients who received ASV decreased from 30 to 4 events per hour, while the apnea hypopnea index of patients who received BPAP with a backup rate decreased from 30 to 13 events per hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/12\">",
"     12",
"    </a>",
"    ]. These data suggest that both ASV and BPAP with a backup respiratory rate decrease the frequency of obstructive and central apnea and hypopneas, but ASV may have a slightly larger magnitude of effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18678895\">",
"    <span class=\"h2\">",
"     Continuous positive airway pressure (CPAP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;CPAP provides a constant level of positive airway pressure throughout inspiration and expiration. Observational studies have evaluated the course of patients with CompSA. These studies suggest that CompSA resolves spontaneously in approximately 50 percent of patients who continue to be treated with CPAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35670/abstract/4,22,23\">",
"     4,22,23",
"    </a>",
"    ]. Confidence in this estimate is limited by the high drop-out rates in the studies and possible selection bias of the population returning for serial polysomnography. The observation that CompSA resolves spontaneously in many patients who continue CPAP, suggests that continuing CPAP may be a viable treatment option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18679170\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complex sleep apnea (CompSA, also called &ldquo;treatment-emergent central sleep apnea&rdquo;) is the emergence or increase of central apneas and hypopneas during the titration of continuous positive airway pressure therapy (or bilevel positive airway pressure without a backup respiratory rate) for obstructive sleep apnea. (See",
"      <a class=\"local\" href=\"#H18678839\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CompSA presents as an incidental polysomnographic finding during the initial in-laboratory titration of continuous positive airway pressure therapy (or bilevel positive airway pressure without a backup respiratory rate) for obstructive sleep apnea. (See",
"      <a class=\"local\" href=\"#H9126221\">",
"       'Presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who continue the same positive airway pressure regimen on which the CompSA was detected may remain asymptomatic or manifest symptoms and signs of disrupted sleep due to the central apneas and accompanying arousals. They may also report symptoms related to recurrent oxyhemoglobin desaturation. There are no physical findings that are specific for CompSA, but most patients have physical features that are typical of patients with obstructive sleep apnea. (See",
"      <a class=\"local\" href=\"#H16270696\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic criteria for CompSA include the following (see",
"      <a class=\"local\" href=\"#H4855760\">",
"       'Diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients must have confirmed OSA, defined as predominantly obstructive or mixed apneas occurring at a frequency of &ge;5 events per hour.",
"     </li>",
"     <li>",
"      Upon exposure to continuous positive airway pressure or bilevel positive airway pressure without a backup respiratory rate, all of the following must be present: an apnea hypopnea index &gt;5 events per hour, central apneas and hypopneas make up more than 50 percent of the apnea hypopnea index, central apnea hypopnea index &gt;5 events per hours, and symptoms of excessive daytime sleepiness or disrupted sleep.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with CompSA, we recommend that positive airway pressure therapy not be discontinued (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For the same patients, we suggest adaptive servo-ventilation rather than continuous positive airway pressure (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) and we suggest adaptive servo-ventilation rather than bilevel positive airway pressure with a backup respiratory rate (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In situations in which adaptive servo-ventilation is not available or too expensive, bilevel positive airway pressure with a backup rate is a reasonable alternative. Bilevel positive airway pressure without a backup rate may be harmful. (See",
"      <a class=\"local\" href=\"#H18678874\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/1\">",
"      Gay PC. Complex sleep apnea: it really is a disease. J Clin Sleep Med 2008; 4:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/2\">",
"      Morgenthaler TI, Kagramanov V, Hanak V, Decker PA. Complex sleep apnea syndrome: is it a unique clinical syndrome? Sleep 2006; 29:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/3\">",
"      Malhotra A, Bertisch S, Wellman A. Complex sleep apnea: it isn't really a disease. J Clin Sleep Med 2008; 4:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/4\">",
"      Javaheri S, Smith J, Chung E. The prevalence and natural history of complex sleep apnea. J Clin Sleep Med 2009; 5:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/5\">",
"      Gilmartin GS, Daly RW, Thomas RJ. Recognition and management of complex sleep-disordered breathing. Curr Opin Pulm Med 2005; 11:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/6\">",
"      Marrone O, Stallone A, Salvaggio A, et al. Occurrence of breathing disorders during CPAP administration in obstructive sleep apnoea syndrome. Eur Respir J 1991; 4:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/7\">",
"      Lehman S, Antic NA, Thompson C, et al. Central sleep apnea on commencement of continuous positive airway pressure in patients with a primary diagnosis of obstructive sleep apnea-hypopnea. J Clin Sleep Med 2007; 3:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/8\">",
"      Westhoff M, Arzt M, Litterst P. Prevalence and treatment of central sleep apnoea emerging after initiation of continuous positive airway pressure in patients with obstructive sleep apnoea without evidence of heart failure. Sleep Breath 2012; 16:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/9\">",
"      Bitter T, Westerheide N, Hossain MS, et al. Complex sleep apnoea in congestive heart failure. Thorax 2011; 66:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/10\">",
"      Younes M, Ostrowski M, Thompson W, et al. Chemical control stability in patients with obstructive sleep apnea. Am J Respir Crit Care Med 2001; 163:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/11\">",
"      Thomas RJ, Terzano MG, Parrino L, Weiss JW. Obstructive sleep-disordered breathing with a dominant cyclic alternating pattern--a recognizable polysomnographic variant with practical clinical implications. Sleep 2004; 27:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/12\">",
"      Allam JS, Olson EJ, Gay PC, Morgenthaler TI. Efficacy of adaptive servoventilation in treatment of complex and central sleep apnea syndromes. Chest 2007; 132:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/13\">",
"      Buckle P, Millar T, Kryger M. The effect of short-term nasal CPAP on Cheyne-Stokes respiration in congestive heart failure. Chest 1992; 102:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/14\">",
"      Johnson KG, Johnson DC. Bilevel positive airway pressure worsens central apneas during sleep. Chest 2005; 128:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/15\">",
"      Nussbaumer-Ochsner Y, Schuepfer N, Ulrich S, Bloch KE. Exacerbation of sleep apnoea by frequent central events in patients with the obstructive sleep apnoea syndrome at altitude: a randomised trial. Thorax 2010; 65:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/16\">",
"      Ambrogio C, Lowman X, Kuo M, et al. Sleep and non-invasive ventilation in patients with chronic respiratory insufficiency. Intensive Care Med 2009; 35:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/17\">",
"      Meza S, Mendez M, Ostrowski M, Younes M. Susceptibility to periodic breathing with assisted ventilation during sleep in normal subjects. J Appl Physiol 1998; 85:1929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/18\">",
"      Dempsey JA. Crossing the apnoeic threshold: causes and consequences. Exp Physiol 2005; 90:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/19\">",
"      Skatrud JB, Dempsey JA, Badr S, Begle RL. Effect of airway impedance on CO2 retention and respiratory muscle activity during NREM sleep. J Appl Physiol 1988; 65:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/20\">",
"      Khoo MC, Gottschalk A, Pack AI. Sleep-induced periodic breathing and apnea: a theoretical study. J Appl Physiol 1991; 70:2014.",
"     </a>",
"    </li>",
"    <li>",
"     Local Coverage Determination (LCD) for Respiratory Assist Devices (L11493). https://www.noridianmedicare.com/dme/coverage/docs/lcds/current_lcds/respiratory_assist_devices.htm (Accessed on July 18, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/22\">",
"      Dernaika T, Tawk M, Nazir S, et al. The significance and outcome of continuous positive airway pressure-related central sleep apnea during split-night sleep studies. Chest 2007; 132:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/23\">",
"      Kuzniar TJ, Pusalavidyasagar S, Gay PC, Morgenthaler TI. Natural course of complex sleep apnea--a retrospective study. Sleep Breath 2008; 12:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/24\">",
"      Cassel W, Canisius S, Becker HF, et al. A prospective polysomnographic study on the evolution of complex sleep apnoea. Eur Respir J 2011; 38:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/25\">",
"      Morgenthaler TI, Gay PC, Gordon N, Brown LK. Adaptive servoventilation versus noninvasive positive pressure ventilation for central, mixed, and complex sleep apnea syndromes. Sleep 2007; 30:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/26\">",
"      Teschler H, D&ouml;hring J, Wang YM, Berthon-Jones M. Adaptive pressure support servo-ventilation: a novel treatment for Cheyne-Stokes respiration in heart failure. Am J Respir Crit Care Med 2001; 164:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/27\">",
"      Arzt M, Wensel R, Montalvan S, et al. Effects of dynamic bilevel positive airway pressure support on central sleep apnea in men with heart failure. Chest 2008; 134:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/28\">",
"      Pepperell JC, Maskell NA, Jones DR, et al. A randomized controlled trial of adaptive ventilation for Cheyne-Stokes breathing in heart failure. Am J Respir Crit Care Med 2003; 168:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/29\">",
"      Antonescu-Turcu A, Parthasarathy S. CPAP and bi-level PAP therapy: new and established roles. Respir Care 2010; 55:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/30\">",
"      Javaheri S, Goetting MG, Khayat R, et al. The performance of two automatic servo-ventilation devices in the treatment of central sleep apnea. Sleep 2011; 34:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/31\">",
"      Randerath WJ, Galetke W, Kenter M, et al. Combined adaptive servo-ventilation and automatic positive airway pressure (anticyclic modulated ventilation) in co-existing obstructive and central sleep apnea syndrome and periodic breathing. Sleep Med 2009; 10:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35670/abstract/32\">",
"      Ku��niar TJ, Kasibowska-Ku��niar K, Freedom T. Trials of bilevel positive airway pressure - spontaneous in patients with complex sleep apnoea. Pneumonol Alergol Pol 2012; 80:214.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14911 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-59FAC149C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_53_35670=[""].join("\n");
var outline_f34_53_35670=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18679170\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18678839\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18678846\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18678853\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16270696\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9126221\">",
"      Presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9126308\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9126315\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4855760\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16270712\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18678874\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18678881\">",
"      Adaptive servo-ventilation (ASV)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18678888\">",
"      Bilevel positive airway pressure (BPAP) with a back-up respiratory rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10817986\">",
"      ASV versus BPAP with a back-up respiratory rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18678895\">",
"      Continuous positive airway pressure (CPAP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18679170\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/14911\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/14911|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/35/5680\" title=\"figure 1\">",
"      Adaptive servo-ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/14911|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/4/4171\" title=\"table 1\">",
"      Complex sleep apnea contributors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/29/44502?source=related_link\">",
"      Central sleep apnea: Risk factors, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39239?source=related_link\">",
"      Central sleep apnea: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=related_link\">",
"      Sleep related breathing disorders in adults: Definitions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_53_35671="Sjögren-Larsson syndrome";
var content_f34_53_35671=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sj&ouml;gren-Larsson syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/53/35671/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35671/contributors\">",
"     Amy T Waldman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35671/contributors\">",
"     Alan K Percy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/53/35671/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35671/contributors\">",
"     Francisco Gonzalez-Scarano, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35671/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/53/35671/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35671/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/53/35671/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sj&ouml;gren-Larsson syndrome (SLS; MIM #270200) is an autosomal recessive neurocutaneous disorder caused by an inborn error of metabolism involving fatty alcohol oxidation. The disorder was first described in 1957 by Sj&ouml;gren and Larsson, who reported a series of 28 patients with a clinical triad of ichthyosis, spastic diplegia or quadriplegia, and mental retardation (oligophrenia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the pathogenesis, clinical features, diagnosis, and management of SLS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sj&ouml;gren-Larsson syndrome is a disorder of fatty alcohol metabolism (",
"    <a class=\"graphic graphic_figure graphicRef82067 \" href=\"mobipreview.htm?1/49/1812\">",
"     figure 1",
"    </a>",
"    ) caused by a deficiency of the enzyme fatty aldehyde dehydrogenase (FALDH), a component of the fatty alcohol:nicotinamide-adenine dinucleotide oxidoreductase (FAO) enzyme complex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FAO is composed of two distinct proteins that sequentially catalyze the oxidation of fatty alcohols to fatty aldehydes and then to fatty acids (",
"    <a class=\"graphic graphic_figure graphicRef66427 \" href=\"mobipreview.htm?13/30/13806\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fatty alcohol dehydrogenase (FADH), which catalyzes the oxidation of medium- and long-chain fatty alcohols to fatty aldehydes",
"     </li>",
"     <li>",
"      FALDH, which catalyzes the oxidation of fatty aldehydes to fatty acids",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lipid accumulation is the probable mechanism of cutaneous and neurologic disease in SLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Fatty alcohols accumulate in the skin, disrupting the epidermal water barrier, and resulting in transepidermal water loss and ichthyosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/3\">",
"     3",
"    </a>",
"    ]. Despite their disrupted oxidation, the plasma concentration of fatty alcohols is not elevated in all patients with SLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the precise mechanism of neurologic disease in SLS is uncertain, the deficiency of fatty alcohol oxidation may impair the structural",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    functional integrity of myelin membranes in the central nervous system, thereby leading to the neurologic features, including leukoencephalopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In SLS, myelination is delayed, and some patients have unmyelinated subcortical association fibers, suggesting that the process of myelination does not reach completion in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Myelin deficiency (retarded myelination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dysmyelination) may involve the brainstem (corticospinal tracts) and, in severe cases, the corpus callosum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. The cerebellum and cerebral gray matter are spared [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The deficiency of FALDH also affects the metabolism of leukotriene B4 (LTB4), a proinflammatory mediator. Normally, LTB4 is inactivated by sequential oxidation, first to omega-hydroxy-LTB4, then to omega-aldehyde-LTB4, and lastly, in a step catalyzed by FALDH, to omega-carboxy-LTB4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]. Other pathways cannot compensate for the FALDH deficiency in patients with SLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/10\">",
"     10",
"    </a>",
"    ], leading to accumulation of LTB4 and omega-hydroxy-LTB4. These products are probably responsible for the severe pruritus that is characteristic of the disease. However, it is unclear if the defective degradation of LTB4 contributes to the neurologic involvement in SLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sj&ouml;gren-Larsson syndrome is caused by mutations in the FALDH (ALDH3A2) gene on chromosome 17p11.2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. There are multiple mutations in the FALDH gene that can lead to the phenotype of SLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/12,13,15,16\">",
"     12,13,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Vasterbotten county, Sweden, where Sj&ouml;gren and Larsson identified this syndrome, the prevalence of SLS was 8.3 per 100,000, perhaps due to inbreeding, whereas the overall prevalence in Sweden was 0.4 per 100,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/17\">",
"     17",
"    </a>",
"    ]. Although SLS occurs worldwide in various ethnic groups, the prevalence and incidence outside of Sweden are unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sj&ouml;gren-Larsson syndrome is associated with the following characteristic clinical features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/1,4,15,19\">",
"     1,4,15,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ichthyosis and pruritus",
"     </li>",
"     <li>",
"      Spastic diplegia or quadriplegia",
"     </li>",
"     <li>",
"      Mental retardation",
"     </li>",
"     <li>",
"      Ocular abnormalities: photophobia, macular degeneration with retinal crystals, and decreased visual acuity",
"     </li>",
"     <li>",
"      Leukoencephalopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The neurologic manifestations of SLS superficially resemble those of cerebral palsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Most of the clinical symptoms of SLS are apparent in the first years of life, after which they persist with little or no change [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/7,15,20\">",
"     7,15,20",
"    </a>",
"    ]. In older children and adults, there is no apparent correlation of disease severity with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, the severity of the cutaneous symptoms does not correlate with severity of the neurologic manifestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even within individual families affected by SLS, there is phenotypic heterogeneity. Some children have a mild form of SLS, with less severe dermatologic and neurologic difficulties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cutaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dermatologic features are typically the earliest presenting symptoms, beginning with skin erythema at birth. In the latter half of the first year of life, the skin becomes dry, rough, and scaly, due to a defect in keratinization, and it has a brown-yellow discoloration. The flexor surfaces of the extremities, neck, axilla, and umbilicus are predominantly affected, while the face is usually spared.",
"   </p>",
"   <p>",
"    Severe pruritus is nearly universal in SLS and distinguishes SLS from other ichthyoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A collodion membrane at birth (\"collodion baby\") is unusual in SLS, whereas it is characteristic of lamellar ichthyosis and congenital ichthyosiform erythroderma. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Motor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with SLS usually develop pyramidal signs in the first two years of life. The legs are usually more severely affected than the arms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/4\">",
"     4",
"    </a>",
"    ]. Despite the insidious onset of the spasticity, children with SLS may nevertheless learn to walk. However, most become wheelchair dependent during late childhood or early adolescence, and joint contractures frequently develop in the legs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/15\">",
"     15",
"    </a>",
"    ]. Generalized dystonia was reported in one child with SLS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cognitive",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developmental delay is usually apparent during the first year of life, and most patients with SLS have mild to moderate mental retardation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/15\">",
"     15",
"    </a>",
"    ]. However, a minority have normal intelligence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/5\">",
"     5",
"    </a>",
"    ]. The disease is not neurodegenerative, and there is usually no loss of acquired skills.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Speech and language",
"    </span>",
"    &nbsp;&mdash;&nbsp;Speech and language problems in SLS are related to both motor and cognitive impairments. In one series, children severely affected with SLS could speak only in short sentences and often produced incomprehensible syllables due to pseudobulbar dysarthria, whereas language comprehension was relatively spared [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ocular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinal crystals, which appear as foveal and perifoveal glistening white dots, are present in all patients with SLS beginning in early childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/4,23,24\">",
"     4,23,24",
"    </a>",
"    ]. Younger patients are often difficult to examine due to poor cooperation related to photophobia during the funduscopic examination; this problem may explain the absence of reports of retinal crystals in children younger than two to four years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decreased visual acuity is common in SLS, and in some patients may be due to dysmyelination of the optic tracts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Additional",
"    </span>",
"    &nbsp;&mdash;&nbsp;The affected children are often born prematurely. The frequency of seizures in patients with SLS ranges from 0 to 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/4,5,19\">",
"     4,5,19",
"    </a>",
"    ]. Growth delay and contractures may lead to short stature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with SLS, brain magnetic resonance imaging (MRI) shows delayed myelination (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68733 \" href=\"mobipreview.htm?3/59/4016\">",
"     image 1",
"    </a>",
"    ) with high signal on T2-weighted imaging in the periventricular white matter with either frontal (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61461 \" href=\"mobipreview.htm?23/23/23920\">",
"     image 2",
"    </a>",
"    ) or parieto-occipital (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82286 \" href=\"mobipreview.htm?13/34/13856\">",
"     image 3",
"    </a>",
"    ) predominance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/7\">",
"     7",
"    </a>",
"    ]. The same areas appear normal or mildly hypointense on T1-weighted images. The severity of white matter abnormalities on MRI does not correlate with the age of the patient or the symptomatology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some patients, magnetic resonance spectroscopy (MRS) shows a high abnormal lipid peak measuring 1.3 ppm in the periventricular white matter, especially around the frontal and posterior trigones, with a greater prominence in the latter (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59484 \" href=\"mobipreview.htm?43/42/44704\">",
"     image 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/7\">",
"     7",
"    </a>",
"    ]. The lipid peak suggests local accumulation of the unusual free lipids or lipophilic substances, such as long-chain fatty alcohols. In one study, two patients had this abnormality on MRS before white matter abnormalities were detectable on conventional MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/4\">",
"     4",
"    </a>",
"    ]. The intensity of the white matter lipid peak at 1.3 ppm may be inversely correlated with age in adults with SLS, leading to speculation that an unknown compensatory mechanism leads to reduced lipid accumulation and disease severity over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the cerebral white matter, MRS shows another, smaller peak at 0.8 to 0.9 ppm. The peaks at 0.8 to 0.9 and 1.3 ppm reflect the methyl (CH3) and methylene (CH2) groups on separate lipid molecules. In addition, creatine, choline, and myoinositol were elevated in cerebral white matter, while N-acetylaspartate and glutamate were normal. These findings on MRS suggest that SLS leads to gliosis without significant axonal loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key findings in SLS are gliosis and absence of myelin. Multiple features reflecting abnormal myelin structure have been reported. The cerebral white matter, cerebellar white matter, and pyramidal tracts have a decreased number of myelinated nerve fibers. One autopsy report revealed a reduction of in the number of axons in the retina and optic nerve, as well as a loss of neurons in the lateral geniculate bodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/25\">",
"     25",
"    </a>",
"    ]. While some axonal loss occurs, gliosis is more striking. Gross sections of brain reveal diffuse cerebral atrophy with gliosis.",
"   </p>",
"   <p>",
"    Microscopically, lipoid deposits are found in multiple regions, including subpial, subependymal, and perivascular glial layers; subpial and perivascular spaces; cerebral white matter; and the brainstem. Perivascular macrophages contain lipofuscin-like pigments in the cytoplasm that probably represent the breakdown products of the lipoid substances. Similarly, ellipsoid bodies, found in the white matter, subpial, and periventricular glial layers, may reflect degraded products of the astrocytic processes as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/26\">",
"     26",
"    </a>",
"    ]. Finally, spheroid bodies, representing axonal injury, have been reported in the relay nuclei, reticular formation, and periventricular gray matter of the fourth ventricle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of SLS is confirmed by demonstrating fatty aldehyde dehydrogenase (FALDH) deficiency in cultured skin fibroblasts or leukocytes. In patients with SLS, the activity of FALDH is reduced to &lt;15 percent of normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the genetic diagnosis of SLS can be confirmed by mutation analysis of the ALDH3A2 gene that encodes FALDH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of SLS should be suspected in infants and children with both ichthyosis and neurologic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/5\">",
"     5",
"    </a>",
"    ]. The diagnosis may be delayed or missed in the neonatal period and early infancy, a time when the cutaneous manifestations are typically mild [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/15\">",
"     15",
"    </a>",
"    ], and the neurologic signs and symptoms are usually occult. However, suspicion for the diagnosis of SLS should be raised in any infant with congenital ichthyosis, particularly when the ichthyosis has the characteristic brownish-yellow discoloration and wrinkled hyperkeratosis observed in SLS.",
"   </p>",
"   <p>",
"    The preferred method for prenatal diagnosis involves amniocentesis or chorionic villus sampling; the prenatal diagnosis can be made by demonstrating deficient FAO and FALDH activity in amniocytes and cultured chorionic villi cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. The prenatal diagnosis of SLS was first demonstrated by fetal skin biopsy at 23-weeks gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/29\">",
"     29",
"    </a>",
"    ], but the diagnosis can be missed if the analysis is performed earlier in the pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical presenting symptoms of SLS in newborns and early infancy are dermatologic, and the differential diagnosis includes the primary ichthyoses. Once neurologic symptoms have developed, neuroichthyotic disorders must be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Primary ichthyoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ichthyoses are a heterogeneous group of dermatoses caused by abnormal keratinization with variable modes of inheritance. Ichthyosis may be a primary disorder, in which the skin is predominantly or solely affected, or a component of a multisystem disorder. The dermatologic features of SLS may resemble those of several primary ichthyoses:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ichthyosis vulgaris (MIM #146700)",
"     </li>",
"     <li>",
"      X-linked ichthyosis (MIM +308100)",
"     </li>",
"     <li>",
"      Lamellar ichthyosis (MIM #242300)",
"     </li>",
"     <li>",
"      Congenital ichthyosiform erythroderma (MIM #242100)",
"     </li>",
"     <li>",
"      Epidermolytic hyperkeratosis (MIM #113800)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These disorders are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24586?source=see_link&amp;anchor=H2#H2\">",
"     \"The genodermatoses\", section on 'Disorders of keratinization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Neurocutaneous disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in SLS, ichthyosis may also be seen in other systemic, metabolic, and neurologic diseases. Although data are limited, anecdotal observations indicate that only about one-half of patients with cutaneous and neurologic features of SLS turn out to have FALDH deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pseudo-SLS is a term sometimes applied to an SLS-like disorder when the etiology cannot be established [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Refsum disease (MIM #266500) is an autosomal recessive disorder associated with the accumulation of phytanic acid in plasma and tissues. The skin manifestations are typically mild, resembling ichthyosis vulgaris. Other symptoms include night blindness due to atypical retinitis pigmentosa, peripheral neuropathy, cerebellar ataxia, and elevated protein concentration in the cerebrospinal fluid. Classic Refsum disease is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/602?source=see_link&amp;anchor=H13#H13\">",
"       \"Hereditary neuropathies associated with generalized disorders\", section on 'Refsum disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rud syndrome (MIM 308200) is another ichthyosis that presents in infancy. In addition to the skin manifestations, the most common symptoms are hypogonadism and mental retardation. The index patient suffered from ichthyosis, infantilism, hypogonadism, small stature, epilepsy, macrocytic anemia, tetany, and polyneuritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chanarin-Dorfman syndrome (MIM #275630), also known as neutral lipid storage disease with ichthyosis, is an autosomal recessive disorder characterized by ichthyosis, mild myopathy, and hepatomegaly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/32-35\">",
"       32-35",
"      </a>",
"      ] due to mutations in the CGI-58 (ABHD5) gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/36\">",
"       36",
"      </a>",
"      ]. Intracellular lipid vacuoles are present in most tissues.",
"     </li>",
"     <li>",
"      Gaucher disease type 2 (MIM #230900) is an autosomal recessive disorder that results from deficiency of glucocerebrosidase. It is characterized by early onset, typically in the first year after birth, and by rapidly progressive neurologic deterioration. Visceral involvement is extensive and severe. This disorder rarely presents with congenital ichthyosis or \"collodion baby.\" (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/11/9402?source=see_link&amp;anchor=H19#H19\">",
"       \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\", section on 'Type 2 (GD2)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Multiple sulfatase deficiency (MIM #272200) is an autosomal recessive disorder caused by mutations in the sulfatase modifying factor 1 gene (SUMF1 gene) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/37-39\">",
"       37-39",
"      </a>",
"      ]. Affected patients develop enzymatic and phenotypic features of multiple individual sulfatase deficiencies, including features of metachromatic leukodystrophy due to arylsulfatase A deficiency, and ichthyosis due to steroid sulfatase deficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no cure for SLS. However, most patients with SLS survive until adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/18\">",
"     18",
"    </a>",
"    ]. Management involves therapies directed towards controlling ichthyosis, spastic paraparesis, contractures, seizures, and ocular problems.",
"   </p>",
"   <p>",
"    Most children with SLS require a broad range of interventions as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Speech and language therapy",
"     </li>",
"     <li>",
"      Occupational therapy",
"     </li>",
"     <li>",
"      Physical therapy and rehabilitation including mobility and postural support",
"     </li>",
"     <li>",
"      Family counseling and support",
"     </li>",
"     <li>",
"      Behavioral intervention",
"     </li>",
"     <li>",
"      Educational assistance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evaluation and management of mental retardation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/8/5257?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40887?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Management; outcomes; and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some children may benefit from surgical procedures for spasticity and joint contractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrent seizures are managed with standard anticonvulsants. General recommendations for the evaluation and management of seizures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37386?source=see_link\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gene therapy is under investigation as a possible treatment option for SLS. In a preliminary study, delivery of a recombinant viral vector containing the human cDNA of functional FALDH into keratinocytes derived from patients with SLS restored FALDH activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/41\">",
"     41",
"    </a>",
"    ]. Further research is needed to determine the clinical utility of this method as a treatment for SLS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Skin care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ichthyosis and pruritus are treatable but require constant attention and care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/18\">",
"     18",
"    </a>",
"    ]. These cutaneous symptoms are managed with keratolytic agents and measures to maintain skin hydration, including daily water baths and topical moisturizing creams [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/21\">",
"     21",
"    </a>",
"    ]. Moisturizers include preparations that contain urea or lactate (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19059?source=see_link\">",
"     lactic acid with ammonium hydroxide",
"    </a>",
"    ) and come in different vehicles and strengths. Topical retinoids have been used successfully to treat the ichthyosis in adults; however, their use in children is limited due to side effects.",
"   </p>",
"   <p>",
"    Dietary restriction of lipids with supplementation of medium-chain triglycerides was initially reported to be promising for reducing cutaneous symptoms and behavioral disturbances in two patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/42\">",
"     42",
"    </a>",
"    ], but was not beneficial in later studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/29,43\">",
"     29,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17940?source=see_link\">",
"     Zileuton",
"    </a>",
"    , a drug that inhibits the synthesis of leukotriene B4, may be used to treat pruritus in patients with SLS. However, evidence of benefit is limited to a case report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/44\">",
"     44",
"    </a>",
"    ] and a small case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35671/abstract/45\">",
"     45",
"    </a>",
"    ]. In the latter report, pruritus was improved at three months in four of five patients with SLS (14 to 21 years old) who were treated with zileuton 600 mg three times daily for the first six weeks and 600 mg four times daily for the last six weeks of the study.",
"   </p>",
"   <p>",
"    Given these data, we suggest treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17940?source=see_link\">",
"     zileuton",
"    </a>",
"    600 mg three to four times daily for severe refractory pruritus in patients with SLS, despite the unproven benefit. Of note, zileuton is not approved for use in SLS, and safety has not been established in children &lt;12 years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sj&ouml;gren-Larsson syndrome is a disorder of fatty alcohol metabolism caused mutations in the ALDH3A2 gene that encodes for the enzyme fatty aldehyde dehydrogenase (FALDH). Lipid accumulation is the probable mechanism of cutaneous and neurologic disease in SLS. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sj&ouml;gren-Larsson syndrome is associated with the following characteristic clinical features (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ichthyosis and pruritus",
"     </li>",
"     <li>",
"      Spastic diplegia or quadriplegia",
"     </li>",
"     <li>",
"      Mental retardation",
"     </li>",
"     <li>",
"      Ocular abnormalities: photophobia, macular degeneration with retinal crystals, and decreased visual acuity",
"     </li>",
"     <li>",
"      Leukoencephalopathy",
"      <br/>",
"      <br/>",
"      The dermatologic features are typically the earliest presenting symptoms. Severe pruritus is nearly universal in SLS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Brain MRI shows delayed myelination with high signal on T2-weighted imaging in the periventricular white matter with either frontal or parieto-occipital predominance. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of SLS is confirmed by demonstrating FALDH deficiency in cultured skin fibroblasts or leukocytes. The genetic diagnosis of SLS can be confirmed by mutation analysis of the ALDH3A2 gene that encodes FALDH. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the neonatal period and early infancy, the differential diagnosis of SLS includes the primary ichthyoses, particularly X-linked ichthyosis, lamellar ichthyosis, and congenital ichthyosiform erythroderma. Once neurologic symptoms have developed, neuroichthyotic disorders must be considered. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no cure for SLS. However, most patients survive until adulthood. Management involves therapies directed towards controlling ichthyosis, spastic paraparesis, contractures, seizures, and ocular problems. The spastic paraparesis and mild to moderate mental retardation that occurs with SLS are addressed by multidisciplinary interventions and educational assistance. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cutaneous symptoms of SLS are treatable with keratolytic agents and measures to maintain skin hydration, including daily water baths and topical moisturizing creams. For patients &ge;12 years old with SLS who have severe pruritus refractory to keratolytic agents and measures to maintain skin hydration, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17940?source=see_link\">",
"       zileuton",
"      </a>",
"      600 mg three to four times daily (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This recommendation to use zileuton places a relatively high value on a possible but uncertain benefit for improvement of pruritus, and a low value on the high cost and potential risks of such treatment. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Skin care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/1\">",
"      SJOGREN T, LARSSON T. Oligophrenia in combination with congenital ichthyosis and spastic disorders; a clinical and genetic study. Acta Psychiatr Neurol Scand Suppl 1957; 113:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/2\">",
"      Rizzo WB, Dammann AL, Craft DA. Sj&ouml;gren-Larsson syndrome. Impaired fatty alcohol oxidation in cultured fibroblasts due to deficient fatty alcohol:nicotinamide adenine dinucleotide oxidoreductase activity. J Clin Invest 1988; 81:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/3\">",
"      Rizzo WB, Craft DA. Sj&ouml;gren-Larsson syndrome. Deficient activity of the fatty aldehyde dehydrogenase component of fatty alcohol:NAD+ oxidoreductase in cultured fibroblasts. J Clin Invest 1991; 88:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/4\">",
"      van Domburg PH, Willemsen MA, Rotteveel JJ, et al. Sj&ouml;gren-Larsson syndrome: clinical and MRI/MRS findings in FALDH-deficient patients. Neurology 1999; 52:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/5\">",
"      Rizzo WB. Sj&ouml;gren-Larsson syndrome: explaining the skin-brain connection. Neurology 1999; 52:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/6\">",
"      Willemsen MA, de Jong JG, van Domburg PH, et al. Defective inactivation of leukotriene B4 in patients with Sj&ouml;gren-Larsson syndrome. J Pediatr 2000; 136:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/7\">",
"      Willemsen MA, Van Der Graaf M, Van Der Knaap MS, et al. MR imaging and proton MR spectroscopic studies in Sj&ouml;gren-Larsson syndrome: characterization of the leukoencephalopathy. AJNR Am J Neuroradiol 2004; 25:649.",
"     </a>",
"    </li>",
"    <li>",
"     van der Knaap, MS, Valk, J. Sj&ouml;gren-Larsson Syndrome. In: Magnetic Resonance of Myelination and Myelin Disorders, 3rd Edition. Springer: New York 2005 p.384.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/9\">",
"      Willemsen MA, Rotteveel JJ, de Jong JG, et al. Defective metabolism of leukotriene B4 in the Sj&ouml;gren-Larsson syndrome. J Neurol Sci 2001; 183:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/10\">",
"      Sutyak J, Austen KF, Soberman RJ. Identification of an aldehyde dehydrogenase in the microsomes of human polymorphonuclear leukocytes that metabolizes 20-aldehyde leukotriene B4. J Biol Chem 1989; 264:14818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/11\">",
"      Pigg M, Jagell S, Sill&eacute;n A, et al. The Sj&ouml;gren-Larsson syndrome gene is close to D17S805 as determined by linkage analysis and allelic association. Nat Genet 1994; 8:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/12\">",
"      De Laurenzi V, Rogers GR, Hamrock DJ, et al. Sj&ouml;gren-Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene. Nat Genet 1996; 12:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/13\">",
"      Rogers GR, Markova NG, De Laurenzi V, et al. Genomic organization and expression of the human fatty aldehyde dehydrogenase gene (FALDH). Genomics 1997; 39:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/14\">",
"      Chang C, Yoshida A. Human fatty aldehyde dehydrogenase gene (ALDH10): organization and tissue-dependent expression. Genomics 1997; 40:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/15\">",
"      Willemsen MA, IJlst L, Steijlen PM, et al. Clinical, biochemical and molecular genetic characteristics of 19 patients with the Sj&ouml;gren-Larsson syndrome. Brain 2001; 124:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/16\">",
"      Sill&eacute;n A, Anton-Lamprecht I, Braun-Quentin C, et al. Spectrum of mutations and sequence variants in the FALDH gene in patients with Sj&ouml;gren-Larsson syndrome. Hum Mutat 1998; 12:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/17\">",
"      Jagell S, Gustavson KH, Holmgren G. Sj&ouml;gren-Larsson syndrome in Sweden. A clinical, genetic and epidemiological study. Clin Genet 1981; 19:233.",
"     </a>",
"    </li>",
"    <li>",
"     Rizzo, WB. Sj&ouml;gren-Larsson syndrome. file://emedicine.medscape.com/article/949023-overview (Accessed on September 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/19\">",
"      Jagell S, Heijbel J. Sj&ouml;gren-Larsson syndrome: physical and neurological features. A survey of 35 patients. Helv Paediatr Acta 1982; 37:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/20\">",
"      Lossos A, Khoury M, Rizzo WB, et al. Phenotypic variability among adult siblings with Sj&ouml;gren-Larsson syndrome. Arch Neurol 2006; 63:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/21\">",
"      Gordon N. Sj&ouml;gren-Larsson syndrome. Dev Med Child Neurol 2007; 49:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/22\">",
"      Cubo E, Goetz CG. Dystonia secondary to Sj&ouml;gren-Larsson syndrome. Neurology 2000; 55:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/23\">",
"      Jagell S, Polland W, Sandgren O. Specific changes in the fundus typical for the Sj&ouml;gren-Larsson syndrome. An ophthalmological study of 35 patients. Acta Ophthalmol (Copenh) 1980; 58:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/24\">",
"      Caglayan AO, Gumus H. A very rare neurocutaneous disorder in 2 siblings: Sj&ouml;gren-Larsson syndrome. J Child Neurol 2010; 25:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/25\">",
"      McLennan JE, Gilles FH, Robb RM. Neuropathological correlation in Sj&ouml;gren-Larsson syndrome. Oligophrenia, ichthyosis and spasticity. Brain 1974; 97:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/26\">",
"      Yamaguchi K, Handa T. Sj&ouml;gren-Larsson syndrome: postmortem brain abnormalities. Pediatr Neurol 1998; 18:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/27\">",
"      Rizzo WB, Carney G, Lin Z. The molecular basis of Sj&ouml;gren-Larsson syndrome: mutation analysis of the fatty aldehyde dehydrogenase gene. Am J Hum Genet 1999; 65:1547.",
"     </a>",
"    </li>",
"    <li>",
"     Sjogren-Larsson syndrome. file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/clinical_disease_id/26985?db=genetests (Accessed on September 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/29\">",
"      Rizzo WB. Sj&ouml;gren-Larsson syndrome. Semin Dermatol 1993; 12:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/30\">",
"      Rizzo WB, Craft DA, Kelson TL, et al. Prenatal diagnosis of Sj&ouml;gren-Larsson syndrome using enzymatic methods. Prenat Diagn 1994; 14:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/31\">",
"      Rud, E. Et tilfaelde af infantilisme med tetani, epilepsi, polyneuritis, ichthyosis og anaemi of pernicios type. Hospitalstidende 1927; 70:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/32\">",
"      Williams ML, Koch TK, O'Donnell JJ, et al. Ichthyosis and neutral lipid storage disease. Am J Med Genet 1985; 20:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/33\">",
"      Dorfman ML, Hershko C, Eisenberg S, Sagher F. Ichthyosiform dermatosis with systemic lipidosis. Arch Dermatol 1974; 110:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/34\">",
"      Chanarin I, Patel A, Slavin G, et al. Neutral-lipid storage disease: a new disorder of lipid metabolism. Br Med J 1975; 1:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/35\">",
"      Fischer J, Faure A, Bouadjar B, et al. Two new loci for autosomal recessive ichthyosis on chromosomes 3p21 and 19p12-q12 and evidence for further genetic heterogeneity. Am J Hum Genet 2000; 66:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/36\">",
"      Lef&egrave;vre C, Jobard F, Caux F, et al. Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome. Am J Hum Genet 2001; 69:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/37\">",
"      Kihara H. Genetic heterogeneity in metachromatic leukodystrophy. Am J Hum Genet 1982; 34:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/38\">",
"      Casta&ntilde;o Su&aacute;rez E, Segurado Rodr&iacute;guez A, Guerra Tapia A, et al. Ichthyosis: the skin manifestation of multiple sulfatase deficiency. Pediatr Dermatol 1997; 14:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/39\">",
"      Diez-Roux G, Ballabio A. Sulfatases and human disease. Annu Rev Genomics Hum Genet 2005; 6:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/40\">",
"      Haddad FS, Lacour M, Harper JI, Fixsen JA. The orthopaedic presentation and management of Sj&ouml;gren-Larsson syndrome. J Pediatr Orthop 1999; 19:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/41\">",
"      Haug S, Braun-Falco M. Restoration of fatty aldehyde dehydrogenase deficiency in Sj&ouml;gren-Larsson syndrome. Gene Ther 2006; 13:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/42\">",
"      Guilleminault CG, Harpey JP, Lafourcade J. Sj&ouml;gren-Larsson syndrome. Report of two cases in twins. Neurology 1973; 23:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/43\">",
"      Maaswinkel-Mooij PD, Brouwer OF, Rizzo WB. Unsuccessful dietary treatment of Sj&ouml;gren-Larsson syndrome. J Pediatr 1994; 124:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/44\">",
"      Willemsen MA, Rotteveel JJ, Steijlen PM, et al. 5-Lipoxygenase inhibition: a new treatment strategy for Sj&ouml;gren-Larsson syndrome. Neuropediatrics 2000; 31:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35671/abstract/45\">",
"      Willemsen MA, Lutt MA, Steijlen PM, et al. Clinical and biochemical effects of zileuton in patients with the Sj&ouml;gren-Larsson syndrome. Eur J Pediatr 2001; 160:711.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1699 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-A1F0AAE071-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_53_35671=[""].join("\n");
var outline_f34_53_35671=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cutaneous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Motor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cognitive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Speech and language",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ocular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Additional",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Primary ichthyoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Neurocutaneous disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Skin care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1699\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1699|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?3/59/4016\" title=\"diagnostic image 1\">",
"      SLS MRI 5 16 35 months",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/23/23920\" title=\"diagnostic image 2\">",
"      SLS MRI 16 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?13/34/13856\" title=\"diagnostic image 3\">",
"      SLS MRI 9 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?43/42/44704\" title=\"diagnostic image 4\">",
"      SLS MRS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1699|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/49/1812\" title=\"figure 1\">",
"      Fatty alcohol cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/30/13806\" title=\"figure 2\">",
"      FALDH catalytic pathway",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/11/9402?source=related_link\">",
"      Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/602?source=related_link\">",
"      Hereditary neuropathies associated with generalized disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/8/5257?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40887?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Management; outcomes; and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37386?source=related_link\">",
"      Overview of the treatment of seizures and epileptic syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_53_35672="Alcoholic cardiomyopathy";
var content_f34_53_35672=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Alcoholic cardiomyopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/53/35672/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35672/contributors\">",
"     Ihsan M Rafie, MRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35672/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/53/35672/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35672/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/53/35672/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35672/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/53/35672/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low to moderate levels of alcohol intake are associated with reduced cardiovascular risk, primarily the risks of coronary heart disease and ischemic stroke although the mechanism of benefit has not been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/1\">",
"     1",
"    </a>",
"    ]. However, with further increases in alcohol intake, the harmful effects of alcohol consumption outweigh the benefits, resulting in a J-shaped relationship between alcohol intake and survival (",
"    <a class=\"graphic graphic_figure graphicRef82332 \" href=\"mobipreview.htm?26/32/27150\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=see_link\">",
"     \"Cardiovascular benefits and risks of moderate alcohol consumption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommended maximum alcohol consumption for women and men in the United States is 7 drinks (14 units) and 14 drinks (28 units) per week, respectively. In the United Kingdom, the limit for men is the same (28 units) but for women it is higher at 21 units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef80372 \" href=\"mobipreview.htm?10/16/10507\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Similar to the abuse of alcohol and the development of liver disease, the association between chronic alcohol consumption and alcoholic heart disease in humans is well recognized. Both acute and chronic consumption of excessive amounts of alcohol have a deleterious effect on myocardial structure and function.",
"   </p>",
"   <p>",
"    Long-term excess alcohol consumption is a leading cause of secondary, nonischemic dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. However, recovery of cardiac function can occur if the disease is diagnosed early and further alcohol intake is reduced or halted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19465?source=see_link\">",
"     \"Causes of dilated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY OF MYOCARDIAL DAMAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact pathogenesis responsible for alcoholic cardiomyopathy is not fully understood. It was once thought that alcohol causes cardiomyopathy through dietary deficiencies, but it is now clear that malnutrition is not a leading factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. There are several proposed mechanisms by which alcohol consumption may directly or indirectly cause myocardial damage and cardiomyopathy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ethanol induced apoptosis (programmed cell death) leading to myocytes loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/9\">",
"       9",
"      </a>",
"      ]. Loss of cardiac cells will result in inotropic incompetence followed in the early stage by hypertrophy and later by left ventricular dilation. As the disease progresses, the left ventricular wall thickness may become normalized or reduced. Established alcoholic cardiomyopathy is characterized by pronounced left ventricular (LV) dilatation, increased LV mass, thin (or normal thickness) LV walls, diastolic dysfunction (asymptomatic phase) and systolic impairment (symptomatic phase) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/10-12\">",
"       10-12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An acute and transient toxic effect on cardiac performance, resulting in impaired contraction of the myocardium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. This effect on myocardial function can become permanent with chronic alcohol consumption. The best known toxin is acetaldehyde, a metabolite of alcohol produced in the liver by alcohol dehydrogenase. Acetaldehyde is thought to cause myocardial depression through an incompletely understood process that probably involves mitochondrial dysfunction, oxidative damage, and impaired Ca2+ homeostasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/7,8,15-18\">",
"       7,8,15-18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/5/30807?source=see_link&amp;anchor=H2#H2\">",
"       \"Pathogenesis of alcoholic liver disease\", section on 'Alcohol metabolism'",
"      </a>",
"      .) Defects in myofibrillar protein turnover occur during both acute and chronic alcohol consumption; and oxygen free radical-mediated damage to lipids and protein may also be involved [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/15\">",
"       15",
"      </a>",
"      ]. Reduced amounts of heat shock proteins may result in poor assembly and protection of proteins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/7\">",
"       7",
"      </a>",
"      ]. The net effect of these changes in energetics, signaling, and sarcomeric proteins is impaired myocardial contractility [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Activation of the renin angiotensin system (RAS) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/21\">",
"       21",
"      </a>",
"      ]. A six-month study of LV function and RAS level in dogs exposed to alcohol showed that RAS activation contributed to progressive decrease in heart function. The use of angiotensin receptor blocker",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/37/21079?source=see_link\">",
"       irbesartan",
"      </a>",
"      preserved myocardial contraction and relaxation (systolic and diastolic). Alcohol-induced hypertension observed in humans, which is associated with RAS activation, may also contribute to the development of cardiomyopathy. Patients who have more than two drinks per day have a 1.5 to 2-fold increase in the incidence of hypertension compared to nondrinkers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/22\">",
"       22",
"      </a>",
"      ]; this effect is dose-related and is most prominent when intake exceeds five drinks per day [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=see_link&amp;anchor=H8#H8\">",
"       \"Cardiovascular benefits and risks of moderate alcohol consumption\", section on 'Hypertension'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nutritional deficiency, particularly that of thiamine. Beriberi heart disease, even though classified as alcoholic heart disease, is distinct from alcoholic cardiomyopathy and should not be regarded as such. In contrast to alcoholic cardiomyopathy, beriberi heart disease is rapidly reversible after thiamine therapy, manifests predominantly as right heart failure, is associated with increased cardiac output (high output failure), and exhibits normal myocardial histology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/47/9978?source=see_link&amp;anchor=H14#H14\">",
"       \"High-output heart failure\", section on 'Beriberi'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Additives to an alcoholic beverage, for example cobalt, may rarely exert a toxic effect on the myocardium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19465?source=see_link&amp;anchor=H2392034#H2392034\">",
"       \"Causes of dilated cardiomyopathy\", section on 'Trace elements'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21932729\">",
"    <span class=\"h2\">",
"     Possible role of ACE gene polymorphism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma and tissue concentrations of angiotensin converting enzyme (ACE) are determined in part by the ACE gene, which is located on chromosome 17. This gene may manifest insertion (I) or deletion (D) polymorphism and therefore three genotypes (DD, II, and ID). Plasma and cardiac levels of ACE are 1.5 to 3-fold higher in patients with the DD compared to those with II genotype; they are intermediate in patients with ID genotype. The DD polymorphism has been linked to an increased risk of a number of cardiac disorders including left ventricular hypertrophy and progressive idiopathic dilated cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36825?source=see_link&amp;anchor=H4#H4\">",
"     \"Actions of angiotensin II on the heart\", section on 'ACE gene polymorphism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The DD polymorphism may predispose to alcoholic cardiomyopathy. In a study in which 30 alcoholic men with symptomatic cardiomyopathy were compared to 27 alcoholic men with normal cardiac function, the DD genotype was much more common in the men with cardiomyopathy (57 versus 7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/26\">",
"     26",
"    </a>",
"    ]. The odds ratio for developing left ventricular dysfunction in alcoholics with the DD compared to the ID or ID genotype was 16.4.",
"   </p>",
"   <p>",
"    It is not surprising that there may be genetic susceptibility to alcoholic cardiomyopathy since genetic factors also can affect the likelihood of developing cirrhosis. It is likely that currently unrecognized genetic factors contribute to the susceptibility to alcoholic cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/5/30807?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis of alcoholic liver disease\", section on 'Alcohol metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Development of cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of developing left ventricular dysfunction and alcoholic cardiomyopathy is related to both the mean daily alcohol intake and the duration of drinking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/11,27-29\">",
"     11,27-29",
"    </a>",
"    ]. Alcohol can produce asymptomatic cardiac dysfunction even when ingested by healthy individuals in smaller quantities typical of social drinking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/30\">",
"     30",
"    </a>",
"    ]. Most patients in whom alcoholic cardiomyopathy develops have been drinking more than 80 to 90 g of ethanol per day for more than five years (some studies quoted the average of 15 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/5,11,27,28,31,32\">",
"     5,11,27,28,31,32",
"    </a>",
"    ]. This corresponds to approximately one liter of wine, eight standard sized beers, or one-half pint of hard liquor each day. The risk is based upon the absolute amount of ethanol, so consumption of one type of beverage (such as wine) is not protective.",
"   </p>",
"   <p>",
"    The exact prevalence of alcoholic cardiomyopathy is not well defined. In one series of 50 asymptomatic alcoholic women and 100 asymptomatic alcoholic men, approximately one-third had evidence of left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/33\">",
"     33",
"    </a>",
"    ]. There also appears to be a rough correlation between left ventricular dysfunction and cirrhosis. In one series, cirrhosis was found in 43 percent of 30 alcoholics with cardiomyopathy compared to only 6 percent of 30 alcoholics without cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/34\">",
"     34",
"    </a>",
"    ]. Fifty percent of 20 alcoholics with cirrhosis had evidence of dilated cardiomyopathy. Cardiac function was normal in a control group of patients with nonalcoholic cirrhosis.",
"   </p>",
"   <p>",
"    The prevalence of alcoholic cardiomyopathy is similar in men and women with no significant differences in age, nutritional, or clinical status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/33,35\">",
"     33,35",
"    </a>",
"    ]. The likelihood of developing cardiomyopathy correlates with the total lifetime dose of ethanol adjusted for body weight regardless of sex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/33\">",
"     33",
"    </a>",
"    ]. However, when patients were matched for left ventricular ejection fraction, women consumed a lower total dose of ethanol adjusted for body weight compared to men. Thus, women appear to have increased sensitivity of cardiac toxicity; a similar predisposition has been identified for alcoholic liver disease and alcoholic myopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/33\">",
"     33",
"    </a>",
"    ]. A proposed mechanism for this sex difference is excess accumulation of ethanol metabolites in women due to lower gastric metabolism of ethanol and higher rates of ethanol metabolism in the liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/5/30807?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathogenesis of alcoholic liver disease\", section on 'Gastric metabolism of alcohol'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no significant difference in the prevalence of atrial arrhythmias and sustained or non-sustained ventricular tachycardia (VT) in patients with alcoholic cardiomyopathy in comparison to patients with idiopathic dilated cardiomyopathy (IDCM). The most common manifestation is paroxysmal atrial arrhythmias, especially atrial fibrillation, but ventricular arrhythmias may also occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. Prolongation of the corrected QT interval on the surface ECG (QTc), a major risk factor for ventricular arrhythmias, is found in significant proportion of alcoholics compared with non-alcoholics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/41\">",
"     41",
"    </a>",
"    ]. Hypomagnesemia and hypokalemia, which occur with increased frequency in chronic alcoholics, may be contributing factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Abstinence appears to reduce the frequency of arrhythmic events (",
"    <a class=\"graphic graphic_figure graphicRef69005 \" href=\"mobipreview.htm?13/36/13901\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atrial fibrillation occurs in up to 60 percent of binge drinkers with or without underlying myocardial damage, and an increased risk of atrial fibrillation has been reported among men with chronic heavy alcohol consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/38,40,45\">",
"     38,40,45",
"    </a>",
"    ]. Most of the cases related to binge drinking occur over weekends or holidays, producing what has been termed \"the holiday heart syndrome.\" (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28522?source=see_link&amp;anchor=H29#H29\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\", section on 'Alcohol'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gross and microscopic findings in alcoholic cardiomyopathy are usually nonspecific and are generally similar to those observed in idiopathic dilated cardiomyopathy. However, certain ultrastructural details may be suggestive of alcoholic cardiomyopathy. Alcohol, even in small amounts, may result in alterations of mitochondrial structure and function, and endomyocardial biopsy material from patients with chronic alcoholism exhibits structural alterations of the mitochondrial reticulum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The progression of gradually developing structural changes is related to the stage of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/46\">",
"     46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The early stage is characterized by spatial reorganization of the mitochondrial reticulum; intermitochondrial junctions disappear and the mitochondria form separate clusters, uniformly distributed within a myocyte.",
"     </li>",
"     <li>",
"      In the second and third stages, destructive irreversible changes in the ultrastructural organization of mitochondria develop. Megamitochondria and septate mitochondria appear. A third compartment, containing granules, forms in mitochondria. Many lipofuscin granules appear due to the accumulation of lipids in mitochondria. Structural changes in the mitochondrial reticulum are considered a compensatory adaptation in response to altered myocardial function in alcohol cardiomyopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Changes in enzymatic activity in the myocardium have also been observed in established alcoholic cardiomyopathy. A decrease in the activity of the majority of oxidation-reduction mitochondrial enzymes, normal or increased activity of malate dehydrogenase, and increased activity of lysosomal and microsomal enzymes are seen. However, these alterations in activity are nearly identical to those seen in patients with idiopathic dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with alcoholic cardiomyopathy presents with symptoms and physical findings that are similar to those in patients with a dilated cardiomyopathy of any etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms may develop insidiously, although in some patients, symptoms of left-sided congestive heart failure may be acute in onset. Dyspnea, orthopnea, and paroxysmal nocturnal disease are frequently observed. Palpitation and syncope due to tachyarrhythmias, usually supraventricular, are occasionally present. Angina pectoris does not occur unless there is concomitant coronary artery disease or aortic stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination usually reveals a narrow pulse pressure, often with an elevated diastolic pressure secondary to excessive peripheral vasoconstriction. Cardiomegaly, protodiastolic (S3) and presystolic (S4) gallop sounds are common. An apical systolic murmur of mitral regurgitation, due to papillary muscle dysfunction, is often found. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9705?source=see_link\">",
"     \"Etiology, clinical features, and evaluation of chronic mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22410?source=see_link\">",
"     \"Auscultation of heart sounds\"",
"    </a>",
"    .) The severity of right heart failure varies, but jugular venous distention, ascites, and peripheral edema are common in advanced disease.",
"   </p>",
"   <p>",
"    Measurement of the jugular venous pressure may be an important distinguishing feature in determining whether ascites is due to alcoholic cardiomyopathy or cirrhosis. The jugular venous pressure is typically normal or low-normal in cirrhosis unless there is tense ascites which, via upward pressure on the diaphragm, can increase the intrathoracic pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/48\">",
"     48",
"    </a>",
"    ]. Thus, in the absence of tense ascites, an elevated jugular venous pressure is highly suggestive of at least a contribution from cardiac dysfunction. On the other hand, a low normal jugular venous pressure makes heart failure much less likely as the cause of ascites. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/36/34375?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and diagnosis of edema in adults\", section on 'Distribution of edema and central venous pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33719?source=see_link\">",
"     \"Examination of the jugular venous pulse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of alcoholic cardiomyopathy is based upon the history of heavy and prolonged alcohol intake and signs and symptoms of heart failure as described above; the diagnosis can be confirmed by invasive and noninvasive studies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-half of asymptomatic alcoholic subjects have mild increase in left ventricular wall thickness without echocardiographic evidence of decreased myocardial contractility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Compared to normal control subjects, chronic alcoholics in one series had increases in the thickness of the left ventricular wall (10.4 versus 8.8 mm) and interventricular septum (11.7 versus 9.6 mm) and in left ventricular mass (145 versus 101",
"    <span class=\"nowrap\">",
"     g/m2)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/50\">",
"     50",
"    </a>",
"    ]. These abnormalities were present despite normal echocardiographic indices of myocardial contractility including ejection fraction, wall excursion, and velocity, and circumferential fiber shortening. Systolic time intervals revealed shortening of ejection time and prolongation of the pre-ejection period,",
"   </p>",
"   <p>",
"    It is frequently possible to demonstrate mild depression of cardiac function in chronic alcoholics even before a reduced ejection fraction becomes clinically manifest on the echocardiogram [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/11,51,52\">",
"     11,51,52",
"    </a>",
"    ]. Diastolic dysfunction usually precedes systolic dysfunction and occurs more frequently once systolic impairment becomes apparent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, as noted above, left ventricular function is impaired in many asymptomatic alcoholics or those with cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/34\">",
"     34",
"    </a>",
"    ]. In an echocardiographic study of 89 asymptomatic alcoholics and 30 healthy subjects, LV dilation was the initial manifestation of alcoholic cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/11\">",
"     11",
"    </a>",
"    ]. LV dilation was followed by an increase in the LV myocardial mass, posterior wall thickness and diastolic interventricular wall thickness. The extent of diastolic dysfunction was related to the duration of heavy drinking, being most apparent in those with a duration of alcoholism for more than 16 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory tests, even though not diagnostic for alcoholic cardiomyopathy, may reveal findings suggestive of alcohol abuse among patients with dilated cardiomyopathy. These include higher values for mean red cell corpuscular volume and hemoglobin (MCV and MCH), a mild thrombocytopenia, and elevated serum levels of gammaglutamyl transpeptidase. Serum magnesium and zinc are often decreased, but copper level is increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4710?source=see_link\">",
"     \"Alcohol abuse and hematologic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5686020\">",
"    <span class=\"h2\">",
"     Endomyocardial biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrastructural studies from a myocardial biopsy may allow distinctions between different etiologies for a dilated cardiomyopathy, including alcoholic cardiomyopathy (if performed before substantial fibrosis has occurred) and myocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/56\">",
"     56",
"    </a>",
"    ]. In practice, however, endomyocardial biopsy is not usually performed when there is a clinical history strongly suggesting chronic alcoholism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/26/7592?source=see_link\">",
"     \"Endomyocardial biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5686051\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis includes other causes of dilated cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19465?source=see_link\">",
"     \"Causes of dilated cardiomyopathy\"",
"    </a>",
"    .) The diagnosis of alcoholic cardiomyopathy is generally made clinically in patients with a history of heavy and prolonged alcohol intake. However, other potential causes should be considered, as highlighted by a series that included 7 patients with alcoholism; endomyocardial biopsy revealed hemochromatosis in two, amyloidosis in one, doxorubicin-related toxicity in one, and evidence of alcoholic heart disease in three [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29124014\">",
"    <span class=\"h3\">",
"     Distinction from cirrhotic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While alcoholic cardiomyopathy is one cause of heart disease in patients with cirrhosis, experimental and observational studies have found that cirrhosis is associated with myocardial dysfunction independent of alcohol exposure. The causes and manifestations of cirrhotic cardiomyopathy are not well established. The condition has been defined as an otherwise unexplained chronic cardiac dysfunction in patients with cirrhosis with impaired contractile responsiveness to stress",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. Electrical abnormalities include QT interval prolongation, electrical and mechanical dyssynchrony, and chronotropic incompetence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/60\">",
"     60",
"    </a>",
"    ]. The left atrium may be dilated but the left ventricular cavity size is generally normal, although dilatation may develop in some cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The generally accepted treatment of alcoholic cardiomyopathy has been",
"    <strong>",
"     total and perpetual abstinence",
"    </strong>",
"    from alcohol consumption. A number of small studies have demonstrated that, if begun prior to the onset of fibrosis, abstinence can result in significant improvement in left ventricular function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/37,62-68\">",
"     37,62-68",
"    </a>",
"    ]. There are two factors associated with a favorable course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/64\">",
"     64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A short duration of symptoms of heart failure before the initiation of therapy; patients with less fibrosis generally do better",
"     </li>",
"     <li>",
"      Abstinence from alcohol",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The potential efficacy of abstinence is illustrated by the following observations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 14 patients with alcoholic cardiomyopathy and severe heart failure, 9 patients were followed for 36 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/68\">",
"       68",
"      </a>",
"      ]. The left ventricular ejection fraction in the 9 patients improved significantly at six months (mean of 37 versus 22 percent at baseline) with continued improvement at 36 months (mean of 43 percent). &nbsp;",
"     </li>",
"     <li>",
"      In an echocardiographic study of 13 patients with alcoholic cardiomyopathy, five demonstrated normalization of left ventricular ejection fraction (LVEF) to 55 percent or more and reduction of left ventricular end-diastolic dimension (LVEDd) to 5.7 cm or less after total abstinence for six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/67\">",
"       67",
"      </a>",
"      ]. The normalization of LVEF and LVEDd was recognized after 3 to 12 weeks of abstinence. In the remaining eight patients, no improvement was observed, suggesting that the process becomes irreversible at some point, possibly once structural myocardial dilatation and fibrosis have occurred [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/69\">",
"       69",
"      </a>",
"      ]. Consistent with this hypothesis was the observation that the ratio of left ventricular radius to wall thickness",
"      <span class=\"nowrap\">",
"       (R/Th)",
"      </span>",
"      was &le;2.9 in all those showing reversion of cardiomyopathy, but was &ge;2.9 in seven of eight without improvement. No other significant differences were detected between those with and without reversible changes with regard to age, daily intake of alcohol, duration of drinking, NYHA cardiac functional class (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"       table 2",
"      </a>",
"      ), the total period of heart failure symptoms, and cardiothoracic ratio.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the goal is total abstinence from alcohol, this may not be necessary as there is also an improvement in LVEF if alcohol intake is \"controlled\" (ie, 20 to 60 g per day). This was illustrated in a prospective study of 55 men with a cardiomyopathy who consumed &ge;100 g alcohol per day for at least 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/70\">",
"     70",
"    </a>",
"    ]. During a one year follow-up, the improvement in LVEF was the same in abstainers and those who controlled their intake. In contrast, patients who continued to drink &gt;80 g per day had a further deterioration in LVEF. Because one cannot easily measure or control alcohol intake, however, the most prudent course is to recommend abstinence.",
"   </p>",
"   <p>",
"    Treatment of heart failure includes salt restriction, diuretics, beta blockers, angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .) Even in asymptomatic left ventricular dysfunction, prophylactic pharmacotherapy, eg, beta blockers, angiotensin blockers coupled with abstinence may halt or reverse the negative remodeling of the myocardium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28601?source=see_link\">",
"     \"Evaluation and management of asymptomatic left ventricular systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should receive a balanced diet and any nutritional deficiencies should be corrected. Vitamin supplementation with vitamin B12 and folate are important adjuncts for these patients. Attention must be paid to electrolyte disturbances, including hypokalemia and hypomagnesemia. Arrhythmias are treated in the usual fashion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/47/21241?source=see_link\">",
"     \"Ventricular arrhythmias in heart failure and cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24042?source=see_link\">",
"     \"Atrial fibrillation in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of anticoagulation in patients with heart failure is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7048?source=see_link\">",
"     \"Indications for antithrombotic therapy in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have found that the rate of progression and mortality in patients with alcoholic cardiomyopathy was significantly lower than seen in idiopathic cardiomyopathy. In an observational study performed prior to the advent of heart failure management including maximum tolerated doses of ACE inhibition and beta blocker therapy, 23 patients with alcoholic cardiomyopathy had better one (100 versus 89 percent), five (81 versus 48 percent), and 10-year survivals (81 versus 30 percent) than 52 patients with idiopathic cardiomyopathy of comparable severity and ejection fractions (about 30 percent) at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, another study of 50 patients with alcoholic cardiomyopathy found that, after a 47 month follow-up, the cardiac death rate for those who stopped drinking was the same as that for 84 patients with an idiopathic dilated cardiomyopathy; however, mortality was higher for those with alcoholic cardiomyopathy who continued to drink (",
"    <a class=\"graphic graphic_figure graphicRef79337 \" href=\"mobipreview.htm?40/61/41949\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/31\">",
"     31",
"    </a>",
"    ]. In another study of 338 men with a dilated cardiomyopathy, 23 percent had an alcoholic cardiomyopathy; those who continued to drink had a lower seven year transplant-free survival compared to those who stopped drinking or those with an idiopathic cardiomyopathy (27 versus 45 and 53 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alcoholic cardiomyopathy patients who undergo cardiac transplantation also appear to have poorer outcome based on a preliminary report of a registry study. Compared with 10,243 idiopathic dilated cardiomyopathy cases, 134 alcoholic cardiomyopathy patients had higher graft failure rate (HR 1.437, 95% CI 1.050-1.969), including more death from coronary artery disease, rejection, and liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35672/abstract/73\">",
"     73",
"    </a>",
"    ]. Since this was a registry analysis, potential contributing factors such as the rate of recidivism could not be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21932325\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alcoholic cardiomyopathy is not uncommon, and without abstinence is associated with poor prognosis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of alcoholic cardiomyopathy is not fully understood, but experimental data has suggested potential mechanisms including ethanol induced apoptosis, toxic effects of ethanol metabolites, and activation of the renin angiotensin system. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology of myocardial damage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of atrial and ventricular arrhythmias is similar in alcoholic cardiomyopathy to that in idiopathic dilated cardiomyopathy. Atrial fibrillation occurs commonly in binge drinkers with or without alcoholic cardiomyopathy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Arrhythmias'",
"      </a>",
"      above.) Women appear to have increased sensitivity to cardiac toxicity not explained by differences in body size. This sex difference may be due to excess accumulation of ethanol metabolites in women due to lower gastric metabolism of ethanol and higher rates of ethanol metabolism in the liver. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Development of cardiomyopathy'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Alcoholic cardiomyopathy is potentially reversible. Recovery of ventricular function has been observed in some patients following cessation or moderation of alcohol intake, particularly if early in the course of the disease. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mainstay of therapy for alcoholic cardiomyopathy is abstinence from alcohol. Treatment of heart failure includes beta blockers, angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , and diuretics. Vitamin B12 and folate supplements are important adjuncts for these patients. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/1\">",
"      Kloner RA, Rezkalla SH. To drink or not to drink? That is the question. Circulation 2007; 116:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/2\">",
"      International guidelines. News. Brit Med J 1996; 312:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/3\">",
"      Dawson DA, Grant BF, Li TK. Quantifying the risks associated with exceeding recommended drinking limits. Alcohol Clin Exp Res 2005; 29:902.",
"     </a>",
"    </li>",
"    <li>",
"     United States Department of Agriculture and United States Department of Health and Human Services. Alcoholic Beverages. In: Dietary Guidelines for Americans, US Government Printing Office, Washington, DC 2005. p.43.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/5\">",
"      McKenna CJ, Codd MB, McCann HA, Sugrue DD. Alcohol consumption and idiopathic dilated cardiomyopathy: a case control study. Am Heart J 1998; 135:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/6\">",
"      Piano MR, Schwertz DW. Alcoholic heart disease: a review. Heart Lung 1994; 23:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/7\">",
"      Patel VB, Why HJ, Richardson PJ, Preedy VR. The effects of alcohol on the heart. Adverse Drug React Toxicol Rev 1997; 16:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/8\">",
"      Lange LG, Sobel BE. Myocardial metabolites of ethanol. Circ Res 1983; 52:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/9\">",
"      Fern&aacute;ndez-Sol&agrave; J, Fatj&oacute; F, Sacanella E, et al. Evidence of apoptosis in alcoholic cardiomyopathy. Hum Pathol 2006; 37:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/10\">",
"      Piano MR. Alcoholic cardiomyopathy: incidence, clinical characteristics, and pathophysiology. Chest 2002; 121:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/11\">",
"      Lazarevi�� AM, Nakatani S, Neskovi�� AN, et al. Early changes in left ventricular function in chronic asymptomatic alcoholics: relation to the duration of heavy drinking. J Am Coll Cardiol 2000; 35:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/12\">",
"      Mathews EC Jr, Gardin JM, Henry WL, et al. Echocardiographic abnormalities in chronic alcoholics with and without overt congestive heart failure. Am J Cardiol 1981; 47:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/13\">",
"      Kelbaek HS. [Alcohol and the heart]. Ugeskr Laeger 1995; 157:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/14\">",
"      Rubin E, Urbano-Marquez A. Alcoholic cardiomyopathy. Alcohol Clin Exp Res 1994; 18:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/15\">",
"      Preedy VR, Atkinson LM, Richardson PJ, Peters TJ. Mechanisms of ethanol-induced cardiac damage. Br Heart J 1993; 69:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/16\">",
"      Zhang X, Li SY, Brown RA, Ren J. Ethanol and acetaldehyde in alcoholic cardiomyopathy: from bad to ugly en route to oxidative stress. Alcohol 2004; 32:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/17\">",
"      Oba T, Maeno Y, Ishida K. Differential contribution of clinical amounts of acetaldehyde to skeletal and cardiac muscle dysfunction in alcoholic myopathy. Curr Pharm Des 2005; 11:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/18\">",
"      Ren J, Wold LE. Mechanisms of alcoholic heart disease. Ther Adv Cardiovasc Dis 2008; 2:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/19\">",
"      Figueredo VM, Chang KC, Baker AJ, Camacho SA. Chronic alcohol-induced changes in cardiac contractility are not due to changes in the cytosolic Ca2+ transient. Am J Physiol 1998; 275:H122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/20\">",
"      Thomas AP, Rozanski DJ, Renard DC, Rubin E. Effects of ethanol on the contractile function of the heart: a review. Alcohol Clin Exp Res 1994; 18:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/21\">",
"      Cheng CP, Cheng HJ, Cunningham C, et al. Angiotensin II type 1 receptor blockade prevents alcoholic cardiomyopathy. Circulation 2006; 114:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/22\">",
"      Klatsky AL, Friedman GD, Siegelaub AB, G&eacute;rard MJ. Alcohol consumption and blood pressure Kaiser-Permanente Multiphasic Health Examination data. N Engl J Med 1977; 296:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/23\">",
"      Kaplan NM. Alcohol and hypertension. Lancet 1995; 345:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/24\">",
"      Gubbay ER. Beri-Beri heart disease. Can Med Assoc J 1966; 95:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/25\">",
"      Alexander CS. Cobalt-beer cardiomyopathy. A clinical and pathologic study of twenty-eight cases. Am J Med 1972; 53:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/26\">",
"      Fern&aacute;ndez-Sol&agrave; J, Nicol&aacute;s JM, Oriola J, et al. Angiotensin-converting enzyme gene polymorphism is associated with vulnerability to alcoholic cardiomyopathy. Ann Intern Med 2002; 137:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/27\">",
"      Wilke A, Kaiser A, Ferency I, Maisch B. [Alcohol and myocarditis]. Herz 1996; 21:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/28\">",
"      Lee WK, Regan TJ. Alcoholic cardiomyopathy: is it dose-dependent? Congest Heart Fail 2002; 8:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/29\">",
"      Kajander OA, Kupari M, Laippala P, et al. Dose dependent but non-linear effects of alcohol on the left and right ventricle. Heart 2001; 86:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/30\">",
"      Kelbaek H, Gj&oslash;rup T, Brynjolf I, et al. Acute effects of alcohol on left ventricular function in healthy subjects at rest and during upright exercise. Am J Cardiol 1985; 55:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/31\">",
"      Fauchier L, Babuty D, Poret P, et al. Comparison of long-term outcome of alcoholic and idiopathic dilated cardiomyopathy. Eur Heart J 2000; 21:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/32\">",
"      Kupari M, Koskinen P, Suokas A, Ventil&auml; M. Left ventricular filling impairment in asymptomatic chronic alcoholics. Am J Cardiol 1990; 66:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/33\">",
"      Urbano-M&aacute;rquez A, Estruch R, Fern&aacute;ndez-Sol&aacute; J, et al. The greater risk of alcoholic cardiomyopathy and myopathy in women compared with men. JAMA 1995; 274:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/34\">",
"      Estruch R, Fern&aacute;ndez-Sol&aacute; J, Sacanella E, et al. Relationship between cardiomyopathy and liver disease in chronic alcoholism. Hepatology 1995; 22:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/35\">",
"      Fern&aacute;ndez-Sol&agrave; J, Estruch R, Nicol&aacute;s JM, et al. Comparison of alcoholic cardiomyopathy in women versus men. Am J Cardiol 1997; 80:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/36\">",
"      Baraona E, Abittan CS, Dohmen K, et al. Gender differences in pharmacokinetics of alcohol. Alcohol Clin Exp Res 2001; 25:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/37\">",
"      Regan TJ. Alcoholic cardiomyopathy. Prog Cardiovasc Dis 1984; 27:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/38\">",
"      Ettinger PO, Wu CF, De La Cruz C Jr, et al. Arrhythmias and the \"Holiday Heart\": alcohol-associated cardiac rhythm disorders. Am Heart J 1978; 95:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/39\">",
"      Buckingham TA, Kennedy HL, Goenjian AK, et al. Cardiac arrhythmias in a population admitted to an acute alcoholic detoxification center. Am Heart J 1985; 110:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/40\">",
"      Frost L, Vestergaard P. Alcohol and risk of atrial fibrillation or flutter: a cohort study. Arch Intern Med 2004; 164:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/41\">",
"      Corovi�� N, Durakovi�� Z, Misigoj-Durakovi�� M. Dispersion of the corrected QT and JT interval in the electrocardiogram of alcoholic patients. Alcohol Clin Exp Res 2006; 30:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/42\">",
"      Fauchier L. Alcoholic cardiomyopathy and ventricular arrhythmias. Chest 2003; 123:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/43\">",
"      Elisaf M, Merkouropoulos M, Tsianos EV, Siamopoulos KC. Pathogenetic mechanisms of hypomagnesemia in alcoholic patients. J Trace Elem Med Biol 1995; 9:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/44\">",
"      Elisaf M, Liberopoulos E, Bairaktari E, Siamopoulos K. Hypokalaemia in alcoholic patients. Drug Alcohol Rev 2002; 21:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/45\">",
"      Mukamal KJ, Tolstrup JS, Friberg J, et al. Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation 2005; 112:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/46\">",
"      Bakeeva LE, Tsiplenkova VG. Ultrastructure of mitochondrial reticulum of human cardiomyocytes in alcohol cardiomyopathy. Biochemistry (Mosc) 1997; 62:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/47\">",
"      Cherpachenko NM. [Changes in the enzymatic activity in the myocardium of patients with idiopathic and secondary dilated cardiomyopathy]. Arkh Patol 1993; 55:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/48\">",
"      Guazzi M, Polese A, Magrini F, et al. Negative influences of ascites on the cardiac function of cirrhotic patients. Am J Med 1975; 59:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/49\">",
"      Orlando E, Gennari P, Boari C. [Echocardiographic study of the left ventricle in chronic alcoholism]. Minerva Med 1980; 71:3235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/50\">",
"      Askanas A, Udoshi M, Sadjadi SA. The heart in chronic alcoholism: a noninvasive study. Am Heart J 1980; 99:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/51\">",
"      Dancy M, Bland JM, Leech G, et al. Preclinical left ventricular abnormalities in alcoholics are independent of nutritional status, cirrhosis, and cigarette smoking. Lancet 1985; 1:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/52\">",
"      Kelbaek H, Eriksen J, Brynjolf I, et al. Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver. Am J Cardiol 1984; 54:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/53\">",
"      Fern&aacute;ndez-Sol&agrave; J, Nicol&aacute;s JM, Par&eacute; JC, et al. Diastolic function impairment in alcoholics. Alcohol Clin Exp Res 2000; 24:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/54\">",
"      Wang RY, Alterman AI, Searles JS, McLellan AT. Alcohol abuse in patients with dilated cardiomyopathy. Laboratory vs clinical detection. Arch Intern Med 1990; 150:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/55\">",
"      Avaroglu, D, Inal, TC, Demir, M, et al Biochemical indicators and cardiac function tests in chronic alcohol abusers. Croation Medical Journal 2005; 46:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/56\">",
"      Tsyplenkova VG, Postnov IuV. [Diagnostic value of the endomyocardial biopsy in the cardiologic therapeutic clinic]. Arkh Patol 1991; 53:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/57\">",
"      Ocel JJ, Edwards WD, Tazelaar HD, et al. Heart and liver disease in 32 patients undergoing biopsy of both organs, with implications for heart or liver transplantation. Mayo Clin Proc 2004; 79:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/58\">",
"      Milani A, Zaccaria R, Bombardieri G, et al. Cirrhotic cardiomyopathy. Dig Liver Dis 2007; 39:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/59\">",
"      M&oslash;ller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol 2010; 53:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/60\">",
"      Zardi EM, Abbate A, Zardi DM, et al. Cirrhotic cardiomyopathy. J Am Coll Cardiol 2010; 56:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/61\">",
"      Timoh T, Protano MA, Wagman G, et al. A perspective on cirrhotic cardiomyopathy. Transplant Proc 2011; 43:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/62\">",
"      Renault A, Mansourati J, Genet L, Blanc JJ. [Dilated cardiomyopathies in severe cardiac failure in chronic alcoholics: clinical course after complete withdrawal]. Rev Med Interne 1993; 14:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/63\">",
"      Nethala V, Brown EJ Jr, Timson CR, Patcha R. Reversal of alcoholic cardiomyopathy in a patient with severe coronary artery disease. Chest 1993; 104:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/64\">",
"      Demakis JG, Proskey A, Rahimtoola SH, et al. The natural course of alcoholic cardiomyopathy. Ann Intern Med 1974; 80:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/65\">",
"      Mansourati J, Forneiro I, Genet L, et al. [Regression of dilated cardiomyopathy in a chronic alcoholic patient after abstinence from alcohol]. Arch Mal Coeur Vaiss 1990; 83:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/66\">",
"      Agatston AS, Snow ME, Samet P. Regression of severe alcoholic cardiomyopathy after abstinence of 10 weeks. Alcohol Clin Exp Res 1986; 10:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/67\">",
"      Masani F, Kato H, Sasagawa Y, et al. [An echocardiographic study of alcoholic cardiomyopathy after total abstinence]. J Cardiol 1990; 20:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/68\">",
"      Guillo P, Mansourati J, Maheu B, et al. Long-term prognosis in patients with alcoholic cardiomyopathy and severe heart failure after total abstinence. Am J Cardiol 1997; 79:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/69\">",
"      Teragaki M, Takeuchi K, Takeda T. Clinical and histologic features of alcohol drinkers with congestive heart failure. Am Heart J 1993; 125:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/70\">",
"      Nicol&aacute;s JM, Fern&aacute;ndez-Sol&agrave; J, Estruch R, et al. The effect of controlled drinking in alcoholic cardiomyopathy. Ann Intern Med 2002; 136:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/71\">",
"      Prazak P, Pfisterer M, Osswald S, et al. Differences of disease progression in congestive heart failure due to alcoholic as compared to idiopathic dilated cardiomyopathy. Eur Heart J 1996; 17:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/72\">",
"      Gavazzi A, De Maria R, Parolini M, Porcu M. Alcohol abuse and dilated cardiomyopathy in men. Am J Cardiol 2000; 85:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35672/abstract/73\">",
"      Brinkley DM, Geltman EM. Alcohol cardiomyopathy is associated with worse graft survival after cardiac transplant. J Card Fail 2011; 12:S75.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3467 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-6A12EA632A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_53_35672=[""].join("\n");
var outline_f34_53_35672=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21932325\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY OF MYOCARDIAL DAMAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21932729\">",
"      Possible role of ACE gene polymorphism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Development of cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5686020\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5686051\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29124014\">",
"      - Distinction from cirrhotic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21932325\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3467\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3467|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/32/27150\" title=\"figure 1\">",
"      Alcohol consumption mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/36/13901\" title=\"figure 2\">",
"      Arrhythmias alcoholic CMP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/61/41949\" title=\"figure 3\">",
"      Survival alcoholic cardiomyop",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3467|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/16/10507\" title=\"table 1\">",
"      Units of alcohol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36825?source=related_link\">",
"      Actions of angiotensin II on the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4710?source=related_link\">",
"      Alcohol abuse and hematologic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=related_link\">",
"      Cardiovascular benefits and risks of moderate alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19465?source=related_link\">",
"      Causes of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/36/34375?source=related_link\">",
"      Clinical manifestations and diagnosis of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/26/7592?source=related_link\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9705?source=related_link\">",
"      Etiology, clinical features, and evaluation of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28601?source=related_link\">",
"      Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33719?source=related_link\">",
"      Examination of the jugular venous pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/47/9978?source=related_link\">",
"      High-output heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7048?source=related_link\">",
"      Indications for antithrombotic therapy in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/5/30807?source=related_link\">",
"      Pathogenesis of alcoholic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/47/21241?source=related_link\">",
"      Ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_53_35673="Bone tumors: Diagnosis and biopsy techniques";
var content_f34_53_35673=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bone tumors: Diagnosis and biopsy techniques",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/53/35673/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35673/contributors\">",
"     Daniel Rosenthal, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35673/contributors\">",
"     Francis J Hornicek, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/53/35673/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35673/contributors\">",
"     Thomas F DeLaney, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35673/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/53/35673/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35673/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/53/35673/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 17, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most bone tumors are benign, although the true incidence of benign bone tumors is unknown because most are asymptomatic and are usually discovered as an incidental lesion. As a rough estimate, they may occur more than one hundred times more often than primary malignant tumors of bone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24522?source=see_link\">",
"     \"Overview of benign bone tumors in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary malignant bone tumors are uncommon but are a significant cause of cancer morbidity and mortality, especially among young people. Although relatively rare in childhood, primary malignant bone tumors represent the sixth most common neoplasm in children, while in adolescents and young adults, they are the third most frequent, exceeded only by leukemias and lymphomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In the United States, it is estimated that about three thousand primary malignant bone tumors (excluding malignancies arising in the bone marrow) are diagnosed annually, and approximately half as many deaths result [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary malignant bone tumors are classified according to their cytologic features and cellular products (",
"    <a class=\"graphic graphic_table graphicRef81481 \" href=\"mobipreview.htm?41/39/42620\">",
"     table 1",
"    </a>",
"    ). For many of these tumors, most notably osteosarcoma and the Ewing sarcoma family of tumors (EFT), remarkable progress in surgical techniques and multidisciplinary management over the last 40 years has resulted in significant improvements in the likelihood of cure and limb salvage.",
"   </p>",
"   <p>",
"    The initial work-up and staging evaluation of a patient with a suspected primary bone tumor, particularly the diagnostic biopsy, is a critical component of successful management. Here we will discuss the diagnostic evaluation and biopsy techniques for primary tumors of bone. The classification, epidemiology, clinical features, and treatment of specific types of bone tumors are considered elsewhere. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a bone tumor (primary malignant or metastatic) typically come to medical attention because of localized pain or swelling of a few weeks' or months' duration. Trauma, often minor, may be the initiating event that calls attention to a benign or malignant bone tumor. However, benign bone tumors are most often asymptomatic. The pain associated with malignant tumors, which may be mild at first, may be aggravated by exercise and is often worse at night. A distinct soft tissue mass can sometimes be appreciated. When present, it is usually firmly attached to the bone and moderately to markedly tender to palpation.",
"   </p>",
"   <p>",
"    The first diagnostic test to arouse suspicion for a primary malignant bone tumor is generally a plain radiograph of the affected area. At that point, a diagnostic evaluation is usually undertaken.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC AND STAGING WORK-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a bone tumor is suspected, the goals of the diagnostic evaluation are to establish the tissue diagnosis, evaluate disease extent, and assess the feasibility of surgical resection using the principles of limb-sparing surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37690?source=see_link\">",
"     \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Radiographic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although plain radiographs can often predict the probable histology of a potentially malignant bone lesion, the definition of tumor size and local intraosseous and extraosseous extent is most accurately achieved by magnetic resonance imaging (MRI). In general, CT scans are less useful than MRI for assessing primary bone tumors. However, CT is the best method to evaluate the thorax for metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important component of the initial radiographic evaluation is imaging of the entire involved bone to avoid missing skip metastases (ie, medullary disease within the same bone, but not in direct contiguity with the primary lesion)&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differential diagnosis depends upon recognition of the tissue type and the degree of aggressiveness. Tissue types that can usually be recognized on imaging are bone, cartilage, and fat. Recognition of fat within a tumor is generally a sign that it is benign. Aggressiveness can be estimated by the lesion size and the way it interacts with surrounding tissues (invasiveness).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteosarcoma &ndash; Osteosarcoma is by far the most common primary malignant tumor arising in bone (myeloma excluded). Osteosarcoma, which is most common in the second and third decades of life, is usually a high-grade malignancy, although the parosteal form is a notable exception. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=see_link\">",
"       \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Most often osteosarcoma is located in the metaphysis of a long bone (",
"      <a class=\"graphic graphic_figure graphicRef76662 \" href=\"mobipreview.htm?22/53/23391\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef50795 \" href=\"mobipreview.htm?13/34/13864\">",
"       figure 2",
"      </a>",
"      ) and usually has demonstrable internal bone formation. Tumor bone formation can be recognized by its amorphous \"cloud-like\" character. Its density never exceeds the density of normal cortex.",
"      <br/>",
"      <br/>",
"      Characteristic features of conventional osteosarcomas (which account for the majority of cases) include destruction of the normal trabecular bone pattern, indistinct margins, and lack of endosteal bone response. There is usually a mixture of radiodense and radiolucent areas, with periosteal new bone formation, and sometimes formation of Codman's triangle (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70494 \" href=\"mobipreview.htm?23/21/23903\">",
"       image 1",
"      </a>",
"      ). The associated soft tissue mass may be ossified in a radial or \"sunburst\" pattern. The degree to which the tumor is ossified is highly variable and roughly related to the degree of cellular differentiation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=see_link&amp;anchor=H13#H13\">",
"       \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A primarily lytic osteosarcoma may be difficult to distinguish from Ewing sarcoma or other non-matrix forming tumors on imaging studies.",
"     </li>",
"     <li>",
"      Chondrosarcoma &ndash; Chondrosarcoma, a condition of middle aged and older adults, is usually of low or intermediate grade. Cartilage can be recognized on imaging because it tends to grow in nodules, has a very high water content (making it bright on T2 weighted MRI and dark on CT scan), and deposits mineral in dense \"rings and arcs\" whose density can focally exceed cortical bone (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70323 \" href=\"mobipreview.htm?8/19/8496\">",
"       image 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35450?source=see_link\">",
"       \"Chondrosarcoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ewing sarcoma &ndash; Ewing sarcoma of the bone (as well as the other members of the Ewing family of tumors, and all of the \"small round blue cell tumors) has a \"permeative\" or \"moth-eaten\" pattern on imaging with very poorly defined margins. The tumors can be large, and frequently involve the diaphysis (",
"      <a class=\"graphic graphic_figure graphicRef50795 \" href=\"mobipreview.htm?13/34/13864\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62643 \" href=\"mobipreview.htm?39/49/40734\">",
"       image 3",
"      </a>",
"      ). The characteristic periosteal reaction produces layers of reactive bone, deposited in an \"onion peel\" appearance (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61818 \" href=\"mobipreview.htm?17/0/17408\">",
"       image 4",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      The cortex at the site of the lesion is often permeated by tumor which extends into the soft tissues. The soft tissue component of the tumor rarely shows any calcification or ossification. Sclerosis of bone, if present, represents a secondary bone reaction rather than the primary bone formation that characterizes osteosarcoma. A pathologic fracture is present at diagnosis in 10 to 15 percent of cases. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37769?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\", section on 'Radiographic studies'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Ewing tumors may resemble subacute osteomyelitis on imaging, and the clinical presentation may also be similar (ie, presence of fever and an elevated sedimentation rate, intense radiotracer uptake on bone scan) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/8\">",
"       8",
"      </a>",
"      ]. Aspiration of a tumor may yield purulent-appearing material; however, it will be sterile on culture.",
"     </li>",
"     <li>",
"      Other tumors &ndash; Other malignant tumors that should be considered in the differential diagnosis of a primary lytic lesion include fibrosarcoma (formerly referred to as malignant fibrous histiocytoma or even more generally, a &ldquo;spindle cell sarcoma&rdquo; of bone), which tends to resemble osteosarcoma but without ossification, primary lymphoma of bone, and metastasis from a non-bone tumor (",
"      <a class=\"graphic graphic_table graphicRef81481 \" href=\"mobipreview.htm?41/39/42620\">",
"       table 1",
"      </a>",
"      ). Primary lymphoma of bone occurs in an older age group and is generally associated with less bone destruction than ES.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    \"Benign\" bone tumors that can present as lytic lesions include hemangioma, various types of cysts, lipomas, eosinophilic granuloma and giant cell tumor of bone. Destructive eosinophilic granulomas usually occur at a younger age and are not associated with a sizable soft tissue mass. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/33/5658?source=see_link\">",
"     \"Giant cell tumor of bone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24522?source=see_link\">",
"     \"Overview of benign bone tumors in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/50/32551?source=see_link\">",
"     \"Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Evaluation of the rest of the skeleton",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radionuclide bone scans or total body positron emission tomography (PET) can evaluate the entire skeleton for the presence of multiple lesions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80098 \" href=\"mobipreview.htm?41/53/42847\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef88299 \" href=\"mobipreview.htm?25/44/26307\">",
"     image 6",
"    </a>",
"    ). Although radioisotope bone scans are more sensitive than plain radiography, some metastases may be missed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/9\">",
"     9",
"    </a>",
"    ]. The addition of single photon tomography (SPECT) may improve sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bone scans are also limited by a lack of specificity, with most false-positive results due to trauma, whether recalled by the patient or not. As a result, the diagnosis of metastatic bone disease usually requires radiographic confirmation, especially if the number of lesions is small (fewer than four)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    limited to the ribs (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71563 \" href=\"mobipreview.htm?7/18/7471\">",
"     image 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/12\">",
"     12",
"    </a>",
"    ]. The probability that an abnormal scan represents metastatic tumor is directly related to the number of abnormal foci.",
"   </p>",
"   <p>",
"    There is growing consensus that PET scans represent an excellent approach to the clinical evaluation of bone metastases and possibly, in the evaluation of a primary bone tumor. PET uptake correlates with the degree of cell metabolism and may be seen with many benign conditions. However, in some cases (eg, chondrosarcoma), the degree of uptake appears to be related to the histologic grade of malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35450?source=see_link&amp;anchor=H20#H20\">",
"     \"Chondrosarcoma\", section on 'Role of PET'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For some malignancies (ie, lung and breast cancer), PET scans are more specific than bone scans for detection of bone metastases, although they are possibly less sensitive (especially for osteoblastic foci) and clearly more expensive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/8,13-18\">",
"     8,13-18",
"    </a>",
"    ]. Although at least one study suggests that PET scans may be inferior to bone scans for detecting osseous metastases from osteosarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/19\">",
"     19",
"    </a>",
"    ], a major benefit of PET scanning over bone scans is its ability to screen for distant metastases at sites other than bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Another benefit is to look at response of the tumor to cancer chemotherapeutic. Guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    suggest either PET or bone scan in the staging workup of a primary bone tumor, and imaging guidelines from the Children&rsquo;s Oncology Group Bone Tumor Committee for both osteosarcoma and Ewing sarcoma recommend radionuclide bone scan",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PET scan for whole body staging. This subject is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=see_link&amp;anchor=H15#H15\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\", section on 'Imaging studies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37769?source=see_link\">",
"     \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiographic skeletal surveys are obsolete, except in multiple myeloma, and possibly in patients with thyroid cancer, where the propensity for purely lytic bone metastases renders the bone scan insensitive to lesions at risk for a pathological fracture (",
"    <a class=\"graphic graphic_table graphicRef54124 \" href=\"mobipreview.htm?21/17/21787\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef86427 \" href=\"mobipreview.htm?23/60/24516\">",
"     image 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83492 \" href=\"mobipreview.htm?38/35/39476\">",
"     image 9",
"    </a>",
"    ). A similar, but less frequent, lack of sensitivity for bone scanning is seen in renal cell and head and neck cancer, in which lytic bone metastases predominate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Bone pain'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whole body MRI has the potential to detect more lesions in the axial skeleton (particularly the spine) than bone scan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/24-26\">",
"     24-26",
"    </a>",
"    ], but it is generally not feasible in most centers due to time constraints. Whole body MRI techniques are rapidly advancing and may replace other means of imaging bones, such as radionuclide bone scans, in the future [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The staging system used by the Musculoskeletal Tumor Society for primary bone sarcomas was developed by Enneking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/28\">",
"     28",
"    </a>",
"    ]. This system characterizes nonmetastatic malignant bone tumors by grade (low grade [stage I] versus high grade [stage II]), and further subdivides these stages according to the local anatomic extent (intracompartmental [A] versus extracompartmental [B]). The compartmental status is determined by whether the tumor extends through the cortex of the involved bone. Patients with regional nodal or distant metastases are categorized as stage III.",
"   </p>",
"   <p>",
"    The American Joint Committee on Cancer (AJCC) adopted a similar staging system in its 1997 fifth edition, but this was modified in 2002, with additional minor refinements in the latest 2010 edition (",
"    <a class=\"graphic graphic_table graphicRef62124 \" href=\"mobipreview.htm?25/43/26301\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/29\">",
"     29",
"    </a>",
"    ]. These staging criteria specifically define the extent of the primary tumor (T), the histologic grade of differentiation (G), and any spread to nodes (N) or distant sites (metastasis, M category). Regional nodal involvement from primary bone sarcomas is rare, and regional lymph node",
"    <span class=\"nowrap\">",
"     sampling/lymphadenectomy",
"    </span>",
"    is usually not performed. As a result, the N stage is typically assigned clinically (cN) while the primary tumor is classified according to pathologic stage (pT, pG) after definitive surgery. The TNM classification is not widely used for primary bone tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INDICATION FOR BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the majority of patients with a primary malignant or metastatic bone tumor present with localized pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    swelling. The first diagnostic test to arouse suspicion for a bone tumor is generally a plain radiograph of the affected area. Depending upon the clinical history and the degree of suspicion, a staging workup may then be instituted (see above), or a diagnostic biopsy considered. Bone biopsy is indicated in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Whenever there is significant doubt as to the diagnosis of a benign or malignant lesion",
"     </li>",
"     <li>",
"      When the histologic distinction among possible diagnoses could alter the planned course of treatment",
"     </li>",
"     <li>",
"      When definitive confirmation of the diagnosis is required before undertaking a hazardous, costly, or potentially disfiguring treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Doubtful diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A symptomatic lesion with demonstrable anatomical abnormality requires tissue diagnosis unless a specific entity can be confidently identified from the radiographic imaging studies. As an example, a radiographic diagnosis of \"nonossifying fibroma\" may not require a definitive tissue biopsy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80711 \" href=\"mobipreview.htm?21/11/21695\">",
"     image 10",
"    </a>",
"    ), while a \"benign-appearing bone lesion\" warrants biopsy confirmation.",
"   </p>",
"   <p>",
"    For certain lesions, a definitive operative procedure can be planned without requiring a biopsy. As an example, the diagnosis of a low-grade parosteal osteogenic sarcoma is readily apparent on imaging studies in most cases (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65573 \" href=\"mobipreview.htm?36/34/37422\">",
"     image 11",
"    </a>",
"    ). A preoperative biopsy may be avoided in such cases because of the difficulty in determining the appropriate biopsy site within the lesion, and in obtaining tumor tissue in the characteristically hard thick bone. However, even for such lesions, preoperative biopsy is appropriate if the diagnosis is in doubt, or if there is concern about the possibility of dedifferentiation to a higher-grade lesion, which would prompt more aggressive treatment. On imaging studies, areas of high-grade tumor involvement tend to be hypervascular and show the least amount of recognizable bone (less mineralized) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74439 \" href=\"mobipreview.htm?20/63/21502\">",
"     image 12",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A bone biopsy may sometimes be indicated to confirm the diagnosis of metastatic disease prior to definitive treatment with radiation or chemotherapy. Among patients with metastatic disease, the role if surgery is generally limited to maintenance of structure integrity, management of refractory pain, and improvement in quality of life. Metastases represent the most common bone tumor, particularly in the elderly, and are the most frequent indication for a bone biopsy. Taken together, tumors of the breast, prostate, thyroid, lung, kidney, and pancreas account for more than 80 percent of primary tumors in patients presenting with metastatic bone disease. In children, neuroblastoma is the most frequent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/15/15609?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma\", section on 'Metastatic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a primary tumor is known, a skeletal lesion with a typical appearance on imaging studies (either lytic or osteoblastic, (",
"    <a class=\"graphic graphic_table graphicRef54124 \" href=\"mobipreview.htm?21/17/21787\">",
"     table 2",
"    </a>",
"    )) may be presumed to be metastatic, especially if there are multiple lesions. However, because of the dire prognostic implications of metastatic disease, and the outside possibility of a second occult primary malignancy, histologic confirmation of the initial site of metastasis is recommended. It is neither feasible nor desirable to confirm each metastatic lesion by biopsy.",
"   </p>",
"   <p>",
"    Although the prognosis for patients who present with metastatic disease is usually poor, identification of the primary tumor may permit some patients to benefit from therapy that is tailored to the specific type of malignancy. Biopsy of the metastatic deposit may or may not indicate the most likely source of the primary malignancy, even when sophisticated histologic techniques are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In the past, this scenario prompted the performance of elaborate imaging evaluations in an attempt to locate the primary site, but with limited success. It is now recommended that the diagnostic work-up be selectively chosen based upon the patient's gender, the clinical findings, and laboratory tests. The topic of neoplasms of unknown primary site is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/26/14758?source=see_link\">",
"     \"Overview of the classification and management of cancers of unknown primary site\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Planning the biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biopsy must be carefully planned to ensure that adequate diagnostic tissue is obtained without compromising the oncologic outcome. An incorrectly performed biopsy can jeopardize not only the opportunity for limb salvage, but also the possibility of cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The biopsy must be performed such that the entire biopsy tract can be easily excised during later definitive surgery, and not affect the final surgical approach; otherwise, there is a danger of tumor implantation in the scar (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef67748 graphicRef67024 \" href=\"mobipreview.htm?17/59/18352\">",
"       image 13A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. The length of the biopsy incision should be kept to a minimum so that the final resection does not sacrifice excessive normal tissue, and the wound is easily closed (",
"      <a class=\"graphic graphic_picture graphicRef54850 \" href=\"mobipreview.htm?4/32/4608\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Open biopsies that are performed with a transverse rather than longitudinal incision may compromise more than one compartment, and the neurovascular bundle may also be contaminated. This may result in the need for amputation when a limb-sparing procedure might have been otherwise possible.",
"     </li>",
"     <li>",
"      Many bone tumors are hypervascular, and can bleed profusely after even a small incisional biopsy. Careful hemostasis is mandatory, since a hematoma can permit the spread of tumor cells into adjacent compartments, compromise the possibility of limb salvage, and increase the likelihood of a wound infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Biopsies should take place after the completion of the staging studies, and the surgeon, radiologist, and pathologist should review these studies in detail so that each member of the team is fully apprised of the diagnostic considerations. Since the site, approach, and method selected for biopsy is intimately connected to the planned operative procedure, the biopsy should generally be performed at the hospital where definitive surgery will be carried out.",
"   </p>",
"   <p>",
"    The biopsy of a suspected primary neoplasm must yield enough tissue to permit complete histopathological evaluation, including grading. It is desirable for the biopsy to include the highest grade of tumor tissue found within the lesion, to the extent that it is possible, since this is what determines the final stage, and therefore, prognosis. As noted above, areas of high-grade tumor involvement tend to be hypervascular, and show the least amount of recognizable matrix (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71563 \" href=\"mobipreview.htm?7/18/7471\">",
"     image 7",
"    </a>",
"    ). Areas of cystic necrosis seen on imaging studies should be avoided in particular, because necrotic tissue can be histologically uninterpretable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     BIOPSY TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sample of the tumor can be obtained by either open (operative) or needle biopsy techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Operative biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An operative or open biopsy is performed following standard skin preparation and draping. Antibiotics are not typically administered prior to the biopsy; they are not necessary as long as standard sterile technique is used. Furthermore, since infection (osteomyelitis) can sometimes masquerade as a neoplastic process, the use of antibiotics may compromise the utility of cultures taken at the time of biopsy.",
"   </p>",
"   <p>",
"    An incisional biopsy can be performed for primary bone tumors and until recently, was more frequently done for primary bone tumors than an image-guided needle biopsy. Although excisional biopsies may be appropriate for small tumors involving the soft tissue (eg, subcutaneous dermatofibromas or lipomas), they are not advisable for lesions surrounding neurovascular structures, or in locations deep to the fascia. In such cases, inappropriate excision may jeopardize definitive treatment.",
"   </p>",
"   <p>",
"    If an open biopsy is performed, the incision should be placed in accordance with the planned surgical resection. If done properly, the primary tumor and the entire biopsy tract should be resected en bloc. Meticulous hemostasis and the judicious use of a drain are important to avoid the spread of hematoma containing tumor cells. If a soft tissue mass is not present, or material is nondiagnostic, a bone defect may be required to obtain tissue. If so, it should be a small, round or oval defect, and a polymethylmethacrylate plug should be used to close the hole in order to minimize hematoma. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Planning the biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Needle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progress in imaging technology and needle guidance has made it possible to biopsy virtually all parts of the body safely and effectively. Advantages of needle biopsies are that they do not usually require general anesthesia or the operating room, are less expensive, and can be scheduled more readily than an operative biopsy. If the biopsy is performed with image-guidance, the needle can be directed to the lesion and its location documented.",
"   </p>",
"   <p>",
"    The major disadvantage is the limited amount of tissue that is obtained for diagnostic studies (particularly with a fine needle rather than core biopsy), and the possibility of sampling error. The use of the largest possible core biopsy devices to sample the most promising portions of the tumor helps to minimize this problem. However, in view of the extensive adjunctive tissue studies that may be required for a definitive diagnosis (see below), a needle sample may not be adequate, even if appropriately obtained.",
"   </p>",
"   <p>",
"    Needle biopsies may be accomplished with a fine needle, producing a specimen for cytologic analysis, or with cutting needles of various calibers (core needle biopsy). They may be guided either by palpation (\"blind\") or by radiologic imaging, usually CT or ultrasound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     FNA biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fine needle aspiration (FNA) biopsy can be performed with or without image guidance. FNA is an excellent method to confirm metastatic disease in bone and to document tumor recurrence. It is also suitable for diagnosis of infection, although identification of a specific organism in chronic osteomyelitis can be difficult by any method. In contrast, FNA is usually insufficient for making a primary diagnosis of a bone tumor, because of the lack of tissue architecture, and because it can only rarely provide information concerning tumor grade. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/34/4649?source=see_link\">",
"     \"Overview of osteomyelitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Core biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Core biopsies without image guidance can be performed in the clinic setting if the mass is large and easily palpable, and this may result in considerable cost savings when compared to either image-guided or open biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/37\">",
"     37",
"    </a>",
"    ]. However, it is important that the mass be relatively homogeneous, since it is difficult to target a specific portion of a heterogeneous tumor. Core biopsy with image guidance (ie, fluoroscopy, ultrasound, CT or MRI) provides the opportunity to selectively biopsy specific areas of the tumor.",
"   </p>",
"   <p>",
"    While fluoroscopy and ultrasound are the least expensive and least time-consuming techniques, they each have significant limitations. Fluoroscopy is suitable only for bone lesions, and does not provide information about the soft tissues through which the needle is being advanced. Ultrasound guidance is most suitable for soft tissue lesions and cannot be applied to all bones because of problems with penetration of the sound waves. Nevertheless, in one large series, 63 of 144 patients with a suspected primary bone tumor were considered suitable for an ultrasound-guided biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/38\">",
"     38",
"    </a>",
"    ]. Compared to the final surgical result, the diagnostic accuracy was somewhat greater with ultrasound than for fluoroscopically guided biopsy (98 versus 88 percent).",
"   </p>",
"   <p>",
"    CT is the most versatile of the imaging techniques, although it is relatively time consuming. The use of so-called &ldquo;real-time&rdquo; CT or CT fluoroscopy can minimize the time required. Almost any part of the body can be biopsied safely with CT guidance (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81431 graphicRef66635 \" href=\"mobipreview.htm?3/46/3811\">",
"     image 14A-B",
"    </a>",
"    ), and specific areas of tumor can be targeted for biopsy. The accuracy rate ranges from 70 to &gt;90 percent depending on whether a metastatic focus or a primary tumor is biopsied (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. The introduction of three-dimensional (coaxial) needle guidance systems that make use of CT data is a recent advance that appears highly promising [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although MRI-guided bone biopsies appear to be accurate and safe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/45,46\">",
"     45,46",
"    </a>",
"    ], the requirement for open MRI systems (operating at relatively low field strengths), MRI-compatible non-ferromagnetic needles, and patient monitoring equipment limits the availability of this procedure. In addition, access to the patient is limited by the size of the magnet, adding to the difficulties of performing the biopsy and monitoring the patient. MRI is the most costly of the imaging modalities and is not in widespread use for biopsy guidance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Material for cytological preparations can be obtained using any of the fine-caliber cutting needles (eg, the Chiba needle). Placing the needle into the tumor and moving it rapidly in and out in a piston-like movement while maintaining suction with a small amount of saline in a syringe will usually exfoliate a sufficient number of cells. The sample should be immediately spread on a slide and fixed to prevent air-drying.",
"   </p>",
"   <p>",
"    Side-cutting needles (eg, the Tru-Cut needle) result in well-preserved soft tissue samples. Newer automated spring-loaded biopsy devices (eg, the TEMNO device) come in a variety of gauges and have calibrated sheaths that allow them to be accurately placed at the appropriate depth. The length of the core sample can be adjusted on several of these devices to suit the size of the lesion. In our experience and that of others, these devices provide the best biopsy results for both soft tissues and lytic bone lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of intact bone significantly influences needle choice and procedural technique. The needle may need to pass through dense bone in order to obtain a sample of non-ossified tissue (eg, for a lytic bone marrow lesion) or sampling of a mineralized area may be required. When it is necessary to pass through dense bone (but not biopsy it), a drill may facilitate the procedure and be less painful for the patient compared to a trephine needle.",
"   </p>",
"   <p>",
"    A hand operated mechanical drill may be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/48\">",
"     48",
"    </a>",
"    ], but a simple drill turned by the fingers is adequate in most cases. A particularly clever design is the Bonopty or Monopty drill (RADI Medical Systems, Uppsala, Sweden), which has an eccentric bit that produces a hole that is slightly larger than the drill diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/49\">",
"     49",
"    </a>",
"    ]. This permits a protective canula to be introduced into the drill hole, and the anchored canula then serves as a guide for the biopsy needle. This tool is particularly helpful for transpedicle biopsies of the spine (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/44\">",
"     44",
"    </a>",
"    ]. The drill provides access though dense bone, but does not produce a biopsy sample. It must be used in conjunction with a biopsy device, which could be either one of the automated systems (of appropriate gauge) or a simple fine gauge cutting needle (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81056 \" href=\"mobipreview.htm?36/16/37135\">",
"     image 15",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If the tissue to be sampled contains a considerable amount of bone, a trephine needle (eg, an Ackermann or Jamshidi needle) may be helpful. In our experience, these needles work best in trabecular or partially destroyed bone, but do not penetrate intact cortex very readily.",
"   </p>",
"   <p>",
"    As noted above, the transpedicular approach is useful for biopsies of the spine (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74439 \" href=\"mobipreview.htm?20/63/21502\">",
"     image 12",
"    </a>",
"    ). This approach avoids the risk of damage to the spinal nerves, but may not be suitable for some lesions (eg, if the pedicle is small or if the lesion cannot be reached) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/50\">",
"     50",
"    </a>",
"    ]. In expert hands, more than 50 percent of the vertebral body is accessible via a transpedicle approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most needle biopsies of bone can be performed with local anesthetic, either with or without conscious sedation. In general, malignant lesions, particularly metastatic foci, result in less procedural pain than benign lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/52\">",
"     52",
"    </a>",
"    ]. As a result, local anesthesia is adequate for the majority of cases, and conscious sedation is only occasionally needed. For young adolescents and children who are unable to cooperate because of anxiety, conscious sedation or even general anesthesia may be required.",
"   </p>",
"   <p>",
"    The technique of local anesthetic injection is important, as it can either reassure or alarm the patient about the remainder of the procedure. Anesthetic effectiveness is needed only over the width of the biopsy device; extensive infiltration of the skin and subcutaneous tissue is unnecessary and counterproductive. Xylocaine buffered with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    may result in less pain upon injection than xylocaine alone. The beginning of the procedure should be delayed a few minutes after the anesthetic injection to allow time for the anesthetic effect to develop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Accuracy of needle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"success\" of bone biopsy ranges from 90 to 95 percent for metastatic lesions, with lower rates (70 to 80 percent) reported for primary bone tumors and infectious lesions in most series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/38-42,53-57\">",
"     38-42,53-57",
"    </a>",
"    ]. Sclerotic lesions are more difficult to biopsy than are lytic lesions, and accuracy rates for such lesions tend to be lower in many but not all series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/41\">",
"     41",
"    </a>",
"    ]. Causes of error in the biopsy of primary bone tumors include a non-diagnostic biopsy, biopsy histology that fails to match the resection specimen (discordance), and incorrect histologic grade of differentiation (sampling error).",
"   </p>",
"   <p>",
"    Varying diagnostic rates are partly the result of differing definitions of \"success\". As an example, the pathologists' impression of \"malignant cells\" could be regarded as a successful result if all that is required is confirmation of a metastatic lesion; in contrast, such a reading would be inadequate to diagnose or classify a bone sarcoma.",
"   </p>",
"   <p>",
"    One way of handling this dilemma is the concept of \"effective accuracy\", which is defined as the ability of the procedure to replace an open biopsy. As an example, in one series, percutaneous needle biopsy was similarly accurate in identifying suspected metastatic lesions, musculoskeletal infections, and primary musculoskeletal tumors (82, 90, and 83 percent respectively), but the effective accuracy was highest in identifying metastases, slightly lower for infections, and lowest for suspected primary tumors (77, 72, and 59 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/58\">",
"     58",
"    </a>",
"    ]. The authors postulated that because pathologists tended to ask for more tissue (requiring a repeat procedure) in cases of a suspect primary lesion, this reduced the diagnostic utility of a percutaneous biopsy to less than 20 percent for primary tumors.",
"   </p>",
"   <p>",
"    Although the authors of this study concluded that percutaneous needle biopsy was of limited clinical value, our experience suggests that these results are excessively negative. We routinely advocate image-guided biopsy in the patient with a suspected primary bone tumor, if it can be accomplished safely, recognizing that a certain number of repeat procedures or even open biopsies will be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications are rare with image-guided needle biopsy. Some complications may occur with any procedure that breaks the skin (eg, infection, bleeding), while others are anatomically specific (eg, pneumothorax, nerve injury, airway compromise, damage to the great vessels).",
"   </p>",
"   <p>",
"    Although it was previously thought that spinal biopsies have a higher risk of complications than biopsies of appendicular lesions, in two series with a combined 150 spinal biopsies, there was only one complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. This patient, who had been ingesting significant quantities of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for pain management, had a procedure-related hemorrhage. Inadequate hemostasis with hematoma can rarely be life-threatening but also, as noted previously, must be avoided due to adverse effects on outcome. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Planning the biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The use of large caliber biopsy needles can be associated with a significant complication rate, especially in inexperienced hands. In one report of 82 patients undergoing CT-guided biopsy using a Craig needle, there were six complications, including one aortic puncture, two penetrations of the anterior vertebral cortex with hematoma, one wrong level, and two procedures aborted because of pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35673/abstract/59\">",
"     59",
"    </a>",
"    ]. Ten procedures had to be repeated, three times in one case. This complication rate is unusual, and not reflective of the experience at most centers.",
"   </p>",
"   <p>",
"    As noted above, if an incisional biopsy produces a hole in the bone, it should be plugged or packed with polymethylmethacrylate cement to prevent hematoma and tumor spread. Another complication of open biopsy of a bone lesion is fracture; protected weight bearing or even prophylactic stabilization may be necessary following a biopsy. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Operative biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Specimen handling",
"    </span>",
"    &nbsp;&mdash;&nbsp;FNA biopsy yields cells or cell clusters that are suitable for cytological preparation, which can be done rapidly. Although the specific tissue diagnosis may require additional time and special processing, the presence of diagnostic material in the specimen can often be confirmed during the biopsy procedure. This permits additional \"passes\" to be performed as required and decreases the need for repeat procedures. However, as noted above, cytology is seldom adequate for the diagnosis of primary lesions.",
"   </p>",
"   <p>",
"    Frozen section preparation of large core samples can be performed as for an operative specimen. However, analysis of tissue prepared in this way is less accurate than standard permanent fixation, and if the sample is small, it is preferable not to attempt a frozen section. Furthermore, the presence of bone within the sample interferes with optimum slide preparation and decalcification may be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Special handling requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extensive pathologic evaluation that is often required to ascertain the correct diagnosis may require special handling for all or part of the specimen:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      \"Touch preparations\" stained with Wright's stain for certain hematologic malignancies",
"     </li>",
"     <li>",
"      Cytogenetic (karyotyping), flow cytometric studies, and establishment of cell lines (in tissue culture media)",
"     </li>",
"     <li>",
"      Molecular and specialized immunocytochemical studies for molecular biologic analysis (cryopreserved at -70&ordm;)",
"     </li>",
"     <li>",
"      Ultrastructural examination by electron microscopy (in glutaraldehyde buffered solution)",
"     </li>",
"     <li>",
"      Cytologic imprinting for fluorescence in situ hybridization (FISH) studies (alcohol-fixed and air-dried)",
"     </li>",
"     <li>",
"      A sample of tissue, aspiration of fluid, or swab should be sent for microbial culture if osteomyelitis is in the differential diagnosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If lymphoma is suspected, the hematopathologist should be alerted ahead of time for proper tissue handling. It can be difficult to obtain diagnostic tissue from a lymphoma, due to its susceptibility to severe \"crush artifact\". Multiple biopsies are often needed, and even then may not yield a definitive diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/63/33778?source=see_link\">",
"       \"Patient information: Bone cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary malignant bone tumors are uncommon malignancies, but they are an important cause of cancer morbidity and mortality, especially among teenagers and young adults. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary malignant bone tumors are classified according to their cytologic features and cellular products (",
"      <a class=\"graphic graphic_table graphicRef81481 \" href=\"mobipreview.htm?41/39/42620\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The goals of the preoperative evaluation are to establish the tissue diagnosis, evaluate disease extent, and assess the feasibility of a limb-sparing approach. Although plain radiographs can often predict the probable histology of a potentially malignant bone lesion, the definition of tumor size and local intraosseous and extraosseous extent is most accurately achieved by magnetic resonance imaging (MRI). CT is the best method to evaluate the thorax for metastatic disease. PET scans are increasingly being used in place of radionuclide bone scans to evaluate the rest of the skeleton as well as other distant metastatic sites. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnostic and staging work-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The radiographic differential diagnosis depends upon recognition of the tissue type and the degree of aggressiveness (as determined by lesion size and relationship with the surrounding tissues [invasiveness]). Recognition of fat within a tumor is generally a sign that it is benign. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bone biopsy is indicated in the following circumstances (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Indication for biopsy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Whenever there is significant doubt as to the diagnosis of a benign or malignant lesion",
"     </li>",
"     <li>",
"      When the histologic distinction among possible diagnoses could alter the planned course of treatment",
"     </li>",
"     <li>",
"      When definitive confirmation of the diagnosis is required before undertaking a hazardous, costly, or potentially disfiguring treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The biopsy of a suspected primary bone tumor must be carefully planned to avoid compromising the oncologic outcome. Although a fine needle aspiration biopsy may be adequate for the diagnosis of a metastatic or recurrent bone lesion, core needle biopsy, or an open biopsy is usually required for most primary bone tumors. Open biopsies are being done less frequently since most core needle biopsies can deliver sufficient tissue on multiple passes for all diagnostic studies. Given the heterogeneity of most sarcomas, the ability to guide the core needle to regions of more aggressive tumor is very important to accurately diagnosis and grade the sarcoma. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Biopsy techniques'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The extensive pathologic evaluation that is often required to ascertain the correct diagnosis may require special handling for all or part of the specimen. This process can last one to two weeks depending on the number of tests necessary. Among patients undergoing an open biopsy, frozen section analysis is important in determining whether sufficient tissue has been acquired. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Special handling requirements'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Gurney JG, Swensen AR, Bulterys M. Malignant bone tumors. In: Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995, Ries LA, Smith MAS, Gurney JG, et al (Eds), SEER program, National Cancer Institute, Bethesda MD 1999. p.99. (Pub #99-4649).",
"    </li>",
"    <li>",
"     Smith MA, Gurney JG, Ries LA. Cancer in adolescents 15 to 19 years old. In: Cancer incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995, Ries LA, Smith MAS, Gurney JG, et al (Eds), SEER program, National Cancer Institute, Bethesda MD 1999. (Pub #99-4649).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/3\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/4\">",
"      Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest 2001; 19:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/5\">",
"      Jeffree GM, Price CH, Sissons HA. The metastatic patterns of osteosarcoma. Br J Cancer 1975; 32:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/6\">",
"      Sajadi KR, Heck RK, Neel MD, et al. The incidence and prognosis of osteosarcoma skip metastases. Clin Orthop Relat Res 2004; :92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/7\">",
"      Kager L, Zoubek A, Kastner U, et al. Skip metastases in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 2006; 24:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/8\">",
"      Schirrmeister H, Glatting G, Hetzel J, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001; 42:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/9\">",
"      Bhagia SM, Grimer RJ, Davies AM, Mangham DC. Scintigraphically negative skip metastasis in osteosarcoma. Eur Radiol 1997; 7:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/10\">",
"      Savelli G, Maffioli L, Maccauro M, et al. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med 2001; 45:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/11\">",
"      Ryan PJ, Fogelman I. The bone scan: where are we now? Semin Nucl Med 1995; 25:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/12\">",
"      Jacobson AF, Stomper PC, Jochelson MS, et al. Association between number and sites of new bone scan abnormalities and presence of skeletal metastases in patients with breast cancer. J Nucl Med 1990; 31:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/13\">",
"      Schirrmeister H, Guhlmann A, Kotzerke J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999; 17:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/14\">",
"      Kao CH, Hsieh JF, Tsai SC, et al. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res 2000; 20:2189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/15\">",
"      Cook GJ, Fogelman I. The role of positron emission tomography in the management of bone metastases. Cancer 2000; 88:2927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/16\">",
"      Cook GJ, Houston S, Rubens R, et al. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998; 16:3375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/17\">",
"      Bury T, Barreto A, Daenen F, et al. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998; 25:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/18\">",
"      Coleman RE. Monitoring of bone metastases. Eur J Cancer 1998; 34:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/19\">",
"      Franzius C, Sciuk J, Daldrup-Link HE, et al. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 2000; 27:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/20\">",
"      V&ouml;lker T, Denecke T, Steffen I, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007; 25:5435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/21\">",
"      Peterson JJ. F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors. Semin Musculoskelet Radiol 2007; 11:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/22\">",
"      Staudenherz A, Steiner B, Puig S, et al. Is there a diagnostic role for bone scanning of patients with a high pretest probability for metastatic renal cell carcinoma? Cancer 1999; 85:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/23\">",
"      Brown DH, Leakos M. The value of a routine bone scan in a metastatic survey. J Otolaryngol 1998; 27:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/24\">",
"      Colletti PM, Dang HT, Deseran MW, et al. Spinal MR imaging in suspected metastases: correlation with skeletal scintigraphy. Magn Reson Imaging 1991; 9:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/25\">",
"      Kattapuram SV, Khurana JS, Scott JA, el-Khoury GY. Negative scintigraphy with positive magnetic resonance imaging in bone metastases. Skeletal Radiol 1990; 19:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/26\">",
"      Daldrup-Link HE, Franzius C, Link TM, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 2001; 177:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/27\">",
"      Lauenstein TC, Goehde SC, Herborn CU, et al. Three-dimensional volumetric interpolated breath-hold MR imaging for whole-body tumor staging in less than 15 minutes: a feasibility study. AJR Am J Roentgenol 2002; 179:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/28\">",
"      Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res 1986; :9.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 6th, Greene FL, Page DL, Fleming ID, et al (Eds), Springer Verlag, New York 2002. p.187.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/30\">",
"      Alcalay M, Azais I, Brigeon B, et al. Strategy for identifying primary malignancies with inaugural bone metastases. Rev Rhum Engl Ed 1995; 62:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/31\">",
"      Rougraff BT, Kneisl JS, Simon MA. Skeletal metastases of unknown origin. A prospective study of a diagnostic strategy. J Bone Joint Surg Am 1993; 75:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/32\">",
"      Mankin HJ, Mankin CJ, Simon MA. The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society. J Bone Joint Surg Am 1996; 78:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/33\">",
"      Peabody TD, Simon MA. Making the diagnosis: keys to a successful biopsy in children with bone and soft-tissue tumors. Orthop Clin North Am 1996; 27:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/34\">",
"      Simon MA, Biermann JS. Biopsy of bone and soft-tissue lesions. J Bone Joint Surg Am 1993; 75:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/35\">",
"      Davies NM, Livesley PJ, Cannon SR. Recurrence of an osteosarcoma in a needle biopsy track. J Bone Joint Surg Br 1993; 75:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/36\">",
"      Schwartz HS, Spengler DM. Needle tract recurrences after closed biopsy for sarcoma: three cases and review of the literature. Ann Surg Oncol 1997; 4:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/37\">",
"      Skrzynski MC, Biermann JS, Montag A, Simon MA. Diagnostic accuracy and charge-savings of outpatient core needle biopsy compared with open biopsy of musculoskeletal tumors. J Bone Joint Surg Am 1996; 78:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/38\">",
"      Saifuddin A, Mitchell R, Burnett SJ, et al. Ultrasound-guided needle biopsy of primary bone tumours. J Bone Joint Surg Br 2000; 82:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/39\">",
"      Jelinek JS, Murphey MD, Welker JA, et al. Diagnosis of primary bone tumors with image-guided percutaneous biopsy: experience with 110 tumors. Radiology 2002; 223:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/40\">",
"      Hau A, Kim I, Kattapuram S, et al. Accuracy of CT-guided biopsies in 359 patients with musculoskeletal lesions. Skeletal Radiol 2002; 31:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/41\">",
"      Leffler SG, Chew FS. CT-guided percutaneous biopsy of sclerotic bone lesions: diagnostic yield and accuracy. AJR Am J Roentgenol 1999; 172:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/42\">",
"      Dupuy DE, Rosenberg AE, Punyaratabandhu T, et al. Accuracy of CT-guided needle biopsy of musculoskeletal neoplasms. AJR Am J Roentgenol 1998; 171:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/43\">",
"      Appelbaum AH, Kamba TT, Cohen AS, et al. Effectiveness and safety of image-directed biopsies: coaxial technique versus conventional fine-needle aspiration. South Med J 2002; 95:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/44\">",
"      Ahlstr&ouml;m KH, Astr&ouml;m KG. CT-guided bone biopsy performed by means of a coaxial biopsy system with an eccentric drill. Radiology 1993; 188:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/45\">",
"      Blanco Sequeiros R, Klemola R, Ojala R, et al. MRI-guided trephine biopsy and fine-needle aspiration in the diagnosis of bone lesions in low-field (0.23 T) MRI system using optical instrument tracking. Eur Radiol 2002; 12:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/46\">",
"      Parkkola RK, Mattila KT, Heikkil&auml; JT, et al. Dynamic contrast-enhanced MR imaging and MR-guided bone biopsy on a 0.23 T open imager. Skeletal Radiol 2001; 30:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/47\">",
"      Hopper KD, Abendroth CS, Sturtz KW, et al. Automated biopsy devices: a blinded evaluation. Radiology 1993; 187:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/48\">",
"      Kattapuram SV, Rosenthal DI, Phillips WC. Trephine biopsy of the skeleton with the aid of a hand drill. Radiology 1984; 152:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/49\">",
"      Astr&ouml;m KG, Sundstr&ouml;m JC, Lindgren PG, Ahlstr&ouml;m KH. Automatic biopsy instruments used through a coaxial bone biopsy system with an eccentric drill tip. Acta Radiol 1995; 36:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/50\">",
"      Jelinek JS, Kransdorf MJ, Gray R, et al. Percutaneous transpedicular biopsy of vertebral body lesions. Spine (Phila Pa 1976) 1996; 21:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/51\">",
"      Stringham DR, Hadjipavlou A, Dzioba RB, Lander P. Percutaneous transpedicular biopsy of the spine. Spine (Phila Pa 1976) 1994; 19:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/52\">",
"      Kruyt RH, Oudkerk M, van Sluis D. CT-guided bone biopsy in a cancer center: experience with a new apple corer-shaped device. J Comput Assist Tomogr 1998; 22:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/53\">",
"      Yao L, Nelson SD, Seeger LL, et al. Primary musculoskeletal neoplasms: effectiveness of core-needle biopsy. Radiology 1999; 212:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/54\">",
"      Kattapuram SV, Khurana JS, Rosenthal DI. Percutaneous needle biopsy of the spine. Spine (Phila Pa 1976) 1992; 17:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/55\">",
"      Babu NV, Titus VT, Chittaranjan S, et al. Computed tomographically guided biopsy of the spine. Spine (Phila Pa 1976) 1994; 19:2436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/56\">",
"      Bommer KK, Ramzy I, Mody D. Fine-needle aspiration biopsy in the diagnosis and management of bone lesions: a study of 450 cases. Cancer 1997; 81:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/57\">",
"      Kornblum MB, Wesolowski DP, Fischgrund JS, Herkowitz HN. Computed tomography-guided biopsy of the spine. A review of 103 patients. Spine (Phila Pa 1976) 1998; 23:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/58\">",
"      Fraser-Hill MA, Renfrew DL. Percutaneous needle biopsy of musculoskeletal lesions. 1. Effective accuracy and diagnostic utility. AJR Am J Roentgenol 1992; 158:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35673/abstract/59\">",
"      Olscamp A, Rollins J, Tao SS, Ebraheim NA. Complications of CT-guided biopsy of the spine and sacrum. Orthopedics 1997; 20:1149.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7741 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-AF7A4312D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_53_35673=[""].join("\n");
var outline_f34_53_35673=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSTIC AND STAGING WORK-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Radiographic imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Evaluation of the rest of the skeleton",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Staging system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INDICATION FOR BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Doubtful diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Planning the biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      BIOPSY TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Operative biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Needle biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - FNA biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Core biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Accuracy of needle biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Specimen handling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Special handling requirements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7741\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7741|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/21/23903\" title=\"diagnostic image 1\">",
"      Xray osteosarc distal femur",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/19/8496\" title=\"diagnostic image 2\">",
"      CT chondro",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?39/49/40734\" title=\"diagnostic image 3\">",
"      Ewings sarcoma left tibia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?17/0/17408\" title=\"diagnostic image 4\">",
"      Radiograph onion skinning Ewing sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/53/42847\" title=\"diagnostic image 5\">",
"      Bone scan multiple bone mets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?25/44/26307\" title=\"diagnostic image 6\">",
"      Lymphoma with extensive bony metastases PET scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?7/18/7471\" title=\"diagnostic image 7\">",
"      Plain xray solitary bone met",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/60/24516\" title=\"diagnostic image 8\">",
"      X-ray blastic lytic and mixed metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/35/39476\" title=\"diagnostic image 9\">",
"      CT blastic lytic and mixed metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?21/11/21695\" title=\"diagnostic image 10\">",
"      Radiograph nonossifying fibroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?36/34/37422\" title=\"diagnostic image 11\">",
"      Dedifferent parosteal osteosarc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/63/21502\" title=\"diagnostic image 12\">",
"      Transpedicle CT needle bone bx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?27/1/27678\" title=\"diagnostic image 13A\">",
"      Posterior needle bx bone tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/18/23854\" title=\"diagnostic image 13B\">",
"      Anterior needle bx bone tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/28/42447\" title=\"diagnostic image 14A\">",
"      CT guided bone bx cerv spine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?4/2/4143\" title=\"diagnostic image 14B\">",
"      CT guided bone bx ant sacrum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?36/16/37135\" title=\"diagnostic image 15\">",
"      Drill use for bx femoral cortex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7741|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/53/23391\" title=\"figure 1\">",
"      Components of a long bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/34/13864\" title=\"figure 2\">",
"      Bone tumor locations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7741|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/32/4608\" title=\"picture 1\">",
"      Biopsy incision bone tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7741|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/39/42620\" title=\"table 1\">",
"      Classify primary malignant bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/17/21787\" title=\"table 2\">",
"      Typical radiographic response in bone to select tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/43/26301\" title=\"table 3\">",
"      TNM staging bone tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37690?source=related_link\">",
"      Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35450?source=related_link\">",
"      Chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/15/15609?source=related_link\">",
"      Clinical presentation, diagnosis, and staging evaluation of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37769?source=related_link\">",
"      Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/33/5658?source=related_link\">",
"      Giant cell tumor of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/50/32551?source=related_link\">",
"      Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20842?source=related_link\">",
"      Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24522?source=related_link\">",
"      Overview of benign bone tumors in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/26/14758?source=related_link\">",
"      Overview of the classification and management of cancers of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/63/33778?source=related_link\">",
"      Patient information: Bone cancer (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_53_35674="Inhibition of acute preterm labor";
var content_f34_53_35674=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Inhibition of acute preterm labor",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/53/35674/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35674/contributors\">",
"     Hyagriv N Simhan, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35674/contributors\">",
"     Steve Caritis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/53/35674/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35674/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/53/35674/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/53/35674/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/53/35674/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preterm labor precedes about 50 percent of preterm births, but approximately 30 percent of preterm labor spontaneously resolves, less than 10 percent of women presenting with preterm contractions give birth within seven days, and 50 percent of patients hospitalized for preterm labor give birth at term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. For patients with true preterm labor, tocolytic therapy often abolishes contractions temporarily, but does not remove the underlying stimulus that initiated the process of parturition or reverse parturitional changes in the uterus (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/0/6153?source=see_link\">",
"     \"Physiology of parturition\"",
"    </a>",
"    ). The net result is that a single course of tocolytics may delay delivery by hours to days, but not weeks or months.",
"   </p>",
"   <p>",
"    This topic will discuss use of tocolytics for inhibition of acute preterm labor. Other issues related to preterm labor are reviewed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/30/5608?source=see_link\">",
"       \"Overview of preterm labor and birth\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/40/32393?source=see_link\">",
"       \"Pathogenesis of spontaneous preterm birth\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/3/35898?source=see_link\">",
"       \"Risk factors for preterm labor and delivery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11994?source=see_link\">",
"       \"Prevention of spontaneous preterm birth\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION AND TREATMENT GOALS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1282503\">",
"    <span class=\"h2\">",
"     Indications for tocolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Obstetricians and Gynecologists (ACOG) states that &ldquo;interventions to reduce the likelihood of delivery should be reserved for women with preterm labor at a gestational age at which a delay in delivery will provide benefit to the newborn. Because tocolytic therapy generally is effective for up to 48 hours, only women with fetuses that would benefit from a 48-hour delay in delivery should receive tocolytic treatment&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/6\">",
"     6",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1277522\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation (eg, laboratory tests and examination) of women with preterm contractions and criteria for diagnosis of preterm labor are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/30/5608?source=see_link&amp;anchor=H32276031#H32276031\">",
"     \"Overview of preterm labor and birth\", section on 'Preterm labor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281961\">",
"    <span class=\"h2\">",
"     Treatment goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the limited ability of tocolytic therapy to delay delivery for a prolonged period of time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], the goals of treatment of preterm labor are to [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delay delivery by at least 48 hours so that corticosteroids given to the mother can achieve their maximum",
"      <span class=\"nowrap\">",
"       fetal/neonatal",
"      </span>",
"      effect. Predelivery administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      reduces the risk of neonatal death, respiratory distress syndrome, intraventricular hemorrhage, and necrotizing enterocolitis in premature neonates. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=see_link\">",
"       \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Provide time for safe transport of the mother, if indicated, to a facility that has an appropriate level of neonatal care if the patient delivers preterm.",
"     </li>",
"     <li>",
"      Prolong pregnancy when there are underlying, self-limited conditions that can cause labor, such as pyelonephritis or abdominal surgery, and are unlikely to cause recurrent preterm labor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, tocolysis is not mandatory when antenatal corticosteroids are administered. Antenatal corticosteroids should be administered if postnatal resuscitation is planned, whether or not tocolysis is administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1348457168\">",
"    <span class=\"h2\">",
"     Gestational age limits for tocolytic therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1276501\">",
"    <span class=\"h3\">",
"     Lower limit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tocolytics are generally not indicated prior to neonatal viability since these drugs do not delay delivery for more than a few days. However, the lowest gestational age for which inhibition of preterm labor should be considered is controversial, and there are no definitive data from randomized trials on which to base a recommendation.",
"   </p>",
"   <p>",
"    We feel that gestational age is not as relevant as the underlying etiology of preterm labor. As an example, attempting to inhibit contractions after a self-limited event that has been associated with preterm labor, such as appendicitis with appendectomy, may be reasonable even at a previable gestational age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1276508\">",
"    <span class=\"h3\">",
"     Upper limit",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is greater consensus regarding the upper gestational age limit for treatment of preterm labor. Thirty-four weeks of gestation typically defines the threshold at which perinatal morbidity and mortality are felt to be too low to justify the potential maternal and fetal complications and costs associated with inhibition of labor and short-term delay of delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/6,12-15\">",
"     6,12-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One decision analysis of preterm labor strategies by gestational age concluded that, at &le;32 weeks, tocolysis was preferable to no tocolysis or decisions based on fetal lung maturity assessment, and at &ge;36 weeks, no tocolysis was the preferred approach, but neither strategy was clearly preferable at 34 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/14\">",
"       14",
"      </a>",
"      ]. They also recommended not performing amniocentesis for determination of fetal lung maturity.",
"      <br/>",
"      <br/>",
"      A cost-effectiveness analysis concluded that less than 34 weeks of gestation routine tocolysis of preterm labor was cost-effective compared to amniocentesis with tocolysis limited to pregnancies with immature fetal lung assessment results [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Contraindications to tocolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with preterm contractions without cervical change, especially those with a cervical dilation of &lt;2 cm, generally should not be treated with tocolytics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tocolysis is contraindicated when the",
"    <span class=\"nowrap\">",
"     maternal/fetal",
"    </span>",
"    risks of prolonging pregnancy or the risks associated with these drugs are greater than the risks associated with preterm birth. Established contraindications to labor inhibition include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intrauterine fetal demise",
"     </li>",
"     <li>",
"      Lethal fetal anomaly",
"     </li>",
"     <li>",
"      Nonreassuring fetal status",
"     </li>",
"     <li>",
"      Severe preeclampsia or eclampsia",
"     </li>",
"     <li>",
"      Maternal hemorrhage with hemodynamic instability",
"     </li>",
"     <li>",
"      Intraamniotic infection",
"     </li>",
"     <li>",
"      Maternal contraindications to the tocolytic drug",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Known or suspected fetal pulmonary maturity is not an absolute contraindication to tocolysis, as there are nonpulmonary morbidities associated with preterm birth. As an example, a 30-week fetus with a mature amniotic fluid fetal lung maturity test is still at risk for intraventricular hemorrhage, sepsis, hyperbilirubinemia, and other morbidities unrelated to respiratory distress syndrome. These fetuses could potentially benefit from prolongation of pregnancy and the nonpulmonary benefits of glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inhibition of preterm labor is less likely to be successful when cervical dilation is greater than 3 cm. Tocolysis can still be considered in these cases, especially when the goal is to administer antenatal corticosteroids or safely transport the mother to a tertiary care center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contraindications to use of specific agents are reviewed below in discussions of specific tocolytic drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1277601\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selection of an appropriate labor-inhibiting agent should be based upon efficacy and safety. Ideally, efficacy should be established in terms of significant clinical endpoints (eg, reduction in rate of respiratory distress or perinatal mortality) rather than surrogate endpoints (eg, prolongation of pregnancy by 48 hours or 7 days). The drug should be safe for the mother, fetus, and neonate.",
"   </p>",
"   <p>",
"    A network meta-analysis pools all available direct and indirect evidence on relative treatment effects into a single coherent analysis to estimate the relative effects of each treatment compared with every other treatment in a network, even though some treatment pairs may not have been directly compared. It also allows calculation of the probability that each treatment, or class, is the best for any given outcome. In a systematic review and network meta-analysis of 95 randomized trials of tocolytic therapy for preterm labor, all of the commonly used tocolytic agents (cyclooxygenase inhibitors, beta-adrenergic receptor agonist, calcium channel blockers,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    , oxytocin receptor antagonists) were statistically more effective than",
"    <span class=\"nowrap\">",
"     placebo/no",
"    </span>",
"    therapy for delaying delivery for 48 hours (odds ratios compared to",
"    <span class=\"nowrap\">",
"     placebo/no",
"    </span>",
"    treatment ranged from 1.91 to 5.39) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/18\">",
"     18",
"    </a>",
"    ]. Cyclooxygenase inhibitors and calcium channel blockers had the highest probability of delaying delivery and improving neonatal and maternal outcomes. However, prolongation of pregnancy was not associated with a statistically significant reduction in overall rates of respiratory distress syndrome or neonatal death. This may be related to the rarity of neonatal death and inconsistency in definitions and reported outcomes among trials.",
"   </p>",
"   <p>",
"    If the first tocolytic agent chosen does not successfully inhibit contractions, the clinician can discontinue it and begin therapy with a second agent. There is no consensus on whether women in preterm labor should be evaluated for subclinical infection or the appropriate tests for diagnosis of subclinical infection. We offer amniocentesis to assess for infection when the patient is afebrile, but has nonspecific laboratory or physical findings suggestive of infection, such as leukocytosis, unexplained maternal or fetal tachycardia, or uterine tenderness. We obtain an amniotic fluid gram stain and glucose before beginning a second tocolytic agent, and send the fluid for culture for aerobes, anaerobes, ureaplasma, and mycoplasma. We would not continue the first tocolytic or begin a second tocolytic if these tests were suggestive of subclinical infection. Amniotic fluid cultures are positive in almost 65 percent of women in whom tocolysis with a single agent is not successful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42761?source=see_link\">",
"     \"Intraamniotic infection (chorioamnionitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concurrent use of more than one tocolytic agent should be undertaken with caution because of the increased risk of side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no data on the role of repeated courses of tocolytics for treatment of recurrent preterm labor.",
"   </p>",
"   <p>",
"    In patients receiving antenatal corticosteroids, we discontinue tocolytics 48 hours after administration of the first corticosteroid dose. We offer tocolysis for inhibition of preterm labor when giving a rescue course of steroids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1278239\">",
"    <span class=\"h1\">",
"     TOCOLYTIC OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women 24 to 32 weeks of gestation who are candidates for tocolysis, we use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    as first-line therapy for labor inhibition. Data from randomized trials suggest it is superior to placebo, and it has a relatively favorable maternal and fetal side effect profile. For women 32 to 34 weeks of gestation, we use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    for initial treatment of preterm labor, given the potential for adverse fetal effects with indomethacin use at this gestational age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1279823\">",
"    <span class=\"h2\">",
"     Cyclooxygenase inhibitors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1279954\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclooxygenase (COX, or prostaglandin [PGH] synthase) is the enzyme responsible for conversion of arachidonic acid to prostaglandins (",
"    <a class=\"graphic graphic_figure graphicRef66146 \" href=\"mobipreview.htm?33/29/34269\">",
"     figure 1",
"    </a>",
"    ), which are critical in parturition. Prostaglandins enhance the formation of myometrial gap junctions and increase available intracellular calcium by raising transmembrane influx and sarcolemmal release of calcium. Cyclooxygenase exists in two isoforms, COX 1 and COX 2. COX 1 is synthesized at a constant rate in gestational tissues, while COX 2 is inducible, dramatically increasing in the decidua and myometrium during term and preterm labor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/0/6153?source=see_link\">",
"     \"Physiology of parturition\"",
"    </a>",
"    .) Cyclooxygenase inhibitors decrease prostaglandin production by either general inhibition of cyclooxygenase or specific inhibition of COX 2, depending upon the agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/20-24\">",
"     20-24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1279961\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     Indomethacin",
"    </a>",
"    , a nonspecific COX inhibitor, is the most commonly used tocolytic of this class. A Cochrane review of trials comparing COX inhibitors with placebo for treatment of preterm labor included only two trials involving 70 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/25\">",
"     25",
"    </a>",
"    ]. Due to small numbers, the estimates of effect were imprecise and need to be interpreted with caution. Compared to placebo, COX inhibition showed a trend in reduction in risk of delivery within 48 hours of initiation of treatment (RR 0.20, 95% CI 0.03-1.28) and within seven days (RR 0.41, 95% CI 0.10-1.66). No differences were detected in neonatal outcomes: perinatal mortality, respiratory distress syndrome, premature closure of the ductus, persistent pulmonary hypertension of the newborn, intraventricular hemorrhage, or neonatal renal failure.",
"   </p>",
"   <p>",
"    The findings of this Cochrane review were driven primarily by the results of one trial that randomly assigned 30 women with preterm labor to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/26\">",
"     26",
"    </a>",
"    ]. Indomethacin was significantly more effective than placebo in inhibition of preterm labor during a 24-hour course of therapy; treatment failure during therapy occurred in only 1 of 15 indomethacin-treated patients compared with 9 of 15 placebo-treated patients (P&lt;0.01). There were no differences between the indomethacin and placebo groups with respect to gestational age at delivery, birth weight, or neonatal morbidity and mortality. In particular, there was no evidence of premature closure of the ductus arteriosus, pulmonary hypertension, or increase in bleeding problems among the infants exposed to indomethacin in utero (see",
"    <a class=\"local\" href=\"#H1279975\">",
"     'Fetal side effects'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Three trials involving 415 patients compared COX inhibition to other tocolytics (beta-adrenergic receptor agonists or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/25\">",
"     25",
"    </a>",
"    ]. Compared to the other drugs, COX inhibitors were associated with a trend toward reduction of birth within 48 hours of initiation of treatment (RR 0.59, 95% CI 0.34-1.02), although the results did not reach statistical significance. The effect was more robust when COX inhibition was only compared with beta-adrenergic receptor agonists (RR 0.27, 95% CI 0.08-0.96).",
"   </p>",
"   <p>",
"    Based on these data and the side effect profile described below, a decision analysis suggested",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    as first-line therapy for preterm labor before 32 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/7\">",
"     7",
"    </a>",
"    ]. Indomethacin is also cost-effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is limited information on the use of COX-2 inhibitors for treatment of preterm labor in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/28-32\">",
"     28-32",
"    </a>",
"    ]. Further evaluation of the safety and efficacy of selective COX 2 inhibitors for inhibition of preterm labor is warranted before introducing these drugs into clinical practice; however, most of these agents have either been withdrawn from the market or issued with black box warnings regarding the risk of serious adverse events (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1279968\">",
"    <span class=\"h3\">",
"     Maternal side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal side effects, including nausea, esophageal reflux, gastritis, and emesis, are seen in approximately 4 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    for preterm labor. Platelet dysfunction may occur. Alterations in maternal cardiovascular physiology are minimal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The gastrointestinal side effects of COX 2 inhibitors are less frequent and less severe than those associated with nonspecific cyclooxygenase inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/33\">",
"     33",
"    </a>",
"    ]. However, as discussed above, a black box warning has been added to the labeling of COX 2 inhibitors because of excess adverse cardiovascular outcomes (eg, myocardial infarction, stroke). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1279975\">",
"    <span class=\"h3\">",
"     Fetal side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary fetal concerns with use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    and other COX inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/17/44312?source=see_link\">",
"     sulindac",
"    </a>",
"    , nimesulide) are constriction of the ductus arteriosus and oligohydramnios.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1279982\">",
"    <span class=\"h4\">",
"     Constriction of the ductus arteriosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature narrowing or closure of the ductus arteriosus can lead to pulmonary hypertension, tricuspid regurgitation, and persistent fetal circulation. Several cases of premature ductal closure have been reported in pregnancies in which the duration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    exposure exceeded 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]; however, this complication has not occurred in more than 500 fetuses exposed to shorter durations of indomethacin treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some series, in-utero exposure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    has also been associated with more severe patent ductus arteriosus in premature infants and an increased need for surgical therapy after failed medical management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/39-43\">",
"     39-43",
"    </a>",
"    ], but data have not been consistent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/44\">",
"     44",
"    </a>",
"    ]. Longer in-utero exposure (&gt;72 hours) appears to confer a higher risk. Data from well-designed trials are needed to determine whether this association is real. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/50/15145?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ductal constriction appears to depend upon both gestational age and duration of exposure. It has been described at gestations as early as 24 weeks, but is most common after 31 to 32 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/45\">",
"     45",
"    </a>",
"    ]. Therefore,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    is",
"    <strong>",
"     not",
"    </strong>",
"    recommended after 32 weeks of gestation. Before 32 weeks, fetal echocardiographic evaluation is useful for monitoring ductal effects if the duration of therapy exceeds 48 hours. Sonographic signs of ductal narrowing include tricuspid regurgitation, right ventricular dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/46\">",
"     46",
"    </a>",
"    ], and pulsatility index less than 1.9 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1279989\">",
"    <span class=\"h4\">",
"     Oligohydramnios",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    and other COX inhibitors cause a reduction in fetal urine output, and in turn amniotic fluid volume, because these drugs enhance the action of vasopressin and reduce renal blood flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. For this reason, they have been used as a medical therapy for symptomatic polyhydramnios [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    COX inhibitors can also lead to oligohydramnios in women with normal amniotic fluid volume. As an example, one study on the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    for greater than 72 hours in 67 women with preterm labor reported ultrasound documented oligohydramnios in 70 percent of patients treated with indomethacin and 27 percent of women treated with ibuprofen, but in less than 3 percent of untreated controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/51\">",
"     51",
"    </a>",
"    ]. One of the latter pregnancies was complicated by intrauterine growth restriction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1279996\">",
"    <span class=\"h4\">",
"     Neonatal effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal complications that have been associated with in utero",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    exposure include bronchopulmonary dysplasia, necrotizing enterocolitis, patent ductus arteriosus, periventricular leukomalacia, and intraventricular hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/39,40,52-54\">",
"     39,40,52-54",
"    </a>",
"    ]. These associations are controversial. They were not supported by one meta-analysis of randomized and observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/55\">",
"     55",
"    </a>",
"    ] and only partially supported by another meta-analysis of cohort and case control studies (periventricular leukomalacia [95% CI 1.3-3.1], intraventricular hemorrhage [95% CI 1.1-4.2]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    has long-term developmental effects is also unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Significant variations in study designs and small numbers of subjects preclude making a definitive conclusion about the safety or potential harm of indomethacin tocolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1280003\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal contraindications to COX inhibitors include platelet dysfunction or bleeding disorder, hepatic dysfunction, gastrointestinal ulcerative disease, renal dysfunction, and asthma (in women with hypersensitivity to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1280010\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    for labor inhibition is a 50 to 100 mg loading dose (may be given per rectum), followed by 25 mg orally every four to six hours. Fetal blood concentrations are 50 percent of maternal values, but the half-life in the neonate is substantially longer than that in the mother (15 versus 2.2 hours).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1280017\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;If",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    is continued for longer than 48 hours, sonographic evaluation for oligohydramnios and narrowing of the fetal ductus arteriosus is warranted at least weekly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/26,60\">",
"     26,60",
"    </a>",
"    ]. Evidence of oligohydramnios or ductal constriction should prompt discontinuation of this therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1280923\">",
"    <span class=\"h2\">",
"     Calcium channel blockers",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281059\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium channel blockers directly block the influx of calcium ions through the cell membrane. They also inhibit release of intracellular calcium from the sarcoplasmic reticulum and increase calcium efflux from the cell. The resulting decrease in intracellular free calcium leads to inhibition of calcium-dependent myosin light-chain kinase phosphorylation and results in myometrial relaxation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/0/6153?source=see_link\">",
"     \"Physiology of parturition\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281066\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no large randomized trials directly comparing the efficacy of calcium channel blockers with placebo for treatment of preterm labor.",
"   </p>",
"   <p>",
"    In a meta-analysis of 13 randomized trials (1000 patients) specifically comparing treatment of preterm labor with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    versus beta-adrenergic receptor agonists, patients treated with nifedipine had fewer deliveries within 7 days (RR 0.82, 95% CI 0.70-0.97; 37 versus 45 percent) and before 34 weeks of gestation (RR 0.77, 95% CI 0.66-0.91; 48 versus 62 percent), but there was no significant difference in delivery within 48 hours of treatment (RR 0.84, 95% CI 0.68-1.05; 21 versus 24 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/61\">",
"     61",
"    </a>",
"    ]. Use of nifedipine was also associated with significant reductions in risk of respiratory distress syndrome, necrotizing enterocolitis, intraventricular hemorrhage, neonatal jaundice, and admission to the neonatal intensive care unit, and had a better side effect profile.",
"   </p>",
"   <p>",
"    Meta-analysis of four randomized trials comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    and one randomized trial comparing nifedipine with atosiban did not find significant differences in the rate of delivery within 48 hours or within 7 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/61\">",
"     61",
"    </a>",
"    ]. Nifedipine was associated with fewer adverse maternal drug reactions than magnesium sulfate.",
"   </p>",
"   <p>",
"    The best evidence in favor of use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    as a tocolytic is its relative safety, maternal tolerance, and ease of administration when compared with beta agonists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/62\">",
"     62",
"    </a>",
"    ]. The absolute efficacy of nifedipine is less clear in the absence of placebo-controlled trials. The available comparative studies have been with ritodrine, which was often excessively dosed during intravenous therapy and inadequately dosed during oral therapy. The poor methodological quality of these trials limits their clinical utility and the value of meta-analysis. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281073\">",
"    <span class=\"h3\">",
"     Maternal side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     Nifedipine",
"    </a>",
"    is a peripheral vasodilator, thus it may cause symptoms such as nausea, flushing, headache, dizziness, and palpitations. Arterial relaxation results in decreased total vascular resistance, which is accompanied by a compensatory rise in cardiac output (reflex increase in heart rate and increased stroke volume). These compensatory changes generally maintain blood pressure in women who have no underlying myocardial dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/63\">",
"     63",
"    </a>",
"    ]; however, severe hypotension has been described in case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. By comparison, beta-adrenergic agonists are more frequently associated with adverse cardiovascular changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32966?source=see_link\">",
"     \"Major side effects and safety of calcium channel blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281080\">",
"    <span class=\"h3\">",
"     Fetal side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In animal studies, administration of calcium channel blockers decreased uterine blood flow and fetal oxygen saturation; however, this has not been confirmed in humans and Doppler studies of human fetal systemic, umbilical, and uteroplacental blood flow have been reassuring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/63,69-71\">",
"     63,69-71",
"    </a>",
"    ]. The fetal acid-base status in the umbilical cord at delivery and from percutaneously obtained blood sampling has not shown any clear evidence of fetal hypoxia or acidosis when these agents were used. These findings were based upon studies using 10 mg sublingual dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    . There are no data regarding fetal side effects with oral dosing with the doses commonly used for labor inhibition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281087\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium channel blockers are contraindicated in women with known hypersensitivity to the drug, hypotension, or preload-dependent cardiac lesions and should be used with caution in women with left ventricular dysfunction or congestive heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/6\">",
"     6",
"    </a>",
"    ]. The concomitant use of a calcium-channel blocker and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    could act synergistically to suppress muscular contractility, which could result in respiratory depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281094\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;An optimal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    dosing regimen for treatment of preterm labor has not been established. A common approach is to administer an initial loading dose of 20 mg orally, followed by an additional 20 mg orally in 90 minutes. If contractions persist, 20 mg can be given orally every 3 to 8 hours for up to 72 hours, with a maximum dose of 180",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    The American College of Obstetricians and Gynecologists (ACOG) suggests a 30 mg loading dose and then 10 to 20 mg every four to six hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The half-life of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    is approximately two to three hours and the duration of action of a single orally administered dose is up to six hours. Plasma concentrations peak in 30 to 60 minutes. Nifedipine is almost completely metabolized in the liver and excreted by the kidney.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Beta-adrenergic receptor agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The beta-adrenergic receptor agonists ritodrine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/55/12151?source=see_link\">",
"     terbutaline",
"    </a>",
"    have been studied in several randomized, placebo-controlled trials. Salbutamol and hexoprenaline have also been evaluated, but data are sparse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/73\">",
"     73",
"    </a>",
"    ]. Although ritodrine is the only drug approved by the US Food and Drug Administration (FDA) for the treatment of preterm labor, it is no longer available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The beta-adrenergic receptor agonists cause myometrial relaxation by binding with beta-2 adrenergic receptors and increasing intracellular adenyl cyclase. An increase in intracellular cyclic AMP activates protein kinase and results in the phosphorylation of intracellular proteins. The resultant drop in intracellular free calcium interferes with the activity of myosin light-chain kinase. Interference with myosin light-chain kinase inhibits the interaction between actin and myosin and, thus, myometrial contractility is diminished. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/0/6153?source=see_link\">",
"     \"Physiology of parturition\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Target cells eventually become desensitized to the effect of beta-adrenergic receptor agonists, thereby decreasing efficacy with prolonged use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. The reduction in response over time is known as tachyphylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of beta-adrenergic tocolytic therapy has been evaluated in multiple trials; most used ritodrine as the beta-adrenergic receptor agonist.",
"   </p>",
"   <p>",
"    In a Cochrane review including 1332 patients enrolled in 11 randomized, placebo-controlled trials, use of beta-adrenergic receptor agonists decreased the number of women giving birth within 48 hours (RR 0.63, 95% CI 0.53-0.75) and possibly within 7 days (RR 0.67, 95% CI 0.48-1.01) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/8\">",
"     8",
"    </a>",
"    ]. There was also a trend toward reduction in respiratory distress syndrome (RR 0.87, 95% CI 0.71-1.08), but no effect on the neonatal death rate (RR 1.00, 95% CI 0.48-2.09).",
"   </p>",
"   <p>",
"    These trends, with the upper limit of the confidence interval just crossing the threshold of no effect, suggest that relative risk reductions of the order of 30 percent in respiratory distress syndrome are plausible, and may be demonstrated by trials with a larger total sample size, improved identification of patients with true preterm labor, and exclusion of pregnancies over 34 weeks of gestation. A limitation of many of the trials included in the meta-analysis is that corticosteroids were not routinely administered. Thus, the neonatal benefits of delaying delivery for 48 hours were not fully realized.",
"   </p>",
"   <p>",
"    Comparative data are discussed below (see",
"    <a class=\"local\" href=\"#H1280923\">",
"     'Calcium channel blockers'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Maternal side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the maternal side effects of beta-adrenergic receptor agonists are related to stimulation of beta-1 adrenergic receptors, which increase maternal heart rate and stroke volume, and stimulation of beta-2 adrenergic receptors, which causes peripheral vasodilation, diastolic hypotension, and bronchial relaxation. The combination of these two cardiovascular effects leads to tachycardia, palpitations, and lower blood pressure.",
"   </p>",
"   <p>",
"    In placebo-controlled randomized trials, common symptoms associated with use of these drugs included tremor (39 versus 4 percent with placebo), palpitations (18 versus 4 percent), shortness of breath (15 versus 1 percent), and chest discomfort (10 versus 1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulmonary edema is uncommon, occurring in 0.3 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Pulmonary edema probably results from several additive factors including fluid overload, decreased time for diastolic filling time due to increased heart rate, and the increased plasma volume of pregnancy. Alternatively, pulmonary edema may be unrelated to the beta-adrenergic receptor agonists, and instead may be due to increased vascular permeability related to infection, inflammation, or preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37032?source=see_link&amp;anchor=H6#H6\">",
"     \"Acute respiratory failure during pregnancy and the peripartum period\", section on 'Pulmonary edema'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Beta-adrenergic receptor agonists also have important metabolic effects, including hypokalemia (39 versus 6 percent with placebo), hyperglycemia (30 versus 10 percent with placebo), and lipolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/76\">",
"     76",
"    </a>",
"    ]. Myocardial ischemia is a rare complication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Fetal side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta-adrenergic receptor agonists cross the placenta into the fetal compartment. Fetal effects, such as fetal tachycardia, are analogous to the maternal effects noted above. Neonatal hypoglycemia may result from fetal hyperinsulinemia in response to prolonged maternal hyperglycemia. Fetal",
"    <span class=\"nowrap\">",
"     acid/base",
"    </span>",
"    status and neonatal well-being are not compromised by these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between use of beta-adrenergic receptor agonists for tocolysis and IVH in the neonate is controversial. Most studies have concluded that beta-adrenergic receptor agonist use decreased or did not affect the risk of IVH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/81-83\">",
"     81-83",
"    </a>",
"    ], while some suggested an increase in risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. All of the studies were retrospective and therefore suffer from potential bias, particularly since so many other intrapartum interventions might have impacted neonatal outcome.",
"   </p>",
"   <p>",
"    Prolonged beta-adrenergic receptor overstimulation during critical periods of prenatal development may induce a permanent shift in the balance of sympathetic-to-parasympathetic tone, which may lead to development of certain disease processes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/86\">",
"     86",
"    </a>",
"    ]. Although such observations have been used to hypothesize a relationship between in utero beta-adrenergic agonist exposure and subsequent development of autism spectrum disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/86\">",
"     86",
"    </a>",
"    ], our and other reviews of human and animal studies do not support a relationship [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4698?source=see_link&amp;anchor=H12#H12\">",
"     \"Terminology, epidemiology, and pathogenesis of autism spectrum disorders\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Labor inhibition with a beta-adrenergic receptor agonist is relatively contraindicated among women with tachycardia-sensitive cardiac disease, because of the potent chronotropic effects of these drugs, and women with poorly controlled hyperthyroidism or diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/6\">",
"     6",
"    </a>",
"    ]. On the other hand, well-controlled diabetes mellitus is not a contraindication to beta-adrenergic receptor agonist therapy, as long as glucose and potassium concentrations are monitored carefully and maintained in the normal range. In diabetic women, hourly blood glucose monitoring and an intravenous insulin drip are usually required to maintain euglycemia.",
"   </p>",
"   <p>",
"    Beta-adrenergic receptor agonist should be used with caution in women at risk for massive hemorrhage (such as women with placenta previa or abruption) since the resultant cardiovascular effects (tachycardia, hypotension) may interfere with the ability of the mother to respond to ongoing hemorrhage, and may confuse the clinical presentation.",
"   </p>",
"   <p>",
"    The FDA has warned that injectable",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/55/12151?source=see_link\">",
"     terbutaline",
"    </a>",
"    should not be used in pregnant women for prevention or prolonged treatment (beyond 48 to 72 hours) of preterm labor in either the hospital or outpatient setting because of the potential for serious maternal heart problems and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/89\">",
"     89",
"    </a>",
"    ]. However, there are certain obstetrical conditions where the healthcare professional may decide that the benefit of terbutaline injection for an individual patient in a hospital setting clearly outweighs the risk. For example, a short course of injectable terbutaline is a reasonable option for acute tocolysis or for acute management of tetanic uterine contractions or tachysystole with abnormal fetal heart rate pattern in labor.",
"   </p>",
"   <p>",
"    The FDA also opined that oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/55/12151?source=see_link\">",
"     terbutaline",
"    </a>",
"    should not be used for prevention or any treatment of preterm labor because it has not been shown to be effective and has similar safety concerns.",
"   </p>",
"   <p>",
"    The final decision about use of these medications in these situations requires balancing the perceived benefit of delaying the delivery with potential side effects of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are too limited to support the use of any particular beta-adrenergic receptor agonist over another. In the United States,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/55/12151?source=see_link\">",
"     terbutaline",
"    </a>",
"    is the most commonly used beta-adrenergic receptor agonist for labor inhibition. It is often given subcutaneously by intermittent injection. The dose is variable: 0.25 mg can be administered every 20 to 30 minutes for up to four doses or until tocolysis is achieved. Once labor is inhibited, 0.25 mg can be administered every three to four hours until the uterus is quiescent for 24 hours.",
"   </p>",
"   <p>",
"    It can also be administered as a continuous intravenous infusion. We suggest the infusion be started at 2.5 to 5",
"    <span class=\"nowrap\">",
"     mcg/min;",
"    </span>",
"    this can be increased by 2.5 to 5",
"    <span class=\"nowrap\">",
"     mcg/min",
"    </span>",
"    every 20 to 30 minutes to a maximum of 25",
"    <span class=\"nowrap\">",
"     mcg/min,",
"    </span>",
"    or until the contractions have abated. At this point, the infusion is reduced by decrements of 2.5 to 5",
"    <span class=\"nowrap\">",
"     mcg/min",
"    </span>",
"    to the lowest dose that maintains uterine quiescence.",
"   </p>",
"   <p>",
"    The FDA concluded that the risk of serious adverse events outweighs any potential benefit to pregnant women receiving prolonged treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/55/12151?source=see_link\">",
"     terbutaline",
"    </a>",
"    (beyond 48 to 72 hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;During beta-adrenergic receptor agonist administration, the clinician should carefully monitor cumulative fluid intake, urine output, and maternal symptoms, especially shortness of breath, chest pain, or tachycardia. We suggest the drug be withheld if the maternal heart rate exceeds 120",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"   </p>",
"   <p>",
"    Glucose",
"    and potassium concentrations should be monitored every four to six hours during parenteral drug administration, since hyperglycemia and hypokalemia commonly occur. Significant hypokalemia should be treated to minimize risk of arrhythmias. Significant hyperglycemia can be treated with insulin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281518\">",
"    <span class=\"h2\">",
"     Oxytocin receptor antagonists",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281526\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atosiban is a selective oxytocin-vasopressin receptor antagonist. Although commonly used in Europe, it is not available in the United States. In normal parturition, oxytocin stimulates contractions by inducing conversion of phosphatidylinositol to inositol triphosphate, which binds to a protein in the sarcoplasmic reticulum causing release of calcium into the cytoplasm. Oxytocin receptor antagonists compete with oxytocin for binding to oxytocin receptors in the myometrium and decidua, thus preventing the increase in intracellular free calcium that occurs when oxytocin binds to its receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. Theoretically, atosiban should be more effective at later gestational ages since oxytocin receptor concentration and uterine responsiveness to oxytocin increase with advancing gestation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281533\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Cochrane review analyzed six randomized trials (n = 1695 women) comparing the oxytocin receptor antagonist atosiban to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/93\">",
"     93",
"    </a>",
"    ]. Rescue tocolytic therapy could be initiated at the clinician's discretion (eg, progression of labor, side effects). Use of atosiban increased the risk of birth within 48 hours of initiation of treatment (RR 2.50, 95% CI 0.51-12.35), increased the risk of preterm birth at less than 28 weeks of gestation (RR 2.25, 95% CI 0.80-6.35), and increased the risk of preterm birth at less than 37 weeks (RR 1.17, 95% CI 0.99 1.37), although none of these increases reached statistical significance. All neonatal morbidity and mortality outcomes evaluated were similar in both groups.",
"   </p>",
"   <p>",
"    There was, however, an imbalance in allocation of women with threatened preterm labor in very early gestation (under 26 weeks) such that significantly more women in this subgroup were allocated to the atosiban group. In addition, more women in the placebo group than the atosiban group received rescue treatment, which may have confounded the estimate of the true effects of atosiban when compared to placebo. The use of rescue tocolytics complicated analysis of these trials, since the criteria for switching therapies were not strictly defined. Lastly, the trial protocol did not define how glucocorticoids should be used, which resulted in a great deal of variation in use among study sites.",
"   </p>",
"   <p>",
"    In the absence of demonstration of efficacy in placebo-controlled trials, it is difficult to interpret active-control trials. This difficulty is compounded by the fact that trials using the beta-adrenergic receptor agonists",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/55/12151?source=see_link\">",
"     terbutaline",
"    </a>",
"    and salbutamol as the active-control used controls that have not been proven to be effective. With these limitations, the same Cochrane review found that atosiban was as effective as beta-adrenergic receptor agonists for preventing preterm birth within 48 hours (RR 0.98, 95% CI 0.68-1.41) or 7 days (RR 0.91, 95% CI 0.69-1.20) of initiating treatment. Use of atosiban was associated with a significantly lower risk of maternal side effects requiring cessation of treatment than beta-adrenergic receptor agonists (RR 0.04, 95% CI 0.02-0.11).",
"   </p>",
"   <p>",
"    The FDA declined to approve the use of atosiban for tocolysis because of concerns about the drug's safety when used in fetuses less than 28 weeks of gestation (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/94\">",
"     94",
"    </a>",
"    ]. It is available for clinical use in Europe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281540\">",
"    <span class=\"h3\">",
"     Maternal side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main side effects associated with use of atosiban are hypersensitivity and injection site reactions. Adverse maternal cardiovascular effects have not been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. The overall frequency of side effects in women given atosiban is significantly less than that reported for any other drug used for inhibition of preterm labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/76,97\">",
"     76,97",
"    </a>",
"    ]. Atosiban may compete with antidiuretic hormone (ADH) in the kidney based on incomplete receptor specificity for oxytocin receptor; however, no clinical sequelae related to this mechanism have been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281547\">",
"    <span class=\"h3\">",
"     Fetal side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atosiban crosses the placenta; fetal levels are about 12 percent of maternal levels. The drug has not been proven to cause neonatal cardiovascular or",
"    <span class=\"nowrap\">",
"     acid/base",
"    </span>",
"    alterations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/96,98\">",
"     96,98",
"    </a>",
"    ]. However, one trial showed a trend toward a higher rate of fetal-infant death in patients taking atosiban [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/95\">",
"     95",
"    </a>",
"    ]. These fetal-infant deaths were associated with infection and extreme prematurity, although a relationship to atosiban cannot be excluded. As discussed above, randomization in this trial was not stratified by gestational age and led to an imbalance such that most of the very preterm infants (less than 26 weeks of gestation) were assigned to the atosiban group. Therefore, the mortality difference may be attributable to the lower gestational age of infants in this group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281554\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no absolute contraindications to use of atosiban.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281561\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atosiban is administered intravenously beginning with a bolus of 6.75 mg followed by a 300",
"    <span class=\"nowrap\">",
"     mcg/min",
"    </span>",
"    infusion for three hours, and then 100",
"    <span class=\"nowrap\">",
"     mcg/min",
"    </span>",
"    for up to 45 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/99\">",
"     99",
"    </a>",
"    ]. Initial and terminal half-lives are 13 and 102 minutes, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281568\">",
"    <span class=\"h2\">",
"     Nitric oxide donors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281576\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitric oxide (NO) is produced in a variety of cells and is essential for maintenance of normal smooth muscle tone. NO is synthesized during the oxidation of L-arginine (an essential amino acid) to L-citrulline, which then diffuses from the generator cell. This reaction is catalyzed by the enzyme nitric oxide synthase (NOS). The interaction between NO and soluble guanylyl cyclase (sGC), which is present in nearby effector cells, represents a widespread signal transduction mechanism that couples diverse extracellular stimuli of NO formation to the synthesis of cyclic guanosine 3',5'-monophosphate (cGMP) in target cells. The increase in cGMP content in smooth muscle cells activates myosin light chain kinases leading to smooth muscle relaxation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281583\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is insufficient evidence at this time to recommend NO donors for inhibition of preterm labor. The following examples illustrate the range of findings in controlled studies of NO donors for inhibition of preterm labor.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to placebo",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The Canadian Preterm Labor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"       Nitroglycerin",
"      </a>",
"      Trial randomized 153 women in labor between 24 and 32 weeks to receive either transdermal nitroglycerin or placebo patches [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/101\">",
"       101",
"      </a>",
"      ]. Infants born to transdermal nitroglycerin treated mothers (n = 74) had a lower risk of composite neonatal adverse outcome (IVH, periventricular leukomalacia, bronchopulmonary dysplasia, and necrotizing enterocolitis) compared to placebo treated mothers (n = 79) (RR 0.29, 95% CI 0.08-1.00). There was a non-significant trend towards a reduction in delivery prior to 28 weeks of gestation (RR 0.50, 95% CI 0.23-1.09). Secondary analysis of the data suggested that the improvement in the composite neonatal outcome was due to prolongation of pregnancy and increased likelihood of completing a course of corticosteroid therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/102\">",
"       102",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to beta-adrenergic receptor agonists",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      One trial randomized 235 patients to transdermal glyceryl trinitrate tocolysis or ritodrine therapy for treatment of preterm labor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/103\">",
"       103",
"      </a>",
"      ]. Both drugs were similarly effective in delaying delivery for 48 hours.",
"     </li>",
"     <li>",
"      The Randomized Nitric Oxide Tocolysis Trial (RNOTT) compared glyceryl trinitrate therapy to beta-2 sympathomimetics (salbutamol or ritodrine) in 238 women with preterm labor plus positive fetal fibronectin results or preterm premature rupture of membranes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/104\">",
"       104",
"      </a>",
"      ]. Glyceryl trinitrate did not inhibit contractions as effectively as beta-2 sympathomimetics. Neurodevelopmental performance at 18 months was similar for both groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A randomized trial comparing intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      reported magnesium sulfate therapy was more likely to successfully delay delivery at least 12 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/106\">",
"       106",
"      </a>",
"      ]. Successful tocolysis was achieved in 6 of 16 patients receiving nitroglycerin compared to 11 of 14 receiving magnesium sulfate (38 and 79 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281590\">",
"    <span class=\"h3\">",
"     Maternal side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitric oxide donors cause dilation of arterial smooth muscle, which might result in maternal hypotension. Side effects are similar to those of the calcium-channel blockers: dizziness, flushing, and palpitations. Maternal hypotension could compromise uterine and placental blood flow; however, adverse neonatal effects have not been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281597\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitric oxide donors should not be used in women with hypotension or with preload-dependent cardiac lesions, such as aortic insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281604\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;NO donors may be administered via transdermal patches or intravenously; the optimum dose has not been determined. In general, the drug dose and interval should be titrated to cessation of contractions, while maintaining an adequate blood pressure. Two options are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      10 mg glyceryl trinitrate patch applied to the skin of the abdomen. After one hour, if there is no reduction in contraction frequency or intensity, an additional patch is applied; no more than two patches are administered simultaneously. The patches can be left in place for 24 hours, after which they are removed and the patient reassessed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/107\">",
"       107",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An intravenous infusion rate of 20",
"      <span class=\"nowrap\">",
"       mcg/min",
"      </span>",
"      is reasonable [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Magnesium sulfate",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise mechanism of magnesium's effects on uterine contractions has not been completely elucidated, despite more than 40 years of study. Magnesium probably competes with calcium at the level of the plasma membrane voltage-gated channels. It hyperpolarizes the plasma membrane and inhibits myosin light-chain kinase activity by competing with intracellular calcium at this site. Interference with the activity of myosin light-chain kinase reduces myometrial contractility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/108-110\">",
"     108-110",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/0/6153?source=see_link\">",
"     \"Physiology of parturition\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review including four randomized trials (n = 334",
"    <span class=\"nowrap\">",
"     fetuses/newborns)",
"    </span>",
"    comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    with no treatment or a placebo control concluded there was no evidence of a clinically important tocolytic effect of magnesium sulfate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/111\">",
"     111",
"    </a>",
"    ]. Magnesium sulfate therapy did not significantly reduce the risk of birth within 48 hours (RR 0.75, 95% CI 0.54-1.03), 7 days (RR 1.22, 95% CI 0.94-1.59), or 37 weeks (RR 1.18, 95% CI 0.93-1.51), or neonatal respiratory distress (RR 1.10, 95% CI 0.66-1.85), IVH (RR 0.80, 95% CI 0.26-2.45), or newborn death (RR 1.33, 95% CI 0.45-3.92). However, these results are not definitive given the small number of subjects, significant differences in study design, and wide variation in study results. Furthermore, antenatal corticosteroids were not routinely administered.",
"   </p>",
"   <p>",
"    In 15 comparative trials,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    was neither more nor less effective than other tocolytics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/111\">",
"     111",
"    </a>",
"    ]. For delivery within 48 hours of initiation of treatment, summary risk ratios were: magnesium versus beta-adrenergic agonists (RR 1.23, 95% CI 0.70-2.17), versus calcium channel blockers (RR 1.06, 95% CI 0.63-1.78), versus cyclooxygenase inhibitors (RR 0.84, 95% CI 0.49-1.45), and versus any control (active or placebo) (RR 0.90, 95% CI 0.72-1.13). These comparative trials must be interpreted with caution since they were not designed as equivalence trials, and thus, are inadequately powered to evaluate the equivalence of magnesium sulfate to other tocolytics. Given this important limitation and other data of the efficacy of beta-adrenergic agonists and calcium channel blockers (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Beta-adrenergic receptor agonists'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1280923\">",
"     'Calcium channel blockers'",
"    </a>",
"    above), one should not use this study to conclude that these other tocolytics are no more effective than placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Maternal and fetal side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     Magnesium sulfate",
"    </a>",
"    causes fewer minor maternal side effects than beta-adrenergic agonists, but the risk of major adverse risk events is comparable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/112\">",
"     112",
"    </a>",
"    ]. Diaphoresis and flushing are the most common side effects; magnesium toxicity is related to serum concentration. Maternal therapy causes a slight decrease in baseline fetal heart rate and fetal heart rate variability, which are not clinically important. Antenatal fetal assessment test results (eg, biophysical profile score and nonstress test reactivity) are not significantly altered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=see_link&amp;anchor=H22#H22\">",
"     \"Preeclampsia: Management and prognosis\", section on 'Magnesium regimen and monitoring'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=see_link&amp;anchor=H23#H23\">",
"     \"Preeclampsia: Management and prognosis\", section on 'Complications and side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Neuroprotective effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predelivery administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    is neuroprotective for the neonate. The minimum duration of administration that results in neuroprotection is not known, but is less than 24 hours. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43799?source=see_link\">",
"     \"Neuroprotective effects of in utero exposure to magnesium sulfate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If tocolysis is indicated because of persistent preterm labor in a patient receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    for neuroprotection, the most effective tocolytic with the most favorable side effect profile should be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     Magnesium sulfate",
"    </a>",
"    tocolysis is contraindicated in women with myasthenia gravis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36567?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of myasthenia gravis in pregnancy\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It also should not be used in women with known myocardial compromise or cardiac conduction defects because of its anti-inotropic effects.",
"   </p>",
"   <p>",
"    Magnesium is eliminated by the kidneys. Thus, women with impaired renal function will have an exaggerated rise in serum magnesium and may develop magnesium toxicity at the usual doses of administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     Magnesium sulfate",
"    </a>",
"    is usually administered as a 6 g intravenous load over 20 minutes, followed by a continuous infusion of 2",
"    <span class=\"nowrap\">",
"     g/hour",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/113\">",
"     113",
"    </a>",
"    ]. The infusion rate is titrated based upon assessment of contraction frequency and maternal toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with normal renal function, signs and symptoms of magnesium toxicity can be assessed by history and physical examinations. Routine magnesium levels are not necessary.",
"   </p>",
"   <p>",
"    Since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    is excreted by the kidneys, dosing should be adjusted in women with renal insufficiency (defined as a serum creatinine greater than 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [88.4",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    or an alternative drug should be used. If magnesium sulfate is given, such women should receive a standard loading dose (since their volume of distribution is not altered), but a reduced maintenance dose (1 g per hour or no maintenance dose if the serum creatinine is greater than 2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [221",
"    <span class=\"nowrap\">",
"     &micro;mol/L])",
"    </span>",
"    with close monitoring of the serum magnesium concentration every six hours.",
"   </p>",
"   <p>",
"    Women with renal insufficiency should receive the maintenance phase of treatment only if a patellar reflex is present (loss of reflexes being the first manifestation of symptomatic hypermagnesemia), respirations exceed 12 per minute, and the urine output exceeds 100 mL per four hours. The urine output and deep tendon reflexes should be closely monitored. Magnesium levels may be useful in monitoring women on maintenance magnesium therapy who have concomitant renal disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/9/32914?source=see_link\">",
"     \"Symptoms of hypermagnesemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1278930\">",
"    <span class=\"h1\">",
"     INEFFECTIVE APPROACHES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h2\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although subclinical genital tract infection clearly contributes to the pathogenesis of preterm birth, there is no evidence-based role for antibiotic therapy in the prevention of prematurity in patients with symptomatic preterm labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A Cochrane review evaluated the use of prophylactic antibiotics as an adjunct to tocolysis for inhibiting preterm labor up to 36 weeks of gestation in women with intact membranes; 11 trials involving over 7000 women were included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/115\">",
"     115",
"    </a>",
"    ]. This analysis was dominated by one large trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/116\">",
"     116",
"    </a>",
"    ] that administered broad-spectrum antibiotics orally. Compared to nonuse of antibiotics, use of antibiotics did not prolong pregnancy or result in significant reduction in delivery within 48 hours of initiating treatment, preterm birth less than 36 or 37 weeks, perinatal mortality, respiratory distress syndrome, neonatal sepsis, or any other measure of neonatal morbidity. There was, however, a significant reduction in maternal infection (chorioamnionitis, endometritis) with use of prophylactic antibiotics (RR 0.74, 95% CI 0.64-0.87). Subgroup analysis by type of antibiotic showed that administration of antibiotics against anaerobes was associated with a statistically significant reduction in the number of women delivering within seven days of enrollment (RR 0.62, 95% CI 0.42-0.90) and fewer admissions to the neonatal intensive care unit (RR 0.63, 95% CI 0.43-0.93).",
"   </p>",
"   <p>",
"    A subsequent metaanalysis that was limited to pregnancies up to 34 weeks of gestation also concluded that there was no prolongation of pregnancy with use of antibiotics for treatment of spontaneous preterm labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians should be careful before concluding there are no benefits from antibiotic therapy of preterm labor. A subgroup of women who have subclinical intrauterine infection theoretically may benefit from treatment with antibiotics, but there is no means for identifying these women at this time. It is also possible that the infectious process may be too advanced by the time preterm labor is clinically apparent for treatment to be effective or that the inflammatory cascade has been triggered and will continue to amplify whether or not the inciting infection is treated.",
"   </p>",
"   <p>",
"    However, the potential risks of antibiotic therapy also need to be considered. The ORACLE II trial randomly assigned women with intact membranes in preterm labor to receive antibiotics or placebo treatment. Children of mothers assigned to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    or co-amoxiclav were more likely to be functionally impaired at age 7 years than those who did not receive these drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibiotics for prevention of early-onset group B streptococcal disease and to prolong latency in women with preterm premature rupture of membranes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15866?source=see_link\">",
"     \"Preterm premature rupture of membranes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15866?source=see_link&amp;anchor=H17#H17\">",
"     \"Preterm premature rupture of membranes\", section on 'Antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h2\">",
"     Progesterone supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that progesterone supplementation is effective in women with acute preterm labor, but available studies are few, underpowered, and not blinded. A discussion of use of progesterone supplementation before or after an episode of acute preterm labor can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/33/5657?source=see_link&amp;anchor=H14419401#H14419401\">",
"     \"Progesterone supplementation to reduce the risk of spontaneous preterm birth\", section on 'Acute preterm labor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1277954\">",
"    <span class=\"h2\">",
"     Bedrest, hydration, and sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no high quality evidence of the efficacy of bedrest, hydration, or sedation for prevention or treatment of preterm labor in singleton pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/12,119\">",
"     12,119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following findings have addressed the ineffectiveness of bedrest on preterm birth in different groups of women.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Women at risk of preterm birth",
"      </strong>",
"      &mdash; A review from the Cochrane database that evaluated bedrest versus no intervention for preventing preterm birth included a single randomized trial (n = 1266 women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/120\">",
"       120",
"      </a>",
"      ]) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/121\">",
"       121",
"      </a>",
"      ]. There was no evidence of benefit or harm from use of bed rest at home or in hospital versus usual activity to prevent preterm birth (RR of preterm birth 0.92, 95% CI 0.62-1.37).",
"     </li>",
"     <li>",
"      <strong>",
"       Women with twin pregnancies",
"      </strong>",
"      &mdash; Routine hospitalization for bedrest in women with twin pregnancies does not prolong gestation. In a 2010 Cochrane review, women with a multiple gestation, women with an uncomplicated twin pregnancy, and women with a twin pregnancy complicated by cervical effacement and dilation who were offered hospitalization for bed rest did not have a lower rate of preterm birth compared to ambulatory women with twins who were hospitalized when pregnancy complications developed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/122\">",
"       122",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Women with arrested preterm labor in index pregnancy",
"      </strong>",
"      &mdash; In one trial in which women with arrested preterm labor were assigned to hospitalization or decreased activity at home, the rate of preterm birth was similar for the two groups (29 and 28 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/123\">",
"       123",
"      </a>",
"      ]. In a second trial in which women with arrested preterm labor were assigned to activity restriction or no activity restriction, preterm birth rates were not statistically different (44 and 35 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/124\">",
"       124",
"      </a>",
"      ]. However, both trials were underpowered to detect a small difference in outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Furthermore, extended bedrest appears to increase the prevalence of thromboembolic events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In other randomized trials, neither intravenous hydration nor sedation reduced the rate of preterm birth in women with preterm labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/126,127\">",
"     126,127",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h1\">",
"     MANAGEMENT AFTER CESSATION OF CONTRACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of pregnant women in whom contractions resolve is discussed separately. Maintenance tocolytic therapy is ineffective. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24135?source=see_link\">",
"     \"Management of pregnant women after inhibition of acute preterm labor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a second episode of acute preterm labor occurs, the indications for retreatment are the same as for a primary episode [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/53/35674/abstract/111\">",
"     111",
"    </a>",
"    ]. However, administration of antenatal corticosteroids is generally not repeated, except for one course of salvage (rescue) therapy in selected circumstances. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=see_link&amp;anchor=H667637#H667637\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\", section on 'Use of repeated courses of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/20/27970?source=see_link\">",
"       \"Patient information: Preterm labor (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/52/35650?source=see_link\">",
"       \"Patient information: Preterm labor (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest administration of tocolytics to selected women with preterm labor (preterm labor) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1277522\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of treatment is to delay delivery so that glucocorticoids can be administered and achieve their maximal effect; allow safe transport of the mother, if indicated, to a facility that can provide an appropriate level of neonatal care if the patient delivers preterm, and to prolong pregnancy when there are underlying, self-limited causes of labor, such as abdominal surgery, that are unlikely to cause recurrent preterm labor. Treatment can be discontinued after these goals have been achieved. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The selection of an appropriate labor inhibiting agent should be based upon efficacy and safety. Ideally, efficacy should be established in terms of significant clinical endpoints (eg, reduction in rate of respiratory distress or perinatal mortality) rather than surrogate endpoints (eg, prolongation of pregnancy by 48 hours). However, there is no evidence that tocolytic therapy directly improves any neonatal outcome. Drug safety should be established for the mother, fetus, and neonate. (See",
"      <a class=\"local\" href=\"#H1277601\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the first tocolytic agent chosen does not successfully inhibit preterm labor, we suggest discontinuing it and beginning therapy with a second agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Given lack of proven efficacy and increased risk of side effects, we suggest avoiding routinely administering multiple tocolytics concurrently in patients who fail therapy with a single agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Selective use of combinations of tocolytics is an option in very early gestations. (See",
"      <a class=\"local\" href=\"#H1277601\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h2\">",
"     Choice of drug",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women 24 to 32 weeks of gestation who are candidates for tocolysis and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      for fetal neuroprotection, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      as first-line therapy for labor inhibition (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). It appears to be superior to placebo and has a relatively favorable maternal and fetal side effect profile. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Neuroprotective effects'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43799?source=see_link&amp;anchor=H19#H19\">",
"       \"Neuroprotective effects of in utero exposure to magnesium sulfate\", section on 'Choice of tocolytic for women in preterm labor'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H1279823\">",
"       'Cyclooxygenase inhibitors'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Contraindications to indomethacin use include maternal platelet dysfunction or bleeding disorder, hepatic dysfunction, gastrointestinal ulcerative disease, renal dysfunction, or asthma (in women with hypersensitivity to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ). We avoid the use of indomethacin in gestations over 32 weeks and caution against their use for more than 72 hours because of concern about premature narrowing or closure of the ductus arteriosus. (See",
"      <a class=\"local\" href=\"#H1279823\">",
"       'Cyclooxygenase inhibitors'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      as a second-line agent for women who have a contraindication to indomethacin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). There is an increased risk of maternal side effects when magnesium sulfate is administered concomitantly with calcium channel blockers. (See",
"      <a class=\"local\" href=\"#H1280923\">",
"       'Calcium channel blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women 32 to 34 weeks of gestation, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      as the initial choice for tocolysis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1280923\">",
"       'Calcium channel blockers'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For second-line therapy of pregnancies at 32 to 34 weeks of gestation, we suggest a beta-adrenergic receptor agonist (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In areas where atosiban is available, we suggest use of this agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Beta-adrenergic receptor agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of clinical signs of infection, we suggest avoiding administration of broad spectrum antibiotics as an adjunctive therapy of preterm labor (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Antibiotics are used as prophylaxis against group B beta-streptococcus, when indicated by the clinical setting. (See",
"      <a class=\"local\" href=\"#H54\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/1\">",
"      King JF, Grant A, Keirse MJ, Chalmers I. Beta-mimetics in preterm labour: an overview of the randomized controlled trials. Br J Obstet Gynaecol 1988; 95:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/2\">",
"      Gazmararian JA, Petersen R, Jamieson DJ, et al. Hospitalizations during pregnancy among managed care enrollees. Obstet Gynecol 2002; 100:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/3\">",
"      Scott CL, Chavez GF, Atrash HK, et al. Hospitalizations for severe complications of pregnancy, 1987-1992. Obstet Gynecol 1997; 90:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/4\">",
"      McPheeters ML, Miller WC, Hartmann KE, et al. The epidemiology of threatened preterm labor: a prospective cohort study. Am J Obstet Gynecol 2005; 192:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/5\">",
"      Fuchs IB, Henrich W, Osthues K, Dudenhausen JW. Sonographic cervical length in singleton pregnancies with intact membranes presenting with threatened preterm labor. Ultrasound Obstet Gynecol 2004; 24:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/6\">",
"      American College of Obstetricians and Gynecologists, Committee on Practice Bulletins&mdash;Obstetrics. ACOG practice bulletin no. 127: Management of preterm labor. Obstet Gynecol 2012; 119:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/7\">",
"      Haas DM, Imperiale TF, Kirkpatrick PR, et al. Tocolytic therapy: a meta-analysis and decision analysis. Obstet Gynecol 2009; 113:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/8\">",
"      Anotayanonth S, Subhedar NV, Garner P, et al. Betamimetics for inhibiting preterm labour. Cochrane Database Syst Rev 2004; :CD004352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/9\">",
"      Simhan HN, Caritis SN. Prevention of preterm delivery. N Engl J Med 2007; 357:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/10\">",
"      Allen JR, Helling TS, Langenfeld M. Intraabdominal surgery during pregnancy. Am J Surg 1989; 158:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/11\">",
"      Hunt MG, Martin JN Jr, Martin RW, et al. Perinatal aspects of abdominal surgery for nonobstetric disease. Am J Perinatol 1989; 6:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/12\">",
"      Goldenberg RL. The management of preterm labor. Obstet Gynecol 2002; 100:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/13\">",
"      Korenbrot CC, Aalto LH, Laros RK Jr. The cost effectiveness of stopping preterm labor with beta-adrenergic treatment. N Engl J Med 1984; 310:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/14\">",
"      Macones GA, Bader TJ, Asch DA. Optimising maternal-fetal outcomes in preterm labour: a decision analysis. Br J Obstet Gynaecol 1998; 105:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/15\">",
"      Myers ER, Alvarez JG, Richardson DK, Ludmir J. Cost-effectiveness of fetal lung maturity testing in preterm labor. Obstet Gynecol 1997; 90:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/16\">",
"      Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006; :CD004454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/17\">",
"      Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consens Statement 1994; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/18\">",
"      Haas DM, Caldwell DM, Kirkpatrick P, et al. Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. BMJ 2012; 345:e6226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/19\">",
"      Gomez R, Romero R, Edwin SS, David C. Pathogenesis of preterm labor and preterm premature rupture of membranes associated with intraamniotic infection. Infect Dis Clin North Am 1997; 11:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/20\">",
"      Gross G, Imamura T, Vogt SK, et al. Inhibition of cyclooxygenase-2 prevents inflammation-mediated preterm labor in the mouse. Am J Physiol Regul Integr Comp Physiol 2000; 278:R1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/21\">",
"      Doret M, Mellier G, Benchaib M, et al. In vitro study of tocolytic effect of rofecoxib, a specific cyclo-oxygenase 2 inhibitor. Comparison and combination with other tocolytic agents. BJOG 2002; 109:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/22\">",
"      Yousif MH, Thulesius O. Tocolytic effect of the cyclooxygenase-2 inhibitor, meloxicam: studies on uterine contractions in the rat. J Pharm Pharmacol 1998; 50:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/23\">",
"      Slattery MM, Friel AM, Healy DG, Morrison JJ. Uterine relaxant effects of cyclooxygenase-2 inhibitors in vitro. Obstet Gynecol 2001; 98:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/24\">",
"      Sadovsky Y, Nelson DM, Muglia LJ, et al. Effective diminution of amniotic prostaglandin production by selective inhibitors of cyclooxygenase type 2. Am J Obstet Gynecol 2000; 182:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/25\">",
"      King J, Flenady V, Cole S, Thornton S. Cyclo-oxygenase (COX) inhibitors for treating preterm labour. Cochrane Database Syst Rev 2005; :CD001992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/26\">",
"      Niebyl JR, Blake DA, White RD, et al. The inhibition of premature labor with indomethacin. Am J Obstet Gynecol 1980; 136:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/27\">",
"      Hayes E, Moroz L, Pizzi L, Baxter J. A cost decision analysis of 4 tocolytic drugs. Am J Obstet Gynecol 2007; 197:383.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/28\">",
"      Sawdy R, Slater D, Fisk N, et al. Use of a cyclo-oxygenase type-2-selective non-steroidal anti-inflammatory agent to prevent preterm delivery. Lancet 1997; 350:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/29\">",
"      Locatelli A, Vergani P, Bellini P, et al. Can a cyclo-oxygenase type-2 selective tocolytic agent avoid the fetal side effects of indomethacin? BJOG 2001; 108:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/30\">",
"      Stika CS, Gross GA, Leguizamon G, et al. A prospective randomized safety trial of celecoxib for treatment of preterm labor. Am J Obstet Gynecol 2002; 187:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/31\">",
"      McWhorter J, Carlan SJ, OLeary TD, et al. Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. Obstet Gynecol 2004; 103:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/32\">",
"      Groom KM, Shennan AH, Jones BA, et al. TOCOX--a randomised, double-blind, placebo-controlled trial of rofecoxib (a COX-2-specific prostaglandin inhibitor) for the prevention of preterm delivery in women at high risk. BJOG 2005; 112:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/33\">",
"      Shah AA, Thjodleifsson B, Murray FE, et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 2001; 48:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/34\">",
"      Moise KJ Jr. Effect of advancing gestational age on the frequency of fetal ductal constriction in association with maternal indomethacin use. Am J Obstet Gynecol 1993; 168:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/35\">",
"      Moise KJ Jr, Huhta JC, Sharif DS, et al. Indomethacin in the treatment of premature labor. Effects on the fetal ductus arteriosus. N Engl J Med 1988; 319:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/36\">",
"      Zuckerman H, Shalev E, Gilad G, Katzuni E. Further study of the inhibition of premature labor by indomethacin. Part I. J Perinat Med 1984; 12:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/37\">",
"      Dudley DK, Hardie MJ. Fetal and neonatal effects of indomethacin used as a tocolytic agent. Am J Obstet Gynecol 1985; 151:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/38\">",
"      Niebyl JR, Witter FR. Neonatal outcome after indomethacin treatment for preterm labor. Am J Obstet Gynecol 1986; 155:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/39\">",
"      Norton ME, Merrill J, Cooper BA, et al. Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med 1993; 329:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/40\">",
"      Souter D, Harding J, McCowan L, et al. Antenatal indomethacin--adverse fetal effects confirmed. Aust N Z J Obstet Gynaecol 1998; 38:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/41\">",
"      Hammerman C, Glaser J, Kaplan M, et al. Indomethacin tocolysis increases postnatal patent ductus arteriosus severity. Pediatrics 1998; 102:E56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/42\">",
"      Clyman RI, Chen YQ, Chemtob S, et al. In utero remodeling of the fetal lamb ductus arteriosus: the role of antenatal indomethacin and avascular zone thickness on vasa vasorum proliferation, neointima formation, and cell death. Circulation 2001; 103:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/43\">",
"      Suarez VR, Thompson LL, Jain V, et al. The effect of in utero exposure to indomethacin on the need for surgical closure of a patent ductus arteriosus in the neonate. Am J Obstet Gynecol 2002; 187:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/44\">",
"      Cordero L, Nankervis CA, Gardner D, Giannone PJ. The effects of indomethacin tocolysis on the postnatal response of the ductus arteriosus to indomethacin in extremely low birth weight infants. J Perinatol 2007; 27:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/45\">",
"      Vermillion ST, Scardo JA, Lashus AG, Wiles HB. The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am J Obstet Gynecol 1997; 177:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/46\">",
"      Respondek M, Weil SR, Huhta JC. Fetal echocardiography during indomethacin treatment. Ultrasound Obstet Gynecol 1995; 5:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/47\">",
"      Rasanen J, Debbs RH, Wood DC, et al. Human fetal right ventricular ejection force under abnormal loading conditions during the second half of pregnancy. Ultrasound Obstet Gynecol 1997; 10:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/48\">",
"      Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984; 310:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/49\">",
"      Gordon MC, Samuels P. Indomethacin. Clin Obstet Gynecol 1995; 38:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/50\">",
"      Moise KJ Jr. Indomethacin therapy in the treatment of symptomatic polyhydramnios. Clin Obstet Gynecol 1991; 34:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/51\">",
"      Hendricks SK, Smith JR, Moore DE, Brown ZA. Oligohydramnios associated with prostaglandin synthetase inhibitors in preterm labour. Br J Obstet Gynaecol 1990; 97:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/52\">",
"      Major CA, Lewis DF, Harding JA, et al. Tocolysis with indomethacin increases the incidence of necrotizing enterocolitis in the low-birth-weight neonate. Am J Obstet Gynecol 1994; 170:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/53\">",
"      Doyle NM, Gardner MO, Wells L, et al. Outcome of very low birth weight infants exposed to antenatal indomethacin for tocolysis. J Perinatol 2005; 25:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/54\">",
"      Sood BG, Lulic-Botica M, Holzhausen KA, et al. The risk of necrotizing enterocolitis after indomethacin tocolysis. Pediatrics 2011; 128:e54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/55\">",
"      Loe SM, Sanchez-Ramos L, Kaunitz AM. Assessing the neonatal safety of indomethacin tocolysis: a systematic review with meta-analysis. Obstet Gynecol 2005; 106:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/56\">",
"      Amin SB, Sinkin RA, Glantz JC. Metaanalysis of the effect of antenatal indomethacin on neonatal outcomes. Am J Obstet Gynecol 2007; 197:486.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/57\">",
"      Amin SB, Kamaluddeen M, Sangem M. Neurodevelopmental outcome of premature infants after exposure to antenatal indomethacin. Am J Obstet Gynecol 2008; 199:41.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/58\">",
"      Salokorpi T, Eronen M, von Wendt L. Growth and development until 18 months of children exposed to tocolytics indomethacin or nylidrin. Neuropediatrics 1996; 27:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/59\">",
"      al-Alaiyan S, Seshia MM, Casiro OG. Neurodevelopmental outcome of infants exposed to indomethacin antenatally. J Perinat Med 1996; 24:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/60\">",
"      Van den Veyver IB, Moise KJ Jr. Prostaglandin synthetase inhibitors in pregnancy. Obstet Gynecol Surv 1993; 48:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/61\">",
"      Conde-Agudelo A, Romero R, Kusanovic JP. Nifedipine in the management of preterm labor: a systematic review and metaanalysis. Am J Obstet Gynecol 2011; 204:134.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/62\">",
"      Caritis SN. Metaanalysis and labor inhibition therapy. Am J Obstet Gynecol 2011; 204:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/63\">",
"      Cornette J, Duvekot J, Roos-Hesselink J, et al. Maternal and fetal haemodynamic effects of nifedipine in normotensive pregnant women. BJOG 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/64\">",
"      Impey L. Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks. Br J Obstet Gynaecol 1993; 100:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/65\">",
"      van Veen AJ, Pelinck MJ, van Pampus MG, Erwich JJ. Severe hypotension and fetal death due to tocolysis with nifedipine. BJOG 2005; 112:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/66\">",
"      Ferguson JE 2nd, Dyson DC, Schutz T, Stevenson DK. A comparison of tocolysis with nifedipine or ritodrine: analysis of efficacy and maternal, fetal, and neonatal outcome. Am J Obstet Gynecol 1990; 163:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/67\">",
"      Bracero LA, Leikin E, Kirshenbaum N, Tejani N. Comparison of nifedipine and ritodrine for the treatment of preterm labor. Am J Perinatol 1991; 8:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/68\">",
"      Ferguson JE 2nd, Dyson DC, Holbrook RH Jr, et al. Cardiovascular and metabolic effects associated with nifedipine and ritodrine tocolysis. Am J Obstet Gynecol 1989; 161:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/69\">",
"      Ray D, Dyson D. Calcium channel blockers. Clin Obstet Gynecol 1995; 38:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/70\">",
"      Guclu S, Saygili U, Dogan E, et al. The short-term effect of nifedipine tocolysis on placental, fetal cerebral and atrioventricular Doppler waveforms. Ultrasound Obstet Gynecol 2004; 24:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/71\">",
"      Mari G, Kirshon B, Moise KJ Jr, et al. Doppler assessment of the fetal and uteroplacental circulation during nifedipine therapy for preterm labor. Am J Obstet Gynecol 1989; 161:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/72\">",
"      Feldman S, Karalliedde L. Drug interactions with neuromuscular blockers. Drug Saf 1996; 15:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/73\">",
"      Ashworth MF, Spooner SF, Verkuyl DA, et al. Failure to prevent preterm labour and delivery in twin pregnancy using prophylactic oral salbutamol. Br J Obstet Gynaecol 1990; 97:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/74\">",
"      Caritis SN, Chiao JP, Moore JJ, Ward SM. Myometrial desensitization after ritodrine infusion. Am J Physiol 1987; 253:E410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/75\">",
"      Caritis SN, Chiao JP, Kridgen P. Comparison of pulsatile and continuous ritodrine administration: effects on uterine contractility and beta-adrenergic receptor cascade. Am J Obstet Gynecol 1991; 164:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/76\">",
"      Gyetvai K, Hannah ME, Hodnett ED, Ohlsson A. Tocolytics for preterm labor: a systematic review. Obstet Gynecol 1999; 94:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/77\">",
"      Perry KG Jr, Morrison JC, Rust OA, et al. Incidence of adverse cardiopulmonary effects with low-dose continuous terbutaline infusion. Am J Obstet Gynecol 1995; 173:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/78\">",
"      Lamont RF. The pathophysiology of pulmonary oedema with the use of beta-agonists. BJOG 2000; 107:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/79\">",
"      Takeuchi K, Mochizuki M, Moriyama T, et al. Pulmonary edema as an acute complication of ritodrine therapy in the presence of maternal intrauterine infection. Clin Exp Obstet Gynecol 1998; 25:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/80\">",
"      Golichowski AM, Hathaway DR, Fineberg N, Peleg D. Tocolytic and hemodynamic effects of nifedipine in the ewe. Am J Obstet Gynecol 1985; 151:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/81\">",
"      Weintraub Z, Solovechick M, Reichman B, et al. Effect of maternal tocolysis on the incidence of severe periventricular/intraventricular haemorrhage in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2001; 85:F13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/82\">",
"      Ozcan T, Turan C, Ekici E, et al. Ritodrine tocolysis and neonatal intraventricular-periventricular hemorrhage. Gynecol Obstet Invest 1995; 39:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/83\">",
"      Palta M, Sadek M, Lim TS, et al. Association of tocolytic therapy with antenatal steroid administration and infant outcomes. Newborn Lung Project. Am J Perinatol 1998; 15:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/84\">",
"      Groome LJ, Goldenberg RL, Cliver SP, et al. Neonatal periventricular-intraventricular hemorrhage after maternal beta-sympathomimetic tocolysis. The March of Dimes Multicenter Study Group. Am J Obstet Gynecol 1992; 167:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/85\">",
"      Papatsonis DN, Kok JH, van Geijn HP, et al. Neonatal effects of nifedipine and ritodrine for preterm labor. Obstet Gynecol 2000; 95:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/86\">",
"      Witter FR, Zimmerman AW, Reichmann JP, Connors SL. In utero beta 2 adrenergic agonist exposure and adverse neurophysiologic and behavioral outcomes. Am J Obstet Gynecol 2009; 201:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/87\">",
"      Rodier P, Miller RK, Brent RL. Does treatment of premature labor with terbutaline increase the risk of autism spectrum disorders? Am J Obstet Gynecol 2011; 204:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/88\">",
"      Caritis SN, Simhan HN. Beta adrenergic agonists and neonatal outcome. Am J Obstet Gynecol 2010; 203:e16.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/ucm243539.htm#ds. (Accessed on August 10, 2011).",
"    </li>",
"    <li>",
"     Terbutaline: Label Change - Warnings Against Use for Treatment of Preterm Labor file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm243843.htm (Accessed on February 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/91\">",
"      Goodwin TM, Valenzuela G, Silver H, et al. Treatment of preterm labor with the oxytocin antagonist atosiban. Am J Perinatol 1996; 13:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/92\">",
"      Phaneuf S, Asb&oacute;th G, MacKenzie IZ, et al. Effect of oxytocin antagonists on the activation of human myometrium in vitro: atosiban prevents oxytocin-induced desensitization. Am J Obstet Gynecol 1994; 171:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/93\">",
"      Papatsonis D, Flenady V, Cole S, Liley H. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database Syst Rev 2005; :CD004452.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/ohrms/dockets/ac/98/transcpt/3407t1.rtf (Accessed on February 07, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/95\">",
"      Romero R, Sibai BM, Sanchez-Ramos L, et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol 2000; 182:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/96\">",
"      Greig PC, Massmann GA, Demarest KT, et al. Maternal and fetal cardiovascular effects and placental transfer of the oxytocin antagonist atosiban in late-gestation pregnant sheep. Am J Obstet Gynecol 1993; 169:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/97\">",
"      de Heus R, Mol BW, Erwich JJ, et al. Adverse drug reactions to tocolytic treatment for preterm labour: prospective cohort study. BMJ 2009; 338:b744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/98\">",
"      Valenzuela GJ, Craig J, Bernhardt MD, Holland ML. Placental passage of the oxytocin antagonist atosiban. Am J Obstet Gynecol 1995; 172:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/99\">",
"      Worldwide Atosiban versus Beta-agonists Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. The Worldwide Atosiban versus Beta-agonists Study Group. BJOG 2001; 108:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/100\">",
"      Yallampalli C, Dong YL, Gangula PR, Fang L. Role and regulation of nitric oxide in the uterus during pregnancy and parturition. J Soc Gynecol Investig 1998; 5:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/101\">",
"      Smith GN, Walker MC, Ohlsson A, et al. Randomized double-blind placebo-controlled trial of transdermal nitroglycerin for preterm labor. Am J Obstet Gynecol 2007; 196:37.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/102\">",
"      Smith GN, Guo Y, Wen SW, et al. Secondary analysis of the use of transdermal nitroglycerin for preterm labor. Am J Obstet Gynecol 2010; 203:565.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/103\">",
"      Lees CC, Lojacono A, Thompson C, et al. Glyceryl trinitrate and ritodrine in tocolysis: an international multicenter randomized study. GTN Preterm Labour Investigation Group. Obstet Gynecol 1999; 94:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/104\">",
"      Bisits A, Madsen G, Knox M, et al. The Randomized Nitric Oxide Tocolysis Trial (RNOTT) for the treatment of preterm labor. Am J Obstet Gynecol 2004; 191:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/105\">",
"      Gill A, Madsen G, Knox M, et al. Neonatal neurodevelopmental outcomes following tocolysis with glycerol trinitrate patches. Am J Obstet Gynecol 2006; 195:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/106\">",
"      El-Sayed YY, Riley ET, Holbrook RH Jr, et al. Randomized comparison of intravenous nitroglycerin and magnesium sulfate for treatment of preterm labor. Obstet Gynecol 1999; 93:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/107\">",
"      Smith GN, Walker MC, McGrath MJ. Randomised, double-blind, placebo controlled pilot study assessing nitroglycerin as a tocolytic. Br J Obstet Gynaecol 1999; 106:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/108\">",
"      Cunze T, Rath W, Osmers R, et al. Magnesium and calcium concentration in the pregnant and non-pregnant myometrium. Int J Gynaecol Obstet 1995; 48:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/109\">",
"      Lemancewicz A, Lauda��ska H, Lauda��ski T, et al. Permeability of fetal membranes to calcium and magnesium: possible role in preterm labour. Hum Reprod 2000; 15:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/110\">",
"      Mizuki J, Tasaka K, Masumoto N, et al. Magnesium sulfate inhibits oxytocin-induced calcium mobilization in human puerperal myometrial cells: possible involvement of intracellular free magnesium concentration. Am J Obstet Gynecol 1993; 169:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/111\">",
"      Mercer BM, Merlino AA, Society for Maternal-Fetal Medicine. Magnesium sulfate for preterm labor and preterm birth. Obstet Gynecol 2009; 114:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/112\">",
"      Macones GA, Sehdev HM, Berlin M, et al. Evidence for magnesium sulfate as a tocolytic agent. Obstet Gynecol Surv 1997; 52:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/113\">",
"      Elliott JP, Lewis DF, Morrison JC, Garite TJ. In defense of magnesium sulfate. Obstet Gynecol 2009; 113:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/114\">",
"      ACOG Committee Opinion No. 445: antibiotics for preterm labor. Obstet Gynecol 2009; 114:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/115\">",
"      King J, Flenady V. Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Database Syst Rev 2002; :CD000246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/116\">",
"      Kenyon SL, Taylor DJ, Tarnow-Mordi W, ORACLE Collaborative Group. Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. ORACLE Collaborative Group. Lancet 2001; 357:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/117\">",
"      Hutzal CE, Boyle EM, Kenyon SL, et al. Use of antibiotics for the treatment of preterm parturition and prevention of neonatal morbidity: a metaanalysis. Am J Obstet Gynecol 2008; 199:620.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/118\">",
"      Kenyon S, Pike K, Jones DR, et al. Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial. Lancet 2008; 372:1319.",
"     </a>",
"    </li>",
"    <li>",
"     Berkman ND, Thorp JM Jr, Hartmann KE, Lohr KN, Idicula AE, McPheeters M, et al. Management of preterm labor. Evidence Report/Technology Assessment No. 18 (Prepared by Research Triangle Institute under Contract No. 290-97-0011). AHRQ Publication No. 01-E021. Rockville (MD): Agency for Healthcare Research and Quality; 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/120\">",
"      Hobel CJ, Ross MG, Bemis RL, et al. The West Los Angeles Preterm Birth Prevention Project. I. Program impact on high-risk women. Am J Obstet Gynecol 1994; 170:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/121\">",
"      Sosa C, Althabe F, Beliz&aacute;n J, Bergel E. Bed rest in singleton pregnancies for preventing preterm birth. Cochrane Database Syst Rev 2004; :CD003581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/122\">",
"      Crowther CA, Han S. Hospitalisation and bed rest for multiple pregnancy. Cochrane Database Syst Rev 2010; :CD000110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/123\">",
"      Yost NP, Bloom SL, McIntire DD, Leveno KJ. Hospitalization for women with arrested preterm labor: a randomized trial. Obstet Gynecol 2005; 106:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/124\">",
"      Elliott JP, Miller HS, Coleman S, et al. A randomized multicenter study to determine the efficacy of activity restriction for preterm labor management in patients testing negative for fetal fibronectin. J Perinatol 2005; 25:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/125\">",
"      Kovacevich GJ, Gaich SA, Lavin JP, et al. The prevalence of thromboembolic events among women with extended bed rest prescribed as part of the treatment for premature labor or preterm premature rupture of membranes. Am J Obstet Gynecol 2000; 182:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/126\">",
"      Pircon RA, Strassner HT, Kirz DS, Towers CV. Controlled trial of hydration and bed rest versus bed rest alone in the evaluation of preterm uterine contractions. Am J Obstet Gynecol 1989; 161:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/53/35674/abstract/127\">",
"      Guinn DA, Goepfert AR, Owen J, et al. Management options in women with preterm uterine contractions: a randomized clinical trial. Am J Obstet Gynecol 1997; 177:814.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6742 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-806F72AFFC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_53_35674=[""].join("\n");
var outline_f34_53_35674=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H58\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATIENT SELECTION AND TREATMENT GOALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1282503\">",
"      Indications for tocolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1277522\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1281961\">",
"      Treatment goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1348457168\">",
"      Gestational age limits for tocolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1276501\">",
"      - Lower limit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1276508\">",
"      - Upper limit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Contraindications to tocolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1277601\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1278239\">",
"      TOCOLYTIC OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1279823\">",
"      Cyclooxygenase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1279954\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1279961\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1279968\">",
"      - Maternal side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1279975\">",
"      - Fetal side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1279982\">",
"      Constriction of the ductus arteriosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1279989\">",
"      Oligohydramnios",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1279996\">",
"      Neonatal effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1280003\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1280010\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1280017\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1280923\">",
"      Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1281059\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1281066\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1281073\">",
"      - Maternal side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1281080\">",
"      - Fetal side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1281087\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1281094\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Beta-adrenergic receptor agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Maternal side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Fetal side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1281518\">",
"      Oxytocin receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1281526\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1281533\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1281540\">",
"      - Maternal side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1281547\">",
"      - Fetal side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1281554\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1281561\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1281568\">",
"      Nitric oxide donors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1281576\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1281583\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1281590\">",
"      - Maternal side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1281597\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1281604\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Magnesium sulfate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Maternal and fetal side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Neuroprotective effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1278930\">",
"      INEFFECTIVE APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      Progesterone supplementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1277954\">",
"      Bedrest, hydration, and sedation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      MANAGEMENT AFTER CESSATION OF CONTRACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      Choice of drug",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6742\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6742|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/29/34269\" title=\"figure 1\">",
"      Prostaglandin synthesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37032?source=related_link\">",
"      Acute respiratory failure during pregnancy and the peripartum period",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42761?source=related_link\">",
"      Intraamniotic infection (chorioamnionitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32966?source=related_link\">",
"      Major side effects and safety of calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36567?source=related_link\">",
"      Management of myasthenia gravis in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24135?source=related_link\">",
"      Management of pregnant women after inhibition of acute preterm labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43799?source=related_link\">",
"      Neuroprotective effects of in utero exposure to magnesium sulfate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/30/5608?source=related_link\">",
"      Overview of preterm labor and birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/40/32393?source=related_link\">",
"      Pathogenesis of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/50/15145?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of patent ductus arteriosus in premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/52/35650?source=related_link\">",
"      Patient information: Preterm labor (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/20/27970?source=related_link\">",
"      Patient information: Preterm labor (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/0/6153?source=related_link\">",
"      Physiology of parturition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15866?source=related_link\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11994?source=related_link\">",
"      Prevention of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/33/5657?source=related_link\">",
"      Progesterone supplementation to reduce the risk of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/3/35898?source=related_link\">",
"      Risk factors for preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/9/32914?source=related_link\">",
"      Symptoms of hypermagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4698?source=related_link\">",
"      Terminology, epidemiology, and pathogenesis of autism spectrum disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_53_35675="Systemic autoimmune diseases";
var content_f34_53_35675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Systemic autoimmune diseases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Connective tissue diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid arthritis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic sclerosis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mixed connective tissue disease*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sjogren syndrome",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polymyositis and dermatomyositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Vasculitides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small vessels: Churg-Strauss syndrome",
"        <sup>",
"         &bull;",
"        </sup>",
"        (also called allergic granulomatosis and angiitis), granulomatosis with polyangiitis (GPA, formerly Wegener's granulomatosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medium-sized vessels: polyarteritis nodosa, Kawasaki disease",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Large vessels: Takayasu arteritis, giant cell arteritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Granulomatous diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Autoinflammatory diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial Mediterranean fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TNF receptor-1 associated periodic syndrome (TRAPS)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Diseases with very frequent pericardial involvement (&gt;25 percent).",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Diseases with frequent pericardial involvement (&gt;10 percent).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_53_35675=[""].join("\n");
var outline_f34_53_35675=null;
var title_f34_53_35676="Management IRIS B";
var content_f34_53_35676=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    General management recommendations for IRIS-related syndromes, continued*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Pathogen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Most common clinical manifestations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Management recommendations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prognosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        JC virus",
"       </td>",
"       <td>",
"        Progressive multifocal leukoencephalopathy with inflammatory features",
"       </td>",
"       <td>",
"        <p>",
"         Continue HAART in most cases.",
"        </p>",
"        <p>",
"         Corticosteroids.",
"        </p>",
"       </td>",
"       <td>",
"        Often self-limited, but chronic neurologic sequelae and fatal cases may occur.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HSV, VZV",
"       </td>",
"       <td>",
"        <p>",
"         Perianal herpes",
"        </p>",
"        <p>",
"         Localized zoster",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Continue HAART.",
"        </p>",
"        <p>",
"         Oral acyclovir or famciclovir for 7-14 days.",
"        </p>",
"       </td>",
"       <td>",
"        Self-limited in the vast majority",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis B",
"       </td>",
"       <td>",
"        Hepatitis",
"       </td>",
"       <td>",
"        <p>",
"         Consider direct drug hepatotoxicity (eg, protease inhibitor).",
"        </p>",
"        <p>",
"         Continue or interrupt HAART&Delta;.",
"        </p>",
"        <p>",
"         Tenofovir, lamivudine, emtricitabine, and/or entecavir if indicated.",
"        </p>",
"       </td>",
"       <td>",
"        Often self-limited, but progressive cirrhosis may occur, esp with low functional hepatic reserve.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis C",
"       </td>",
"       <td>",
"        Hepatitis",
"       </td>",
"       <td>",
"        <p>",
"         Consider direct drug hepatotoxicity (eg, protease inhibitor).",
"        </p>",
"        <p>",
"         Continue or interrupt HAART&Delta;.",
"        </p>",
"        <p>",
"         Antiviral therapy may be an option in selected patients.",
"        </p>",
"       </td>",
"       <td>",
"        Same as above.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parvovirus B19",
"       </td>",
"       <td>",
"        <p>",
"         Fever, anemia",
"        </p>",
"        <p>",
"         Encephalitis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Intravenous immunoglobulin (IVIG).",
"        </p>",
"        <p>",
"         Continue or interrupt HAART&Delta;.",
"        </p>",
"       </td>",
"       <td>",
"        Usually self-limited.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"       <td>",
"        Pulmonary",
"       </td>",
"       <td>",
"        <p>",
"         Corticosteroids.",
"        </p>",
"        <p>",
"         Continue HAART.",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune thyroiditis",
"       </td>",
"       <td>",
"        Thryotoxicosis",
"       </td>",
"       <td>",
"        <p>",
"         Anti-thyroid drugs, beta-blockers, and/or thyroid ablation.",
"        </p>",
"        <p>",
"         Continue HAART.",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Based on published clinical experience, but needs to be proven in controlled clinical trials.",
"     <br>",
"      &Delta; Consider temporarilyinterrupting HAART for 1-3 months if eye, neural, liver, or other organinvolvement is particularly severe, progressive, and/or steroidrefractory.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_53_35676=[""].join("\n");
var outline_f34_53_35676=null;
var title_f34_53_35677="Serum EPO and anemia";
var content_f34_53_35677=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F53916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F53916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Serum erythropoietin levels in anemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 530px; background-image: url(data:image/gif;base64,R0lGODlhqQESAsQAAP///wAAAICAgEBAQPDw8HBwcGBgYMDAwODg4KCgoCAgIDAwMFBQUBAQELCwsNDQ0JCQkAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACpARICAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqHMHDyMECQIJBCYIEAIOra+xIq6wsqm/kA8CAQMjC8QBCyUIDQ3HBSLHA8nRyMrA2IzTxCIOAQwADAG3IwUBEAANAQTe4OIO7eHj2fSJB9wAwwL5Afsj0wcAANTHTwBBgiMOGFxoMGC9h3fuFStI8V+AgAP7FTyoMSFDgwP8QRwpR6IICAGg/5lDN+IdgGMPUKo8JxPAyhUGSep8EzPZAQIIAig4oCAAgnANXH3zpgBA0KFFETwlahSnSDzmAqTcGWqb1oAJiipIIKKBAREF1C1gBSCsULJtxcJVkTNPVq1buQJ7UBVIXTx4A+sF5uCqj793AuMdzLgGYjuKtTaeHONxnbtaoVHezMLyZbyaOYtG4Xm06T+lT6vWk3q16zqtX8uGE3u27TW1b+s2k3u37zC9fwvnEny48SvFjyuXkpwIgW0DfC2fns8wFK/4qC9vPiTyUe3KuQuJDH679SfYJ5Y3Lj7Ic63R1x9vP+S7fPbn7+s/Qn+/fxr9/SfgCwEO8R4x0g1oWv+BQqSnoGoMBuHdgwvmNwV5FI4WIRAOZijahj8cGJ+HnIEYhH0kbmZiiv+tyOJ+Lr54X4wyrkcjDHeFJmKCNXJ1owuY5WVAYGf1ONiPLUQWgAgYGumjhUDsyCSGTTqpE5IkdKjklIJZuROWI0wYpGZD4lWklySByeViaIHWCnQ8olmPmgIFpp6cFSYhJZ6n0TkCinxqCGWgGfp5RI6EZmJoEWOeQECZARgQZ6KDLEqEkvBJh112lBZiaXeYEhNkl516OmgZoaYqWammnvGomb6Mqip8rLZqxqYTEaDOrEROWmsfn+awZZ284nXnr4EEi8OwSsoaGKDI+qHsDbiuWWz/YKFFy8e0NryqlaQi4HptXtruwa0P3kZKgJKbklpuHucS0ahTw74L76lsIBpmlfbaEW8T8/Z7x78AuykwHgQfnErCKOirMCYMmxDwEns+LEbEJdS7RIcWA4dvFBqvkC64EhuswoQdg4ExCRpXHK5ix9qkWLYn8JsycR9DMTHH1q7Kss0l8Hwzzl843DOKIQOQdAkuD73Fyi7wW23GQJ8ArdNaQN2C0CPHOTHWamjNQtNAmgw2bjl3cfXZgIjNdiVuvz1J3HJHQvcNXdcdx902TK23G2LnLcPSf6MhNq6QkrwC4YXzlrYTs8Z8gt+Nh/14E7y2IHjllnvRbtWcD3w5/xMjUx46a6NHsfnpqN+xOutl8E2D6bCPIfsMjNfuxe2Dg657F7zHQPvvXwQPw+vEF5968tkYzzzCyz//i/PSwxa9GGRXnwX1LkAaqfa7Xx+G7+BPwX2SipVPdGLpq3/DKrj0MkJhENhH/9ojnM+C92e6L4Mw2ZEGNWS2gGYcxRwFbAD+qlOF7HULTv6bHa0AEI93rKsBAJDJBTNILoV8JCRV4F8EZ5AAAwxgAAVwCA9MQhF9mEQiL8yOBxkCQiqQDwdGkxtVGnBCdQxggTJgIUcEEMMBFJEu4uvBDW3wNbYRQ4VxkVwNWFiTlfBFGe24IgW/gcQqLLEGSnKgxfrXCv+a2aAnC/jJVKICgKI4QBxkcSMcu0gFEUooMkIbIbG+Epe3iOABx2iAZgAZAEFapYEQvKOqgJiyE14siWQY0xct5kiP+QFReTxbJVUGSTWI8WHDgNkjD8FIhYXSTqPUY5o6qcooPOAAsGQLJ1upBnEYK5W0PEMyFjIX5eUSDSh0XBly6L8D8PCEZlyfGJqovl1NcJZjyF31DBk7ViJBmtIrgBFjicvxTZJ4mXyaNQ81M1W+gpfdDAMxZ+CyT/5SBvqzgR1fdkuF+cqSgqgSygQWKSjabpyoal/PHpYWodSPDPEEo0D3yKmDJWAbDCAHNAMxTwC4s1wIEIBYZAk8gJL/IXul7Ncb/SnONFyUeQ8IaRWcF87nDcAA3ggAR8OXhn2WLTN/G8cAFLAAMna0pgttATOxdhGzCECKWfNoElqKAmx2bAFFgYAJ0/nRRL7AqRYz5gKYwZKJpkGlPwvq2VL6R7AyR6lFK2fdanhUqu5hnU57wAAaoIAeInV7aH2nEO4RmAZI1Jd6jWQv3RrYUiRUfRdhKhYOW74BPECbJwwmPgsB18LegLE1GOrDEuDMuy42r9H8prZ8iEzCug6CWH0XNREK2i04KLXlKoBPvboH72hWYYpFTmu1gKHKEjSykqWtHnJr2RxgVnNWxcFJWfRQ4P4VsIAw6/6IFKhT4uW5/z/9hGgzhABYwtIBCwDHZDthU0K1dbyc2C6Fuutd8IpXuG9Y7g0qiibragW7ypQDfaOUXDQ1N7L4zW8cvom84lZmt0/45vDeJQAEnNMgg83uHL4J204lFpXohcM8kVdhSv3kld6dqYTlUDHaLdjALjju4mxW4OMl7p4PYpdp6xAy+argxA8CbmSTWdI+mG6/uFPv71SsgtcJmWpi9dBHIDxjQBw5S6KUkYwzTIgnt+LFNfKulkUs4EIAuV8f3nKT/2BjVl24nvClQzv7m7IGPxgWY35DRYmLYgIh2IYL9Y4Yy5xlBuw4zm7Qp2IM8GWGehZNzmzoiNnnrs8l+WisWv/tP/dQ0aCoKgVW9tBDQwzoNrjM0e4KGoZL5b1DW4HIMIgMoamLAj5LeQHopLIfIkOAi0q3R8GdNCHo3C8DHDPXNCWEq6PFa/PdOQv6KuWwc4lqFUysacW2EpcBMO3POrlK9C1vpxpAUgiY2tjXznNQM52iaQwAArCEQFGOfVl2W2FY6WKTRdD8K7cYi6Q9vqRaP8c0NteKvTDGayAcpqTZOqXOnXG3FuKtmIAjPAXNdgGov/1wE0QcfQV3eMVPcHEWdHjjJOj4CnAM8kMKG8vlMFvJOa7wMdyWBb59EAFgqXHdPuLjbcKWjDirlQZEeNGKwLnSyH0cvp6Qj7I+hND/2VVz+TBgAb4gQHg7DYiXn6zg5b7KedOMCKNd1FkpenrUp550SBBXVreejtG3ge98W0LbTX30gHheyJ93eRKTLPSAZv4T1maC18uejgMGwIC2A50RXQs8ifiCl7RDQeTUivLBfyUAvzqgAS1v9yFW12HFT+e8NTQC/HaRC+ncz+SFoFyH9T4g+yraBwBUjwCvgUAD0jEQDG+05K8qdwW5nuI1gE43uGjBQnKQxyKA/ORSRYIWX/1ZehOiRlzIDRYCYIYLCX24p7wDoh+nuyR4QLVXiI8hHlEE2AdJ5r2IKQMgwN8xYL2AhiGQYmxyr/io4jm0GA+Ir58KfhNtjgJ//w9Cf450f0CARmokFFRxFHIUAHaXfP83BZtjU3vief4xDAewAGm0AMAnQXgBFnLxR4GEfBLYCPxiRwJIIb9HdT42agM1dNCHJ//1Z2U3CE0zId6XPMo3A1eDISuoPj2oA3aEgc8zhDnQNI4nhBO4coDThE7IBkgYhT0whVS4A1Z4hcYFhVp4BsrnakYYQconf8tHbykQc81HgI2jfOoFdyRgdSJAhnXDhr2HaXUog6Fmh3kYOnS4hyyQW1jlhmvIhUkgh/2WKR73RTt4MF+ohiwQUnAIAIb4NlloBGj4JoioO5VoII7oPpsoBJNYPZ+oSPLGbIQoB4LoP5VYYPK1iP+cU4nDw2uhKD2VuDSpmIaZ+Eu1CDSuKIan6ASxCIO7gGVhyDqriHLLMINQhkrp0Ymi+ItbsF9bkiofSDyjuGJ5OI2pgiLOBzvX+HylSE+3BGpLsoxmiIkIUjnfqIfhaFHECB1CQzizCErQqAWheBQ5WDW9yCrr2GrOmAJXs2C36DT9yE7/2HzIiGTtKDcFKQPz2D2sVjgNGQP7aFEH2Wb1GFDKKDIXyYcZSQaTxDHFaEofOQaGiDJBiDUTeTwH2SQDqTcr2QNSwjEVyWAlqWHUVWLCaIw3+QZVAihrlosw2ZOBphiMBC0PKTAxyQNCVjXdqC1LeYkp8JBwR3LREpP/kTiAQplqjyZ01UWUIFOTLfBlXsknMVmWygV/VoksZylaiDKSVwYrHYOVanVToJGUHhkJUrkvlzZCS2kDvLKE6giWujQrevSXmTUzePmKhHkGb9mRtYOYXWhxjTmZp1aZlkkFkpmZJ8iZlLCZnAmamSmalkmak2maVrCXNvkbWVkuqIlnd9gvr3khYmkks6kEe4KWlHKbS4VhrQmVmJlPRplz5EKQwRkItfmVr5GSsnmcgACX/OicgiCYzemZnymd1rkEvOmE27ly3Vly3wly4blx45kC0MmSW9kp5YkCi4kDzMki61kzsTkew1kr8WkCL0mKPhOd2CCWZPOeKXKf/yUwi+60X+6kmi2CnWPAZ4oFOt+RQ78JIwqqB6mYihOjm9QhoExZh+SjMRj6eROaB4rlPQoAYx6anLehoTvgTgRQFGYCjqUYofqhoj0QUr7zNQiagSEadPV5AjKqZDtqB0+Jh/uJnyhqHqphlXr3obcxehZVeqg3Gtj0SUwqG7FnDNYQpaLBpGtJHcK3Re4wD/5nGrICfGRTpbIhffuAENe3ZNpHGbKiOFuzk2j6GmpaEW36QUGKim3Yoz1TjgNCRVtxE2O6pX2ahz8qHAoIFAzIRoXKGR/HMweicv6BHSLoR7e3GTL6aTupnKORo8tgpBtpXntaCUeaoaVaBxgIoP8smKp00J4WmZ6eqhrkNqROQqM6kJ83FmXniaSrQW7Dwqrygas54D0MkJC81z66WoCuOgcicgyd+odRdqq7QaxKBDoX6D3qIo6vVyPWuqFy1yGU06vh0ax3cGI6CDTUKaG34XxUQq0g6huMRI7GYqvwaa6GMKl9BStdGqD4igiWJhj2Uafg8a0J5qcEqx0GCzlB1a8ksrBNQF/26q/74UDrOn//alLIWjI4ZZyigWOJqp4Ziwa5E0aQSaqG2nsFF5FKObJngGOZQ5Ki0Y2S5Kf2ArEwAIluAq8Jqh2waiU46xyJNLFeErRCoJPRmihGGwQ0ybOoSh0ok7A9Ox1N4rD/QOuyrpM40PpMRHu1w7EpHpieF3uvwzEsY1u0WAsZTsusX7t7c5m2qrqxKdexbAm3QuoVckqcdGufdlsHtCO1OnocSQO47Gocg7u2vtq2OxmyL7K0PFBgoGqbfXsHZ4snjquKk5udM3C5npi5mntgnwsJnMuEofsIo/u4J4uy0/GzXmsb64S4M+q5aNBEy7qbsusFRnO4eSgl5Pq0nBEwSWOsL+Ygwlq4m1EvNWZLWrG18OEdtVsot8sF9fI19KqNfnir0bsFGkNMvEK8SSu5onFbuRcq0eEV0RGwfWGW2bsFMVe9csk/rBu7ZRsqiZYXhjmrvrElR8Esi4S/u+E3//zLfP6rGxWIIfDLsnJyujgALfOyI70br+sRufW1vqVLGhRcwZSJwYygwNrDwc+owYvgwbR4wSDcmSV8CCJ8hCRcwinMPC3MgysMwi9sjTGswTM8ZDWMwTesiTlcwTscmT1cuj/sjUEcukPMkyeMCEd8Okucl0mMB076qE88B1eqpVMMB1+aqVccB9YnxVsMB12cpzQUEktWxmZ8xmicxmq8xmzcxm78xnAcx3I8x3Rcx3Ysx4bHB2GcfkdFxnfcxif0x4Dsx4K8xoFcyIZMyIiMxoe8yGfcyI5cxm/6B4uqxUVAJ4biJ5l8bJgcvZZqyUTQydrJbpucBKI8N6TMyf/upsmrrMqmXMQhl8qvPMpKUMpIcMqSwMqzXMuyzMu7zB+wnD+9DMy0/Mu37MrHfJ2+nMzLzMzGfMnILAmwpATTjATVnATXfATZrM15/APbTATf/MXiPM7kXM7mrD68oAttQAsCAAFRB6Vu8Erfkc5N5wW84A/0zBiz5wZecQ373AYPoA7+8M9qENDE0BQvkaV6UUFiugYOUGtFcQAMHWBlAK37MNFrUBSyhNE+Mn0d4QZRMURSKEgevaYffQZ8oQBFAQ4i3dEmvac10dJpwBeFUdJ4egb30IEQKNM6oX9dtQbmUCQ+jRuK0c6Deg4FzQ36MNRcsUbpW0tC0RBOXbn/TsBeQ+J+U53R43AMB5DVeuEWY1GUeLEPYB2BvNERZc0GhORzIpDW5/zWcB3Xcj3XdF3Xdn3XeJ3Xer3XfN3Xfv3XgB3YD1PN3UXVMaBNKzB4Zi0E2mTYrbQqbNo3gBoDr8AkMaMr1WgD94DPdWWdkK0RBHBUEZV8rzAACfAADMAAsnAAfnZu17duAfFGro1+JmQAD/AKtOBgZB3VKDIM3/EKB/BSshDahHcLGSXRZIEA2jTarI1CsvAKb8QArDAkNZQAF+GZWgESGlFAAgATQ1dAQnEMZyEABnBUEMhzpt0O5gANOX1U5q0Owb0k5sBDHOWBFmEA5gAO3A0T9+BD/7qCeSak3lw0DTwlFAnd2Uxigk4YGQLAFyExJPug1NfNDQQAAU+nEdMgAuIgCwUkD9/xfuvwMpaNnyKR4Qnt4OTdD/egGSgBFwggDgZRFHVSDdd30gjYhZ9NRMSwEAEh4T1eDAUEASixDyZe5Eti4iKe5Ir20UYuETy+2cl33S/DEDM+41D+D5mNYjmeDj53ABBAFj6uNMXAgOZA5OPQE7bARShhAB6E5CbOgCiiAO8FECgBDs2QAF6O5x1xRQeQAAxQ5xJ9FkZe46NdFgZHhVuO2lqhALcQ5txg3chw0eqADgWl2slXFH7l5uUYShzla75A4Omo6ELhAFdOQRadD0cuCg6DXicYVOOLLdgrEBSageRHsFOwflkQWOVHMCTdfOu+/uvAHuzCPuzEXuzGfuzInuzKvuzM3uzO/uzQHu3SPu3UXlwhAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This graph indicates the exponential relationship between serum erythropoietin levels (EPO, milliUnits/mL, logarithmic scale) and venous hematocrit (percent, linear scale) in normal and anemic subjects without renal or chronic diseases. EPO was assayed by either bioassay or radioimmunoassay.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Erslev AJ, Wilson J, Caro J. Erythropoietin titers in anemic, nonuremic patients. J Lab Clin Med 1987; 109:429.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_53_35677=[""].join("\n");
var outline_f34_53_35677=null;
var title_f34_53_35678="Clearance CVVH and CVVHDF";
var content_f34_53_35678=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F77486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F77486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    Figure showing clearances of urea and beta2-microglobulin with CVVH and CHHHD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 396px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Figure showing clearance of urea and beta2-microglobulin with continuous venovenous hemofiltration (CVVH) and continuous venovenous hemodiafiltration (CVVHDF) performed at different effluent rates. At a fixed effluent flow rate, clearances during CVVHDF will exceed those provided by CVVH if the replacement fluid is infused pre-filter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Troyanov S, Cardinal J, Geadah D, et al. Solute clearances during continuous venovenous haemofiltration at various ultrafiltration flow rates using Multiflow-100 and HF 1000 filters. Nephrol Dial Transplant 2003; 18:961. Copyright &copy; 2003 St&eacute;phan Troyanov and Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_53_35678=[""].join("\n");
var outline_f34_53_35678=null;
var title_f34_53_35679="Urea clearance NxStage vs conventional";
var content_f34_53_35679=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F65329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F65329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 630px\">",
"   <div class=\"ttl\">",
"    Urea clearance with increasing dialysate flow rates: NxStage approach versus conventional dialysis where dialysate saturation defines efficiency of dialysate use",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 610px; height: 408px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Q",
"     <sub>",
"      b",
"     </sub>",
"     : Blood flow rate",
"     <br>",
"      Q",
"      <sub>",
"       d",
"      </sub>",
"      : Dialysate flow rate",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data reproduced with permission from: NxStage Medical, Inc. Copyright &copy; 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_53_35679=[""].join("\n");
var outline_f34_53_35679=null;
